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 Accumulated data from animal models and human cancer patients strongly 
support the concept that immunity cannot only function as an extrinsic tumor suppressor, 
but also shape tumor immunogenicity.  These observations led to the development of the 
cancer immunoediting hypothesis that stresses the dual host-protective and tumor-
sculpting actions of immunity on developing cancers.  We previously demonstrated 
important roles for lymphocytes and type I (IFN-α/β) and type II (IFN-γ) interferons in 
cancer immunoediting.  In the present work, we confirmed the role of IFN-γ in sculpting 
tumor immunogenicity and provide evidence that antigens expressed by tumors drive the 
destructive or sculpting actions of immunity on cancers. 
 Initial studies confirmed the finding that IFN-γ is a critical mediator of cancer 
immunoediting.  Wild type mice treated with antibodies that neutralize IFN-γ developed 
more sarcomas than control mice.  Furthermore, a subset of sarcomas generated in IFN-γ 
neutralized mice spontaneously reject when transplanted into wild type mice. Finally, 
	   xiv	  
these unedited tumors had differential requirements for IFN-γ responsiveness at the level 
of the host and the tumor to mediate tumor rejection. 
Although many immune components that participate in cancer immunoediting are 
known (e.g. IFN-γ), its underlying mechanisms remain poorly defined. We used 
massively parallel sequencing to characterize the expressed mutations in a highly 
immunogenic sarcoma, d42m1, and identified mutant spectrin-β2 as the major rejection 
antigen.  Moreover, we demonstrate that editing of d42m1 tumor cells occurs via a T cell-
dependent immunoselection process that promotes outgrowth of variants lacking mutant 
spectrin-β2.  Thus, the strongly immunogenic characteristic of an unedited tumor can be 
ascribed to expression of a highly antigenic mutant protein.  
 Subsequent studies established that antigen loss variants of d42m1 and edited 
sarcomas from wild type mice exhibit residual immunogenicity and respond to 
checkpoint blockade immunotherapy (anti-CTLA-4).  Exome sequencing of these tumors 
has laid the groundwork for the eventual identification of the antigens targeted for 
destruction by this form of cancer immunotherapy.  Taken together, these studies 
demonstrate that antigens drive the cancer immunoediting process and point to the future 
potential that cancer genome sequencing may have on the fields of tumor immunology 
and cancer immunotherapy. 
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CHAPTER 1 
 
Introduction to Cancer Immunoediting 
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AN INTRODUCTION TO CANCER AND GENERAL MECHANISMS OF 
CANCER SUPPRESSION 
 
The fundamental mechanisms of cellular division and DNA replication carry the 
inherent danger that the replication machinery will inevitably make mistakes, which 
could compromise the integrity of the genome and potentially results in cancer formation.  
Extensive research over the last half-century has revealed cancer to be a genetic disease 
that arises by an evolutionary process where somatic cells acquire multiple mutations 
overwhelming the barriers that normally restrain their uncontrolled expansion. The 
devastation wreaked by cancer cells can be lethal, but fortunately, a number of intrinsic 
and extrinsic tumor suppressor mechanisms exist to prevent their development.  
A variety of intrinsic tumor-suppressor mechanisms attempt to repair genetic 
mutations and will trigger senescence or apoptosis should repairs fail and cellular 
proliferation become aberrant. Cellular senescence, a state characterized by permanent 
cell-cycle arrest with specific changes in morphology and gene expression that 
distinguish it from quiescence (reversible cell-cycle arrest), is induced by a number of 
cellular proteins (e.g., p53) that sense genomic disturbances caused by mutagenic insults 
(1). In addition, cellular senescence is also triggered by activated oncogenes and it is now 
becoming more evident that escape from oncogene-induced senescence is a prerequisite 
for cellular transformation such that cancer cells must acquire cooperating lesions that 
uncouple mitogenic Ras signaling from senescence to proliferate indefinitely (2). Other 
intrinsic tumor suppressor mechanisms, including p53, sense the activity of oncogenes 
and initiate the programmed cell-death machinery.  In response to cellular stress, injury 
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or lack of survival signals, alterations in mitochondria integrity results in the release of 
pro-apoptotic effectors that trigger cell death by terminal activation of executioner 
caspases (3). In contrast, a second cell-death pathway is activated through ligation of cell-
surface death receptors such as tumor necrosis factor receptor (TNFR), tumor necrosis 
factor apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2, DR5), and Fas/CD95 
(4) with their corresponding ligands of the TNF superfamily to induce the formation of a 
signaling complex that activates the apical caspase 8 to initiate apoptosis.  Additionally, 
increasing attention is being placed on alternative cell death pathways such as necrosis, 
autophagy and mitotic catastrophe that may halt the transformation process (3). In 
general terms, both senescence and apoptosis prevent the acquired capability of cells to 
proliferate without environmental cues and act as a potent barrier to the further 
development of any pre-neoplastic cell. These cell-intrinsic prerequisite steps for the 
transformation of normal cells into cancer cells were graphically illustrated and included 
along with sustained angiogenesis, limitless replicative potential and tissue invasion and 
metastasis by Hanahan and Weinberg in their landmark review “The Hallmarks of 
Cancer” (5). 
Since this famous review, at least three general extrinsic tumor suppressor 
mechanisms have been identified by which cells and their adjacent tissues 'sense' the 
presence of cancerous cells.  All of these, to some extent, can be included under the 
umbrella of mechanisms that prevent cancer cells from invading and spreading to other 
tissues in the host. The first rests upon the mandatory dependency of cells for specific 
trophic signals in the microenvironment that quell their innate suicidal tendencies such as 
the epithelial cell – extracellular matrix association that when disrupted results in cell 
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death (6). A second appears to involve key links between cell polarity genes that control 
cellular junctions and proliferation, preventing cell cycle progression in the face of 
dysregulated junctional complexes (7).  A third extrinsic tumor suppressor mechanism 
involves the limitation of transformation or tumor cell growth by effector leukocytes of 
the immune system.  
The immune system has three primary roles in the prevention of tumors. First, it 
can protect the host from virus-induced tumors by eliminating or suppressing viral 
infections. Second, the timely elimination of pathogens and prompt resolution of 
inflammation can prevent the establishment of an inflammatory environment conducive 
to tumorigenesis. Finally, the immune system can specifically identify and eliminate 
tumor cells in certain tissues on the basis of their expression of tumor-specific antigens. 
This third process, referred to as cancer immunosurveillance, occurs when the immune 
system identifies transformed cells that have escaped cell-intrinsic tumor suppressor 
mechanisms and eliminates them before they can establish malignancy.  These effector 
immune cells employ extremely diverse mechanisms to control tumor targets including 
the induction of tumor cell death by mitochondrial and cell death receptor pathways and 
thus, evasion of immunosurveillance is acknowledged to be an additional hallmark of 
cancer (8-11). However, the immune system not only acts as an extrinsic tumor 
suppressor, but paradoxically, also promotes cancer outgrowth. Together, the dual host-
protective and tumor-promoting actions of immunity are referred to as cancer 
immunoediting. 
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A MODERN HISTORY OF CANCER IMMUNOSURVEILLANCE AND 
CANCER IMMUNOEDITING 
 
 The idea that the immune system, which so effectively protects the host from 
microbial pathogens, might also recognize and destroy tumor cells was conceived 50-100 
years ago (12-14). For over a century, the concept of cancer immunosurveillance has 
been wrought with controversy (reviewed in detail in (8)) and by the early 1990s, little 
attention was paid to the idea that natural immunity could eliminate tumors de novo. 
However, interest in this aspect of tumor immunology was rekindled in the mid-1990s by 
the observations that transplanted tumors grew more robustly in mice treated with 
neutralizing monoclonal antibodies specific for interferon-γ (IFN-γ) (15) and that 
immunodeficient mice which lacked either IFN-γ responsiveness (IFNGR1, a component 
of the IFN-γ receptor) or an intact T cell compartment were more susceptible to 3’-
methylcholanthrene (MCA)-induced sarcoma formation (16-18).  
 In the last decade, work from many laboratories including our own have validated 
the concept of cancer immunosurveillance, demonstrating, unequivocally, that the 
immune system can indeed protect mice from outgrowth of many different types of 
primary and transplantable tumors (15, 16, 19-25). An important study in 2001 provided 
evidence that the immune system not only controlled tumor quantity but also tumor 
quality (i.e., immunogenicity) (19).  Immunodeficient mice lacking either IFN-γ 
responsiveness or recombination activating gene-2 (RAG2) (the latter fail to generate T, 
B, and natural killer T lymphocytes) develop more spontaneous neoplasia upon aging and 
are more susceptible to MCA carcinogen-induced sarcomas compared to wild-type mice.  
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In addition, a significant portion (40%) of MCA sarcomas derived from immunodeficient 
Rag2-/- mice were spontaneously rejected when transplanted into naïve syngeneic WT 
mice, while all MCA sarcomas derived from immunocompetent WT mice grew 
progressively when transplanted into naïve syngeneic WT hosts (19).  Thus, tumors 
formed in the absence of an intact immune system are, as a group, more immunogenic 
than tumors that arise in immunocompetent hosts.  These results show that the immune 
system not only protects the host against tumor formation, but also “edits” tumor 
immunogenicity.  These new data prompted a refinement of the cancer 
immunosurveillance concept and led to the formulation of the cancer immunoediting 
hypothesis, which stresses the dual host-protective and tumor-sculpting actions of 
immunity on developing tumors. 
 We now view cancer immunoediting as a dynamic process comprised of three 
distinct phases: elimination, equilibrium and escape (8, 26-32). Elimination is a 
modernized view of cancer immunosurveillance where molecules and cells of both innate 
and adaptive immunity work together to detect the presence of a developing tumor and 
destroy it long before it becomes clinically apparent. In some instances, where tumor cell 
destruction goes to completion, the elimination phase represents an endpoint of cancer 
immunoediting. However, tumor cell variants may sometimes not be completely 
eliminated but rather enter into an equilibrium phase where the immune system controls 
net tumor cell outgrowth.  In this equilibrium phase, tumor cells can become functionally 
dormant and remain clinically unapparent for the life of the host. Thus, equilibrium also 
represents a potential second stable endpoint of cancer immunoediting. Finally, either as 
a result of changes occurring (a) in the tumor cell population due to an active 
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immunoediting process or (b) in the host immune system, resulting from increases in 
cancer-induced immunosuppression or immune system breakdown due to the natural 
aging process, the functional dormancy of the tumor cell population may be broken, 
leading to progression of these cells into the escape phase, where they begin to grow in 
an immunologically unrestricted manner and emerge as clinically apparent disease.  The 
concept of cancer immunoediting is thus, a comprehensive interpretation of previous and 
current clinical and experimental data, which integrates the immune system’s capacity to 
both protect the host from cancer and promote cancer outgrowth through a multitude of 
mechanisms. The observations that have led to the concept of cancer immunoediting are 
reviewed here, with a particular focus on experimental data from various mouse models 
of cancer and clinical data from human cancer patients.  
 
THE ELIMINATION PHASE: CANCER IMMUNOSURVEILLANCE 
 
Immune-mediated Cancer Elimination in Mice 
In the first phase of the cancer immunoediting process, the elimination phase, 
immune cells locate, recognize and destroy nascent transformed cells and prevent the 
development of malignancy.  This process has never been visualized in vivo, but rather 
has been inferred from the earlier onset or greater penetrance of neoplasia in mice 
defective for certain immune cell subsets, recognition molecules, effector pathways or 
cytokines. Predominantly through the use of gene-targeted mice or by employing 
neutralizing monoclonal antibodies (mAbs) in wild-type mice, this approach has 
demonstrated that a number of immune effector cells and pathways are important for the 
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suppression of tumor development. For the purposes of this introduction we will not 
discuss a large literature where such mice have been challenged by transplanting a bolus 
of tumor cells derived from wild-type (WT) mice, since these tumor cells originated by 
escaping host immunity and therefore have already undergone cancer immunoediting. 
There are three basic mouse models of cancer that are relevant to the discussion of cancer 
immunoediting that illustrate the important role of immunity in eliminating developing 
tumors: 1) carcinogen-induced tumors; 2) spontaneous tumors that arise upon aging; and 
3) tumor development in mice genetically predisposed to cancer. 
 
Carcinogen-induced Tumors in Immunodeficient Mice  
 Historically, the concepts of cancer immunosurveillance and immunoediting have 
predominantly been demonstrated by exposing WT and immunodeficient mice to 
carcinogens and comparing their relative tumor incidences. The advantages of regulating 
tumor penetrance, tissue involvement and location in carcinogen-induced tumor models 
is one reason why these models are widely employed by researchers and in some cases 
they represent good mouse models of human cancer (e.g., asbestosis). The two most 
commonly employed carcinogen-induced tumor models are sarcomas induced using 3’-
methylcholanthrene (MCA) and skin papillomas induced by a combination of 7,12-di-
methylbenz[a]-anthracene (DMBA) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA). 
To date, a number of mice with defined immunodeficiencies have been tested for their 
susceptibility to carcinogens (31).  
 Cells of both the innate and adaptive immune system have been shown to be critical 
for the elimination (i.e., cancer immunosurveillance) of primary MCA-induced sarcomas. 
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Lymphocyte-deficient Rag1-/-, Rag2-/-, severe combined immunodeficient (SCID) and 
nude mice all display an increased susceptibility to tumor induction after MCA exposure 
(17-19, 33).  Interestingly, 40% of tumors derived from Rag2-/- mice are rejected when 
transplanted into WT recipients, but grow progressively in either Rag2-/- hosts or WT 
hosts depleted of CD4+ and CD8+ T cells, whereas tumors derived from WT mice grow 
readily when transplanted into either WT or Rag2-/- hosts. These observations 
demonstrate that carcinogen-induced sarcomas derived from immunodeficient mice are 
more immunogenic than those arising in mice with a functional immune system and 
formed the basis for the cancer immunoediting concept (19). Subsequent studies found 
that mice deficient for either αβ or γδ T cells display increased susceptibility to tumor 
induction, indicating that	  both lymphocyte populations are important in suppressing 
MCA-induced tumors (23, 34). In addition, the innate-like lymphocytes are also critical 
players in eliminating transformed cells. For example, mice lacking CD1d-restricted T 
cells (Cd1d-/-) are more susceptible to MCA-induced sarcomas (35) suggesting that these 
cells, which bridge the innate and adaptive arms of the immune system, also have a role 
in suppressing MCA-induced sarcomas. Furthermore, mice lacking the Jα18 T cell 
receptor (TCR) component are unable to generate the semi-invariant Vα14-Jα18–
containing TCR expressed by natural killer T (NKT) cells, resulting in the absence of 
NKT cells, and rendering these mice more susceptible to MCA-sarcoma induction (36). 
Consistent with a role for the innate immune cells in cancer immunosurveillance, mice 
chronically depleted of NK cells displayed increased tumor incidence (37). One striking 
study revealed that CD8α+ dendritic cells (DCs) of the innate immune compartment are 
absolutely required for antitumor immunity and mice lacking these cells (Batf3-/-) 
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displayed similar antitumor deficiencies as Rag2-/- mice (38).  This may be explained in 
part, due the role of CD8α+ DCs in cross-presenting antigens to lymphocytes.  Even 
eosinophils, whose role is more clearly defined in host-defense against helminths, can 
protect the host from tumor development.  Mice deficient in eosinophils (more 
specifically eotaxin-, CCL11- and/or IL-5-deficient or ΔdblGATA) were more susceptible 
to MCA-induced sarcoma formation than WT mice in both C57BL/6 and BALB/c 
backgrounds (39). Remarkably, mice transgenic for IL-5 have greater circulating 
numbers of eosinophils and were more resistant to MCA-sarcomas compared to WT 
mice, strongly suggesting an immunosurveillance role for these innate immune cells (39).  
 A number of mice deficient for specific immune effector molecules and recognition 
pathways have also been examined in the context of MCA-induced tumor susceptibility, 
including mice lacking perforin (40), IFN-γ (40), IFNGR1 (16, 19), IFNAR1 or IFNAR2 
(components of the type I IFN receptor) (24, 41, 42), TRAIL (43, 44), IL-12 (45), TNF-α 
(42), and (DNAX accessory molecule-1) DNAM-1 (46). Each of these mouse strains 
demonstrated enhanced susceptibility to sarcoma induction after MCA treatment, 
suggesting that interferons and cytotoxic lymphocytes suppress tumor initiation in vivo. 
Although WT mice treated with blocking antibodies specific for NKG2D  (an activating 
receptor expressed by CD8+ T cells, γδ T cells and NK cells) was reported to increase the 
incidence of MCA-induced sarcomas	  in two different mouse strains (47), C57BL/6 
NKG2D-deficient mice had comparable numbers of MCA-induced sarcomas to WT mice 
(48). In addition, although the rate of MCA-induced tumor formation was similar in the 
presence or absence of the NK cell natural cytotoxicity receptor NKp46, the expression 
of its unknown ligands was NKp46-dependent, suggesting some level of immunoediting 
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by cells expressing this receptor (49).  
 Interferons can contribute to antitumor effects in a number of ways. IFN-γ can exert 
direct effects on tumor cells (16) and a major effect of IFN-γ on these cells is to enhance 
MHC class I expression, rendering them better targets for tumor-specific CD8+ T cells 
(19, 50). In addition, IFN-γ signaling in host immune cells (51) and host stroma cells (52) 
also plays an important role in the elimination of tumor cells, indicating that IFN-γ’s 
effects in multiple cellular compartments generates antitumor immunity. Others have 
proposed that IFN-γ contributes to an inflammatory foreign body reaction that results in 
the encapsulation of injected MCA, limiting its spread and thereby reducing its 
carcinogenic effects (53). However, this mechanism does not explain the findings of IFN-
γ preventing the formation of lymphomas induced by the soluble carcinogen N-methyl-N-
nitrosourea (54), where encapsulation of the carcinogen is not possible.  Furthermore, a 
recent report demonstrated that MCA exposure induced more squamous cell carcinomas 
(SCC) in the skin of IFN-γ-deficient mice than WT controls (55), indicating that MCA 
delivery in a different tissue type than the previous subcutaneous injections also supports 
a role for IFN-γ in mediating cancer immunosurveillance.  In contrast to the antitumor 
effects of IFN-γ occurring at both the level of the tumor and the host, the antitumor 
effects of type I IFNs (IFN-α/β) are mediated only at the level of the host’s 
hematopoietic system (24, 25, 56). Specifically, CD8α+ DCs of the innate immune 
compartment are critical responders of type I IFNs such that selective deletion of 
IFNAR1 in CD8α+ DCs results in tumor outgrowth of highly immunogenic sarcomas 
(25). These results suggest that the ability of type I IFNs to induce antitumor activity in 
immune cells might be the critical mode of action for this cytokine family and that IFN-γ 
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and IFN-α/β have distinct, potentially non-overlapping mechanisms of action in 
antitumor immunity.  
   As will be discussed later in this introduction, recent studies reveal that initiation of 
MCA-induced sarcomas requires an inflammatory event.  Along similar lines, skin 
carcinomas induced by the topical application of DMBA (tumor initiator) followed by 
repetitive doses of TPA (tumor promoter) are known to require inflammatory 
components for tumor initiation and promotion.  For example, the induction of 
DMBA/TPA skin carcinomas is MyD88- (42), mitogen-activated protein kinase-activated 
protein kinase-2 (MK2)- (57), TNF-α−	  (58), receptor for advanced glycation end-
products (RAGE)- (59), and IDO-dependent (60). Lesions progress from benign 
papillomas to metastatic SCC, and both the number of lesions and extant of tumor 
progression is dependent on the mouse strain. Despite an inflammatory component, 
DMBA/TPA induced tumors are also detected and destroyed by effector cells and 
molecules of innate and adaptive immunity. For example, γδ T cells and CD8+ T cells 
confer protection from DMBA/TPA-induced papillomas (23, 61). In contrast, CD4+ T 
cells promote tumor progression, implying opposite roles for αβ T cell subsets in the 
protection or promotion of DMBA/TPA skin carcinogenesis (61). One mechanism by 
which γδ T cells and activated CD8+ T cells might regulate tumor development is through 
recognition by NKG2D of the stress ligand retinoic acid early transcript 1 (RAE1) that is 
induced in the skin after DMBA/TPA treatment and has been found to be upregulated in 
transformed cells by the DNA damage pathway (23, 62). NKG2D-expressing dendritic 
epidermal γδ T cells can kill RAE1-expressing targets in vitro (23), but in transgenic 
mice expressing RAE1 in the skin, NKG2D expression is down modulated on 
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lymphocytes and consequently these mice are more susceptible to papilloma induction 
than WT mice (63). A follow up study using inducible RAE1 transgenic mice have 
provided further insight into the previous observation, where acute upregulation of 
NKG2D ligands triggered a swift reorganization of the local skin immune compartment, 
resulting in local Vγ5Vδ1+ T cells limiting carcinogenesis, but unexpectedly Langerhans 
cells promoted DMBA/TPA carcinogenesis	  (64). Another innate recognition receptor, 
DNAM-1 also protects tumor formation as Dnam1-/- mice develop more papillomas than 
their WT counterparts (46).     
 In addition to cellular subsets and recognition receptors, effector molecules and 
cytokines also have a critical function in controlling DMBA/TPA-induced skin tumors. 
For example, although DMBA/TPA-treated TRAIL-R-deficient mice did not show an 
increase in the number of benign papillomas or the rate of progression to squamous cell 
carcinoma when compared to WT mice, metastasis to lymph nodes was significantly 
enhanced, indicating a role for TRAIL-R specifically in the suppression of metastasis	  
(65). One cytokine, IL-12, has been shown to protect mice against DMBA/TPA-induced 
tumors, where mice that lack functional IL-12 (Il12a-/-) develop increased numbers of 
papillomas compared to WT mice (66, 67).	  Interestingly, mice that lack functional IL-23 
(Il23a-/-) are resistant to tumor development (66, 67), however, the mechanism by which 
IL-23 suppresses innate immunity and promotes tumor growth requires further 
clarification since it was unexpectedly IL-17A-independent (67).  Nevertheless, IL-17A-
deficient mice also develop fewer skin papillomas than WT mice after DMBA/TPA 
exposure, suggesting a tumor-promoting role for this cytokine (67).  One peculiarity of 
the DMBA/TPA model is that a loss of IFN-γ or IFNGR1 unexpectedly results in reduced 
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tumorigenesis, hence playing and opposite role than in the MCA tumor model (68). 
These observations demonstrate the pleiotropic effects that a single immune cell or 
molecule can have during carcinogenesis and stress the importance of a multimodal 
analysis.  The interplay between antitumor immunity and cancer-promoting inflammation 
suggested by the above studies is discussed at greater length below. 
 In addition to the demonstration of cancer immunosurveillance by immune effector 
cells and molecules against tumors induced by chemical carcinogens, tumors induced by 
physical carcinogens such as ultraviolet (UV) radiation also seem to be controlled by the 
immune system (69). Interestingly, UV-induced immune suppression is an important 
factor in the development of UV-induced tumors, and these tumors are often 
immunogenic when transplanted into naïve hosts but grow in immunosuppressed or 
CD8+ T cell-depleted (70). These data show that immunoediting can also be observed in 
the UV radiation tumor model as well as the MCA chemical carcinogen model.  
 
Spontaneous Tumor Development In Immunodeficient Mice 
An elegant approach to examine the role of the immune system in controlling 
tumor development is to simply remove specific components of the murine immune 
system and monitor mice as they age for the development of spontaneous tumors. Mice 
have long telomeres and display a very low incidence of spontaneous tumor 
development. For example, we observe incidences of cancer in a variety of inbred WT 
mouse strains that range from only 0-20% over a two-year period. While many 
immunodeficient mice also do not develop cancers over a two-year observation period, 
ageing studies have clearly demonstrated a critical role for certain cytotoxic pathways, 
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lymphocyte cellular subsets, and cytokines in the prevention of spontaneous tumor 
development. One striking example is the penetrance of immunogenic B cell lymphomas 
in aged mice (>1 yr) on either C57BL/6 or BALB/c backgrounds that increases from 0-
6% in wild-type mice to 40-60% in perforin-deficient mice (20, 22). Mice lacking this 
key T cell and NK cell cytotoxic effector pathway develop an even greater prevalence of 
B cell lymphomas with an earlier onset when they additionally lack the MHC class I 
accessory molecule β2-microglobulin (β2m) or IFN-γ compared with perforin alone (22, 
71). The absence of other lymphocyte cytotoxic pathways such as TRAIL or FasL also 
increased the susceptibility of mice to spontaneous lymphomas (72, 73). Collectively, 
these data provide very strong evidence that critical cytotoxic molecules in lymphocytes 
protect the host from spontaneous tumor development.  Intriguingly, human patients with 
specific mutations in perforin that develop adult onset familial hemophagocytic 
lymphohistocytosis (FHL) have recently been identified to also develop leukemia and 
lymphoma, suggesting the possibility that perforin may protect against hematological 
malignancies in humans (74).  
 Ageing experiments have also been performed in mice that lack one or more 
lymphocyte subsets. Although, early studies in athymic nude mice did not document an 
increase in spontaneous tumor development (75), one later study suggested that germ-free 
nude mice did develop a low frequency of B cell lymphoma compared with heterozygote 
littermates (76). Unlike other genetic models of immunodeficiency (e.g., SCID mice), the 
absence of RAG-2 does not affect DNA damage repair pathways in non-immune cells 
undergoing transformation. Helicobacter-negative 129/Sv Rag2-/- mice aged in a specific 
pathogen-free mouse facility and maintained on broad-spectrum antibiotics developed 
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significantly more spontaneous epithelial tumors (35% gastrointestinal and 15% lung of 
all mice analyzed at 15–16 months of age) than their WT counterparts (19).  Consistent 
with these observations, 129/Sv RAG-2-deficient mice that also lack STAT1 (an 
important mediator of signaling induced by both type I and type II IFNs) showed an 
earlier onset and broader spectrum of malignancy, including the development of colon 
and mammary adenocarcinomas (19). The role of specific lymphocyte subsets in the 
prevention spontaneous tumor development has yet to be reported in mice lacking NKT 
cells, γδ+ T cells or NK cells, but C57BL/6 β2m-deficient mice that lack NKT cells and 
many CD8+ T cells did not have elevated tumor formation upon aging (71), suggesting 
that distinct lymphocyte populations may play distinct roles, if any, during cancer 
immunosurveillance of spontaneous tumors. 
Similar to chemical carcinogen models of tumor induction, cytokines are critical 
for the activation of immune effector mechanisms that limit spontaneous tumor 
development. In one study, a small proportion (<15%) of BALB/c IFN-γ deficient mice 
developed lung adenocarcinomas whereas almost half the IFN-γ-deficient mice on a 
C57BL/6 background developed a spectrum of various T cell lymphomas, indicating 
strain-specific differences in the contribution of IFN-γ to prevent spontaneous tumors 
from occurring (22). In addition, C57BL/6 mice deficient for both perforin and IFN-γ 
develop more B cell lymphomas with earlier onset than Pfp-/- mice, suggesting that in the 
absence of perforin, IFN-γ can play a role in controlling lymphomas (22). Finally, female 
mice deficient for the IFN-γ-inducible immunoproteasome subunit LMP2 develop 
spontaneous uterine neoplasms with a disease prevalence of approximately 36% by 12 
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months of age	  (77). This observation suggests that IFN-γ inducible proteasome function 
may be essential for MHC class I-mediated tumor rejection.  
In addition to the role of cytokines in cancer immunosurveillance of spontaneous 
tumors, a possible link between tumor immunity and autoimmune or infection-induced 
inflammation has been raised by several studies.  For example, 50% of mice lacking the 
β2 subunit of the IL-12 receptor (IL-12Rβ2) develop plasmacytomas or lung carcinoma 
concurrently with immune complex mesangial glomerulonephritis	  upon aging (78). It is 
presently unclear why IL-12p40–deficient mice on the same genetic background as the 
IL-12Rβ2–deficient mice do not display either autoimmunity or spontaneous tumor 
development	  (22). Furthermore, mice deficient for both IFN-γ and GM-CSF have been 
found to develop spontaneous tumors in a variety of tissues with age and, in this case, 
tumor development is associated with acute or chronic inflammatory lesions (79). 
Maintaining Gmcsf-/-Ifng-/- mice on a regimen of antibiotics delays tumor onset	  
suggesting that in addition to potentially eliminating tumor cells directly, the immune 
system might also prevent tumor growth by the timely elimination of infections, thereby 
limiting inflammation, which is known to facilitate tumor development (80). However, 
this finding cannot be generalized to all immunodeficient mice that develop spontaneous 
malignancies since heightened tumor incidence was observed in Rag2-/- and Rag2-/-Stat1-/- 
mice maintained on the same antibiotics regimen (as mentioned above).  
 
Genetic Tumor Models in Immunodeficient Mice 
 Data supporting the ability of the immune system to suppress tumor development in 
genetic models of mouse cancer are accumulating rapidly. Mice heterozygous for the 
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tumor suppressor p53 (Trp53+/–) are genetically predisposed to tumor development, but in 
the additional absence of IFNGR1 (16), perforin (20), TRAIL (72), or NKT cells (35), 
more aggressive tumors develop with an earlier onset, providing very strong evidence 
that these immune components participate in the elimination of nascent transformed cells. 
More recently, a key role for perforin in immunosurveillance of B cell malignancies has 
been validated in three different genetic models of B cell malignancies in C57BL/6 mice.  
Similar to Pfp-/-Trp53+/- mice, perforin-deficient mice also heterozygous the tumor-
suppressor Mlh1 developed more B cell lymphomas with faster kinetics than mice 
lacking perforin alone (81).	  Additionally, perforin protects against the development of 
oncogene-driven tumors on a transgenic background, including v-abl-driven 
plasmacytomas, and bcl2-driven follicular lymphomas (81). 
 Other transgenic mice that express oncogenes under the control of tissue-specific 
promoters have also revealed immune-mediated protection from tumor formation.  In one 
example, IFN-γ suppresses tumor development in mice expressing the human T cell 
leukemia virus (HTLV) type 1–derived oncogene Tax under the control of a granzyme B 
promoter (HTLV-Tax transgenic mice) (82). Loss of a single TRAIL-R allele on the 
lymphoma-prone Eµ-myc genetic background significantly reduced median lymphoma-
free survival corroborating an extrinsic tumor suppressor role for this cell death pathway 
(83). The conclusion that NKG2D plays a critical role in cancer immunosurveillance is 
further supported by the fact that mice defective in NKG2D are more susceptible to Eµ-
myc driven pre-B cell lymphomas (48). More recently, in a study using transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mice, investigators assessed whether 
NKG2D controlled the growth of spontaneous oncogene-driven prostate cancer. NKG2D-
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deficient mice developed more aggressive tumors than WT mice and interestingly, these 
aggressive tumors arising in NKG2D-deficient mice expressed higher amounts of 
NKG2D ligands than did similar tumors in wild-type mice, suggesting an NKG2D-
dependent immunoediting mechanism (48). Also in the same prostate cancer model, the 
lack of NKT cells in TRAMP Jα18-/- mice correlated with more aggressive 
adenocarcinoma development (84). Despite the presence of a traceable tumor antigen-
specific T cell response in these mice, no evidence was found to support a correlation 
between the presence of NKT cells and the efficacy of CTL responses in this setting. 
Nevertheless, this study extends the list of spontaneously arising tumors in mice in which 
NKT cells are critical for natural immune surveillance.  
 In summary, various cell types including αβ T cells, γδ T cells, NKT cells and NK 
cells have all been implicated in the processes of elimination and immunoediting, along 
with a number of effector molecules, including perforin and TRAIL, as well as the 
cytokines IFN-γ, type I IFNs, and IL-12.  More is known about the physiologically 
relevant targets of IFN-γ's actions than the other effector molecules or cells during cancer 
immunosurveillance.  Both host and tumor cells are important targets of IFN-γ during the 
development of protective antitumor immune responses and the data substantiating this 
conclusion has already been extensively reviewed (8, 26, 27). It is important to note that 
the effector cells and cytokines thought to be involved in elimination and immunoediting 
differ among models, demonstrating that the success of immunoediting and the evidence 
of its occurrence varies among experimental systems. Indeed, there are models in which 
the immune system seems to have little influence on the rate of tumor onset or 
progression	  (85) and models in which the immune system has a distinct protective role, 
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such as the carcinogen-induced and genetically-predisposed tumor models outlined 
above. The level of immune regulation and tolerance (a state of non-responsiveness to 
specific antigens) imparted by the tumors in each of these models might explain, at least 
in part, why in some cases the effect of subtracting immune elements on tumor 
progression is less overt. Blocking these tolerance mechanisms might reveal the true 
mechanisms of tumor suppressor immunity.  Moreover, recent studies have lent great 
support for the cancer immunoediting hypothesis by validating the existence of the 
equilibrium phase in multiple models and demonstrating that the immune sculpting 
actions on tumor immunogenicity occur during this phase. 
 
THE EQUILIBRIUM PHASE: IMMUNE-MEDIATED TUMOR DORMANCY 
 
Historically, tumor dormancy is the term used to describe latent tumors present in 
patients for decades that may eventually recur as local lesions or form distant metastases 
(86). Tumors in the equilibrium phase are a subset of dormant tumors that are specifically 
controlled by components of the immune system.  In the equilibrium phase, the host 
immune system and tumor cells enter a dynamic balance, wherein powerful antitumor 
immunity contains, but does not fully eradicate, a heterogeneous population of tumor 
cells, some of which have acquired means of evading immune-mediated recognition and 
destruction. The equilibrium phase was originally hypothesized to exist in order to 
explain the long latency period from the initial transformation event to the escape phase 
and emergence of malignant disease.  In this manner, equilibrium may be the longest of 
the immunoediting phases where sculpting forces of immunity select for the tumor cells 
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acquiring the most immunoevasive mutations, potentially leading to clinically detectable 
disease. 
Using a low-dose regimen of the carcinogen MCA, we reported the first 
experimental demonstration that immunity maintains primary occult cancer lesions in an 
equilibrium state (87).  Treatment of naïve WT mice with low doses of MCA led to overt 
tumors in only a low proportion of mice. When the remaining carcinogen-treated mice 
were rendered immunodeficient via depletion of CD4+ and CD8+ cells and/or 
neutralization of IFN-γ, sarcomas rapidly grew out at the original carcinogen injection 
site in approximately 50% of the group. Strikingly, tumor outgrowth was not observed to 
any significant extent (<10%) in similar MCA treated WT or RAG2-deficient mice 
injected weekly with control mAb starting at day 200. Subsequent analyses revealed that 
mAbs that depleted cells of adaptive immunity (such as CD4+ and CD8+ T cells) or 
blocked cytokines that promote adaptive immunity (such as IFN-γ and IL-12) caused 
dormant tumor cells to grow out. In contrast, mAbs that deplete NK cells (anti-NK1.1), 
block NK cell recognition (anti-NKG2D) or inhibit NK cell effector function (anti-
TRAIL) failed to cause the emergence of progressively growing tumors (87). These 
results support the conclusion that adaptive immunity, but not innate immunity, is 
responsible for maintaining the equilibrium phase. They also help to mechanistically 
distinguish this phase from elimination, where both innate and adaptive immunity are 
required.  Histological examination of occult tumors revealed the presence of atypical 
fibroblasts surrounded by a dense infiltration of leukocytes. These atypical fibroblasts 
were truly transformed since they formed progressively growing tumors when 
transplanted into immunodeficient Rag2-/- mice.  Moreover, occult tumors controlled by 
	   22 
immunity displayed fewer Ki67+ atypical fibroblasts and more terminal deoxynucleotidyl 
transferase dUTP end nick labeling (TUNEL) staining cells than progressively growing 
sarcomas.  The visualization of fewer proliferating tumor cells accompanied by more 
cells undergoing apoptosis is supportive of an active immune response controlling 
equilibrium tumors. Occult tumors arising after immunodepletion were, on the whole, 
highly immunogenic with 40% of the cell lines rejecting after transplantation into WT 
mice.  In contrast, the rare spontaneous tumors that grew out of mice treated with control 
mAbs were poorly immunogenic and grew progressively when transplanted into WT 
recipients. Thus, tumor cells held in equilibrium by adaptive immunity remained highly 
immunogenic and displayed an unedited phenotype while dormant sarcoma cells that 
spontaneously escaped immune control to become actively growing tumors displayed 
reduced immunogenicity, indicating that they had undergone editing.   
In hindsight, these findings explain previously reported models of immune-
mediated tumor dormancy. In the past, most experimental models of tumor dormancy 
relied heavily on a vaccination-and-challenge strategy with tumor cell lines to induce 
latent tumor cells. For example, in the BALB/c B cell leukemia/lymphoma 1 (BCL1) 
model of tumor dormancy, mice were immunized with BCL1-derived Ig to create an anti-
idiotype vaccine against the B cell Receptor (BCR) expressed by the lymphoma cells.  
Naïve, non-immunized mice injected with BCL1 tumor cells succumbed to malignancy 
within 30 days.  In contrast, mice initially immunized with BCL1-derived Ig and 
subsequently challenged with BCL1 tumor cells did not develop malignancy although 
tumor cells could be detected in the circulation of cancer-free mice hundreds of days after 
transplantation (88).  Over an extended period of time, vaccinated mice challenged with 
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live BCL1 tumor cells spontaneously developed malignancy, suggesting an escape from 
dormancy.  Interestingly, when mice harboring dormant BCL1 tumor cells were depleted 
of CD8+ T cells or IFN-γ using mAbs, the incidence and duration of dormancy were 
reduced, suggesting that the immune system plays an important role in controlling these 
dormant tumor cells (88).   
 Using a BCR-ABL mouse model of leukemia, dormancy was also achieved via a 
vaccination-and-challenge strategy.  The longer the DA1-3b tumor cells remained 
dormant within the vaccinated host, the greater the expression of programmed cell death 
1 ligand 1 (PD-L1) on the tumor cells, which acted to confer resistance to cytotoxic T 
lymphocyte (CTL)-mediated killing (89). Consistent with the concept of the equilibrium 
phase, DA1-3b tumor cells acquired advantageous changes over time such that those cells 
which remained dormant longer were more resistant to attack by CD8+ T cells. 
Recently, two additional studies using different mouse models of cancer 
corroborated our findings for the existence of the equilibrium phase by additionally 
demonstrating that immunity can control primary carcinomas and metastases for 
extended periods of time.  The first study involved a new mouse model of cancer 
immunosurveillance and equilibrium using ultraviolet B (UVB)-radiation to induce 
squamous cell carcinomas of the skin.  Here, the authors used mice genetically deficient 
in E3 ligase Casitas B-lineage lymphoma b (Cbl-b), which is known to limit the effector 
functions of CTLs (90).  Thus, mice lacking Cbl-b exposed to UVB-radiation developed 
fewer spontaneous squamous cell carcinomas compared to WT mice due to the enhanced 
antitumor activity of CD8+ T cells that lack the Cbl-b regulator.  Cblb-/- mice that failed 
to form carcinomas 400 days after UVB treatment were then divided into two 
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experimental groups.  One group received mAbs that depleted CD8+ T cells, while the 
other group received control mAbs.  Only 10 days after starting mAb treatment, nearly 
50% of mice depleted of CD8+ T cells developed rapidly growing tumors whereas none 
of the mice receiving control mAb developed detectable tumors (90). It will be interesting 
to determine in the future whether WT CD8+ T cells can also maintain occult UVB-
induced carcinomas in an equilibrium state. 
A second study demonstrates that immunity can prevent the outgrowth of 
micrometastases for an extended period of time in an oncogene-driven model of 
melanoma.  In this model, transgenic mice that express the human RET oncogene and a 
chimeric mouse/human MHC antigen (91) specifically in melanocytes were found to 
develop extensive disseminated metastases (92).  Depletion of CD8+ T cells in RET.AAD 
mice significantly accelerated the outgrowth of metastatic lesions to visceral organs, 
indicating that immunity is one significant barrier disseminated tumor cells must 
overcome in order to establish metastatic disease (92).  Interestingly, these CD8+ T cells 
did not seem to directly kill the tumor cells, but rather mediated cytostatic effects on the 
disseminated tumor cells.  One likely mechanism underlying control of disseminated 
tumor cell outgrowth may be via IFN-γ produced by tumor antigen-specific T cells, 
which has been shown in other systems to inhibit cellular proliferation and curtail 
angiogenesis (93-95).  For example, in a pre-clinical model of pancreatic cancer using 
RIP-Tag2 mice, the transfer of IFN-γ producing TNFR1+ CD4+ T cells specific for Tag 
prevented the progression of pancreatic islet cancer (95).  In this study, transferred Tag-
specific T cells arrested tumor cell proliferation and prevented angiogenesis, curtailing 
tumor growth and resulting in the inhibition of multistage carcinogenesis and induction of 
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a period of extended tumor dormancy. In the absence of either TNFR1 signaling or IFN-γ 
receptor signaling, the same T cells paradoxically promoted angiogenesis and multistage 
carcinogenesis.  Currently, the adoptive transfer of cancer-reactive T cells into human 
cancer patients is an experimental therapy with promising results (96) and it will be 
interesting to see if these therapies can be optimized as a viable therapeutic endpoint to 
induce an equilibrium state in some patients. 
 
THE ESCAPE PHASE: FAILURE OF CANCER IMMUNOSURVEILLANCE 
 
 While the processes of cancer elimination and equilibrium largely occur “behind 
the scenes”, a more dramatic result of cancer immunoediting can occur when tumors 
escape immune control, leading to the appearance of overt cancer. Thus, the escape phase 
represents the failure of the immune system to either eliminate or control transformed 
cells, allowing surviving tumor cell variants to grow in an immunologically unrestricted 
manner.  Cancer cells undergoing stochastic genetic and epigenetic changes generate the 
critical modifications necessary to circumvent both innate and adaptive immunological 
defenses. Moreover, the immune system contributes to tumor progression by selecting 
more aggressive tumor variants, suppressing the antitumor immune response, or 
promoting tumor cell proliferation.  The interaction between a heterogeneous population 
of cancer cells undergoing rapid genetic modifications and the constant immunological 
pressure exerted by immune cells allows for the Darwinian selection of the most fit tumor 
variants to survive and form overt cancer in immunocompetent hosts.  Thus, nearly all 
human cancers and experimental cancer cell lines are those that have evaded 
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immunological control. The focus of this section on tumor escape is not to provide an 
exhaustive list of escape mechanisms that have been extensively reviewed elsewhere (8, 
9, 26, 27, 29, 97) but rather to shape the framework of how tumor cells achieve 
immunological escape.  Although, the mechanisms for tumor escape are varied, they can 
be categorized generally as cell-autonomous modifications at the level of the tumor cell 
that directly evade immune detection and destruction or modifications in immune cells 
effected by tumor cells to generate an immunosuppressive network.  
 
Tumor Cell Modifications to Evade Immune Detection or Destruction 
 Tumor escape can result from changes that occur at the level of the tumor by 
directly inhibiting tumor recognition or cytolysis by immune effector cells. In some 
cases, immune evasion by tumors is absolute and the immune system has little impact on 
tumor progression, while in other cases tumor growth is delayed before the immune 
system is overwhelmed, leading to tumor progression. In its simplest form, tumor cells 
that express very weak antigens can evade detection due to the induction of central or 
peripheral tolerance. Central tolerance is a process whereby self-reactive T cells are 
eliminated or converted to a regulatory phenotype in the thymus (98). In this case, and in 
the absence of neoantigen expression, tumors may remain “invisible” to the adaptive 
immune system and are free to grow unhindered. Peripheral tolerance is an important 
process whereby T cells reactive with self-antigens not expressed in the thymus are 
deleted or rendered non-responsive in the periphery. In this case, some level of antitumor 
immune response may be initiated transiently before tolerance is induced leading to 
tumor progression (85, 99). 
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 In addition to tolerance induction, tumor cells can acquire defects in antigen 
processing and presentation pathways that facilitate evasion from adaptive immune 
recognition.  Specifically, loss of TAP1, MHC class I molecules, β2-microglobulin, 
LMP2, LMP7 and the development of IFN-γ or IFN-α/β insensitivity by tumor cells 
prevents T cell-mediated elimination, resulting in tumor progression (28, 100-102). An 
extreme version of this escape process occurs when tumors lose the ability to respond to 
IFN-γ either through mutation or epigenetic silencing of genes encoding the IFN-γ 
receptor signaling components (IFNGR1, IFNGR2, JAK1, JAK2 and STAT1) (103). In 
this case, the affected tumor cells not only fail to upregulate MHC class I proteins but 
also are unable to produce the intracellular machinery that facilitate antigen processing 
and presentation (i.e., TAP1, TAP2 and components of the immunoproteasome). In 
addition, genomic instability within tumor cells may result in the loss of tumor-specific 
antigens creating antigen loss variants that are no longer detectable by antigen-specific 
CD8+ T cells. Similarly, tumors can become unrecognizable to cells of the innate immune 
system through loss of ligands for the NK cell effector molecule, NKG2D (104), or 
suppressing the production of proinflammatory danger signals to impair dendritic cell 
maturation (105). Thus, tumors cells may avoid recognition by adaptive or innate 
immune cells by multiple mechanisms.   
 Additionally, tumor cells that are unable to avoid immune cell detection may 
develop mechanisms to evade immune-mediated killing. Even when antigens continue to 
be expressed, tumors can evade effector lymphocytes by upregulating expression of anti-
apoptotic molecules such as FLIP and BCL-XL (106, 107). Alternatively, resistance to 
lysis by immune cells can be acquired through expression by tumors of mutated inactive 
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forms of death receptors including the TRAIL receptor, DR5 (108), and Fas (109). 
 The above strategies of immune escape can be viewed as passive, involving the loss 
of recognition or reduced sensitivity to apoptosis. However, tumor cells can take a more 
active and direct role in subduing immunity through expression of immune-inhibitory 
ligands on their surface that inhibit the cytotoxic actions of immune cells after tumor cell 
recognition in a cell-contact mediated manner. The expression of B7-H1 (PD-L1) (110), 
HLA-G (111), and HLA-E (112) on the cell surface of tumor cells interacts with 
receptors on the cell surface of T cells to dampen the cytotoxic actions of T cells or 
induce apoptosis within the T cell itself. In addition, tumor cell expression of HLA-E or 
HLA-G can modify the actions of innate immune cells by inducing tolerance in antigen-
presenting cells and inhibiting NK cell-mediated killing (111). The actions of tumor cells 
to impede the development of antitumor immune responses is not limited to changes that 
occur directly at the level of the tumor, but also result from the elaboration of cytokines 
and molecules that act at a distance to generate an extensive immunosuppressive network 
that facilitates tumor progression. 
 
Generating an Immunosuppressive Tumor Microenvironment 
 The development of an immunosuppressive environment concomitantly with tumor 
development is evidenced by observations in which protective responses against 
transplantable tumors can be generated when immunotherapies are delivered prior to 
tumor challenge, but fail against established tumors (113). Importantly, failure of therapy 
against established tumors seems to be due to local immunosuppression in the tumor 
microenvironment since tumor-bearing mice can often respond normally to other antigens 
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(114). The development of an immunosuppressive state is achieved by tumor cells that 
inhibit the function of effector immune cells or recruit the efforts of regulatory immune 
cells to evade immunological elimination in a paracrine or endocrine manner. 
 Tumor cells secrete factors to directly inhibit the function of sentinel immune cells 
of both the innate and adaptive arms of immunity. For example, tumor cells can block T 
cell and NK cell function through secretion of soluble forms of ligands for effector 
molecules, as has been reported for shed ligands of NKG2D (115).  In addition, antitumor 
immunity can be subverted at an early stage by tumor-derived factors that inhibit 
dendritic cell (DC) function. In response to danger signals and cellular stress, DCs are 
stimulated to mature, migrate, and carry tumor antigens to lymph nodes to alert the 
adaptive arm of immunity to the presence of transformed cells. To inhibit this initial 
immune priming event, tumor cells secrete sterol metabolites to suppress the expression 
of CCR7 on the cell surface of DCs, thereby disrupting DC migration to the lymph nodes 
(116). A recent study demonstrates that unknown tumor-derived factors induce the 
expression of scavenger receptor A on DCs, resulting in excessive uptake of extracellular 
lipids that reduces their capacity to process antigens (117). Furthermore, many tumors 
produce VEGF, which is critical for the establishment of one of the hallmarks of cancer 
development, angiogenesis, but also prevents endogenous DC function. Targeted 
monoclonal antibodies against VEGF improve DC function in vivo and improve the 
efficacy of cancer immunotherapies (118). 
 Simultaneous inhibition of multiple stages in the development of antitumor 
immunity can be achieved through the liberation of immunosuppressive cytokines by 
tumor cells. For example, TGF-β secretion by tumor cells leads to inhibition of DC 
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activation as well as direct inhibition of T cell and NK cell function (119). Similarly, IL-
10 present within tumors can suppress DC function and skew T cell responses toward a 
type 2 immune response that is less effective against malignant cells (120). However, the 
role of IL-10 in tumor immunity remains somewhat obscure because it has also been 
shown to enhance immune destruction of tumors (121). 
 Other tumor-derived factors can be more selective in inhibiting particular 
components of immune responses but can still effectively suppress immunity. For 
example, production of galectin can impede T cell activity and survival, and blocking this 
factor can aid tumor rejection in mice (122). In addition to using cytokines and lectins to 
down-regulate immune responses, tumors can secrete enzymes that metabolize amino 
acids within the tumor microenvironment. Specifically, expression of indoleamine 2,3-
dioxygenase (IDO) by tumor cells metabolizes tryptophan to generate kynurenines and 
inhibits CD8+ T cell proliferation and promotes CD4+ T cell apoptosis (123). Two 
potential mechanisms of immune inhibition include starvation, where depletion of this 
important amino acid weakens T cells, and metabolite cytotoxicity, where metabolic 
products of tryptophan degradation inhibit T cell function (124). 
 In addition to the mechanism described above, a variety of immunosuppressive 
regulatory leukocytes can suppress immune function leading to tumor escape. Regulatory 
T cells (Tregs), largely expressing CD4, CD25 and Foxp3 and have been demonstrated to 
inhibit CTL function in a number of ways including IL-10 and TGF-β production, 
CTLA-4 and PD-L1 expression and IL-2 consumption (125). This regulatory lymphocyte 
is the critical mediator of peripheral tolerance under physiological settings, but is often 
recruited to the tumor site where it suppresses antitumor immunity. Furthermore, TGF-β 
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production by tumor cells can induce effector T cells into regulatory T cells that now 
suppress other effector T cells infiltrating the tumor mass (126). Experimental tumor 
models that eliminate regulatory T cells, results in robust antitumor immune responses 
and the rejection of transplanted or primary tumors (127). In addition to Tregs, other 
regulatory lymphocyte populations can be found in subsets of natural killer T cells and B 
cells that inhibit effector responses against transformed cells (128, 129). 
 The production and elaboration of GM-CSF, IL-1β, VEGF, and PGE2 by tumors 
leads to expansion of myeloid-derived suppressor cells (MDSCs) and their accumulation 
within the tumor mass (130). MDSCs are a heterogeneous group of myeloid progenitor 
cells and immature myeloid cells that can inhibit lymphocyte function by a number of 
mechanisms including the production of immunosuppressive cytokines (TGF-β) (131), 
the depletion or sequestration of amino acids arginine or cysteine that are required for T 
cell function (132), the inhibition of T cell activation by TCR nitrosylation (133) and the 
induction of regulatory T cells (134).  The multiplicity of mechanisms that inhibit 
lymphocytes in either an antigen-specific or antigen-nonspecific manner most likely 
reflects distinct cellular subsets within the MDSC heterogeneous population (135).  
 In addition to MDSCs, plasmacytoid dendritic cells (pDCs) are recruited to the 
tumor mass and become key players in the immunosuppressive network.  Ovarian cancer 
cell products activate pDCs, which in turn, induce the expansion of IL-10 producing 
CD8+ regulatory T cells (136).  A potentially novel subset of DCs, sometimes referred to 
as vascular leukocyte cells (VLCs) or Tie2+ monocytes, is recruited to the tumor bed by 
β-defensins and induce their endothelial-like specialization, where they in enhance 
vasculogenesis and suppress conventional DC function through the secretion of VEGF 
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and other pro-inflammatory cytokines (137).  A recent study by Shields et al. identified 
lymphoid tissue inducer (LTi) cells that are recruited by CCL21-secreting melanomas 
and contribute to the development of an immunosuppressive tertiary lymphoid structure 
within the tumor mass that recruits MDSCs, regulatory T cells, and polarizes monocytes 
to M2 macrophages (138).  Many tumors attract tumor-associated macrophages (TAMs) 
by IL-4 and IL-13. M2 macrophages can inhibit antitumor immunity through the 
production of TGF-β and IL-10, and can promote stromal development and angiogenesis 
through secretion of platelet-derived growth factor (PDGF) (139). 
 Together, these examples demonstrate that, in addition to central and peripheral 
tolerance, failure of antitumor immunity can be due to the development of an 
immunosuppressive microenvironment. Any one, or combination of several, of the above 
cellular and molecular mechanisms can contribute to suppression of tumor immunity. The 
balance between these inhibitory mechanisms and immune stimulating conditions 
determines whether or not tumors escape immune responses and the rate of tumor 
progression. In human cancer patients, immunosuppression of lymphocytes within the 
tumor microenvironment has also been widely observed for a variety of cancer types 
(140).  In the next section we will discuss the evidence for cancer immunoediting in 
humans, with particular emphasis on the elimination and equilibrium phases. 
 
EVIDENCE FOR CANCER IMMUNOEDITING IN HUMANS 
 
The extensive studies discussed above clearly demonstrate that the immune 
system not only protects against tumor development, but also shapes tumor 
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immunogenicity in mouse models of cancer. The question therefore naturally arises 
whether cancer immunoediting occurs in humans. Humans are not clean models of 
immune deficiency such as those that exist in experimental mice that live in controlled 
environments. Nevertheless, compelling clinical data support the existence of cancer 
immunoediting in humans. Here, we will not discuss the mechanisms of tumor escape in 
humans since they greatly overlap with those observed in mice (discussed above) and 
have been extensively reviewed elsewhere (8, 9, 26, 27, 29, 97), but rather we will review 
data supporting an active immune response eliminating or controlling cancer in humans. 
 
Acquired Immunodeficiency and Cancer Risk  
While severely immunodeficient humans succumb to infections relatively early, 
advances in the management of acquired immunodeficiencies have led to extended 
survival of patients with partly compromised immune systems. Evidence for 
immunosurveillance can be found in patients with AIDS who have an increased 
frequency of malignancies (141). Most often, these malignancies are virus-associated and 
initiated by viral oncogenes, including lymphomas (Epstein-Barr virus), Kaposi’s 
sarcoma (herpesviruses) and urogenital cancers such as cervical cancer (human papilloma 
viruses) (142). While the antigenic targets of the above malignancies are not fully 
characterized, viral antigens can certainly be expressed, and an argument can be made 
that the increased frequency of virus-associated cancers reflects a breakdown in anti-viral 
immunity rather than reduced immunosurveillance of cancer. However, support for 
immunosurveillance can be found in malignancies of non-viral origin. 
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The incidence of non-virally-induced tumors in AIDS patients is less well 
documented, but, there is evidence of an increased incidence of solid cancers in AIDS 
patients, particularly lung adenocarcinomas (143). While a large proportion of HIV-
infected individuals may be exposed to other lifestyle risk factors, including smoking, the 
association of lung cancer in AIDS patients has been demonstrated to be independent of 
smoking (144), with a 3.5-fold elevated risk of lung cancer for AIDS patients compared 
to the wider population. 
 
Immunosuppressed Organ Transplant Recipients and Cancer Risk 
Some level of immunodeficiency can be induced in humans by the use of 
immunosuppressants following organ transplantation, and an increase in the incidence of 
malignancies in these patients suggests a role for immunosurveillance in humans. Greater 
cancer prevalence among transplant recipients has been observed in a range of transplant 
situations using a variety of immunosuppressants. For example, patients receiving kidney 
transplants display a 3-fold increase over the general population in the overall incidence 
of malignancy. While virus-associated malignancies predominate, there was also an 
increased risk for developing non-infectious cancers of the colon, lung, pancreas, kidney 
and endocrine system (145). Additionally, a dramatic increase in risk (200-fold) of non-
melanoma skin cancers has been demonstrated in renal transplant patients, suggesting a 
particularly important role for cancer immunosurveillance at this site exposed to 
ultraviolet irradiation (146). Finally, melanomas have also been observed to increase in 
frequency in these renal transplant patients, but to a lesser degree (2-10 fold) than other 
skin cancers (146, 147).  
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Interestingly, incidences of some cancers including breast, prostate, ovarian, brain 
and testicular have not been observed to increase in the context of pharmacologically-
induced immunosuppression, but it is not clear if these malignancies are less 
immunogenic or simply take longer to develop. These data support the notion that de 
novo malignancies arise due to the permissive environment created by 
immunosuppressive regimens, which inhibit cancer immunosurveillance mechanisms. 
Further supporting the link between immunosuppression and malignancy are 
observations of spontaneous remissions of lymphomas after cessation of 
immunosuppression (148).  
 
Spontaneous Immune Responses to Cancer 
The spontaneous recognition and destruction of human cancers by cells of the 
adaptive immune system substantiates the occurrence of cancer immunosurveillance in 
humans. As early as the 1970s, screening cancer cell lines with autologous patient serum 
identified spontaneous antibody responses to autologous cancers in a subset of patients 
(149, 150). Antibody responses in patient serum have been reported for over 100 tumor-
associated antigens, although only 8 antigens have been identified in multiple reports 
suggesting that many immunogenic mutations might be unique for each individual cancer 
(reviewed in (151)). Among the shared antibody responses were those against the cancer-
testis antigen NY-ESO-1 and the mutant forms of tumor suppressor p53, which are often 
overexpressed in many different types of human malignancies (152, 153). The high 
frequency of antibodies specific for tumor-associated antigens in cancer patients 
compared to healthy individuals suggests that immunity has been induced in response to 
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malignancy.  The reasons for spontaneous antibody responses in cancer patients are not 
known, but may include an over-abundance of antigen or its enhanced presentation to 
generate immunogenicity in the malignant setting.  
 The phenomenon of spontaneously regressing melanoma lesions accompanied by 
the clonal expansion of T cells is arguably the strongest evidence for the elimination 
phase of cancer immunoediting in humans	  (154-156). These responses, observed in the 
absence of specific immunotherapy, support the ability of the immune system to 
spontaneously recognize antigens on/in tumors. Specific CD4+ and CD8+ T cell activity 
against tumor-associated antigens, including NY-ESO-1, are known to develop 
spontaneously in human cancer patients (157, 158). However, spontaneous T cell 
responses specific for some tumor-associated antigens (TAA) such as the MAGE family 
are very rare (159), while those specific for the melanocyte differentiation antigen 
MART-1/Melan-A have been found in a relatively high percentage (>50%) of healthy 
individuals (160). Thus, there is a strong correlation between spontaneous T cell 
responses and some tumor-associated antigens but not others, and it is not clear whether 
the presence of TAA-specific T cells in healthy individuals reflects past exposure to 
transformed cells expressing the antigen. More studies are needed to identify tumor-
associated and tumor-specific antigens in a variety of cancers to determine the relative 
abundance and uniqueness of tumor antigens. 
 Other spontaneous immune responses against malignant cells have been 
demonstrated in patients with paraneoplastic autoimmune disorders (PND) caused by 
cross-reactivity between the antitumor immune response and neurologic antigens (161). 
In addition to antibody responses, tumor-specific T cells have also been identified in 
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patients with PND (162). Nearly all patients with PND die from cancer or neurologic 
disease; however, the few surviving patients have complete tumor remission in response 
to therapy and no longer manifest any neurological impairment.  These dramatic clinical 
cases demonstrate that the tumor antigens are the driver of both beneficial immune 
responses against neoplastic tissues and pathological immune responses against normal 
tissues (i.e., neurons). Interestingly, PND symptoms can precede tumor diagnosis by a 
number of years (163), indicating that antitumor responses might be primed by 
undetectable, microscopic tumors early in their evolution. It remains to be determined 
whether the antitumor immune response substantially delays tumor growth in patients 
with PND and such analysis is likely to be confounded by the lethality of the neurologic 
complications. Nevertheless, the presence of anti-neuronal antibodies has been reported 
to correlate with improved prognosis at least for some neurological malignancies (164), 
and there are some case reports of spontaneous complete remission in the absence of 
specific treatment (165). Spontaneous tumor regression accompanied by lymphocyte 
infiltration has also been noted for a number of other tumor types (reviewed in (30)) 
however, the role of the lymphocyte infiltrate in tumor regression has not been 
established in these cases due to their rarity.  Even in the absence of spontaneous tumor 
regression, tumor-infiltrating lymphocytes (TILs) appear to be controlling tumor 
outgrowth and enhancing patient survival, as discussed below. 
 
Tumor-Infiltrating Lymphocytes as a Prognostic Indicator  
 Further support for cancer immunoediting can be found in reports that correlate the 
frequency of tumor-infiltrating lymphocytes (TILs) with patient survival. Tumor 
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infiltration by T cells, NK cells, or NKT cells have been associated with an improved 
prognosis for a number of different tumor types (91, 166-172). However, tumor 
infiltration by some leukocytes, such as macrophages and regulatory T cells, has a 
detrimental impact on patient survival (173).  The initial association between favorable 
patient prognosis and TILs was first observed in patients with melanoma (166, 167), 
where it was reported that patients with high levels of CD8+ T cell infiltration survive 
longer than those whose tumors contain low numbers of lymphocytes.  Since then, 
various melanoma-specific antigens have been identified in addition to melanoma-
specific T cells in patients with melanoma (reviewed in (174)).  
 In a landmark study in ovarian cancer, the presence of TILs in ovarian cancer tissue 
specimens correlated with better prognosis. Specifically, 38% of patients with high 
numbers of TILs survived over 5 years as compared to 4.5% of patients with low 
numbers of TILs (168). These findings have been confirmed in subsequent studies for 
ovarian cancer (169) and for other malignancies including melanoma (175) and colon 
cancer (170-172). Particularly elegant studies on colon and lung cancers reveal a tight 
correlation between the quality and quantity of intratumor immune responses and patient 
survival (171, 172). Remarkably, the type and density of lymphocytes infiltrating these 
cancers was a more powerful prognostic indicator than previous pathological criteria for 
tumor staging, underscoring the need for clinical pathologists to consider infiltrating 
immune cells when determining a patient’s prognosis. In fact, the results of these studies 
provide strong evidence for the equilibrium phase of cancer immunoediting in humans. 
Enhanced survival of some cancer patients is associated with particular subsets of T cells 
such as the intratumor localization of CD8+ T cells and Tregs (91, 169, 170). A 
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particularly interesting disagreement concerns the significance of Tregs in tumors, where 
some groups find a correlation between the presence of Foxp3+ Tregs in tumors with a 
poor prognosis (176, 177), while other studies report better prognosis if Tregs are present 
in tumor tissue samples (178, 179). Reasons for these different outcomes are not clear, 
but may be related to the type of malignancy involved.  
 
Immunogenicity of Cancers with Microsatellite Instability  
 All cancers are inherently genetically unstable and this instability seems to be a 
contributing factor in the capacity of immune cells to detect and control tumor cells. For 
example, the infiltration of colorectal cancer by CD8+ T cells is associated with a 
favorable prognosis (170-172), as discussed above, and this association is further 
strengthened in cases where tumors exhibit high levels of a particular type of genetic 
instability referred to as microsatellite instability (MSI), where defects in DNA mismatch 
repair mechanisms lead to the duplication or deletion of short repeated sequences of 
DNA known as microsatellites (180, 181). Strikingly, MSI-high (MSI-H) tumors are 
often strongly infiltrated with lymphocytes, including activated CD8+ T cells (181), and 
contain tertiary-lymphoid follicles (180) indicative of a potent local immune response. 
The high rate of mutation in MSI-H tumors has been shown to result in the generation of 
a number of novel tumor antigens that can be recognized by B cells, CD4+ T cells, and 
CD8+ T cells. Together, these findings suggest that the generation of antigenic peptides 
as a result of genomic instability might result in the priming of a protective CD8+ T cell–
mediated immune response in patients with MSI-H colorectal cancers. An interesting 
possibility is that these findings are not unique to colorectal cancers, but apply to other 
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human cancers as well (182).  
 
Cancer Equilibrium in Human Patients 
A plethora of clinical evidence suggests that occult cancers can lay dormant in 
patients for many years, sometimes exceeding 20 years, before malignant disease 
progresses to clinically detectable levels (183).  For example, 20-45% of patients with 
breast or prostate cancer will relapse years or even decades later (184-186). Such a 
lengthy and protracted period from initial cancer remission to cancer recurrence may, in 
part, be explained by immunological constraints placed on the remaining cancer cells. In 
some cases, circulating disseminated cancer cells exist for decades after treatment 
without the re-establishment of clinical disease from these persistent cancer cells (187).  
This is known as minimal residual disease and it appears to be a common reservoir of 
cancer cells for most cancer types after the initial therapeutic intervention, but whose 
mechanisms for maintenance are poorly understood.  Minimal residual disease is of 
critical importance since the vast majority of morbidity and mortality associated with 
cancer is due to metastatic lesions that are presumed to be seeded by these persistent 
cancer cells. There is evidence that immunosuppressive intervention for various 
conditions can be associated with a greatly increased risk of cancer relapse even after 
long periods of time. In one study, three out of eight patients (37%) experienced cancer 
relapse following immunosuppression after more than 10 years of remission while cancer 
patients in remission for 10 years or more that had not undergone immunosuppressive 
treatment had only a 2% relapse rate (183).  
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One remarkable clinical scenario that suggests immunity can prevent the 
outgrowth of occult lesions is the unintentional transplantation of cancer cells from organ 
donor to immunosuppressed recipient.  In these scenarios, organs were harvested from 
deceased donors, who either had no previous clinical history of malignancy or were in 
cancer remission and had no overt signs of disease at the time of organ donation and 
transplantation into recipients.  The recipient patients undergoing immunosuppression for 
organ engraftment later developed clinically detectable cancers of donor origin (188, 
189). A subset of these donor-derived malignancies were from donors with no previous 
history of cancer, suggesting a state of equilibrium operating between cancer cells in the 
primary lesion and the donor’s immune system that subsequently broke down after 
transplantation into immunosuppressed recipients.  
Clinicians have long-observed that the immune system mounts a response against 
pre-neoplastic cells in monoclonal gammopathy of unknown significance (MGUS) but 
does not eliminate them, eventually allowing MGUS to progress to multiple myeloma 
(190). The ability to detect this premalignant phase of disease allows for immunologic 
monitoring throughout disease progression	  and such monitoring has revealed that T cells 
derived from the bone marrow of patients with MGUS mount strong responses to 
autologous premalignant cells, but these responses are absent in patients with multiple 
myeloma (191). These findings are consistent with the idea that T cells may hold pre-
malignant cells in check for an extended period of time (i.e., equilibrium) but eventually 
fail to control some abnormal plasma cell clones that ultimately give rise to multiple 
myeloma (i.e., escape). Additionally, treatment of low-grade B cell lymphoma by 
administering antibodies specific for the idiotype expressed by the malignant cells results 
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in remission of disease without entirely eliminating the tumor cells and that these 
circulating lymphoma cells are detected up to 8 years after treatment without any other 
signs of progressive disease (192). These results suggest that equilibrium may be a viable 
therapeutic endpoint for the treatment of cancer, and in such a case, interventions may be 
necessary to stabilize the equilibrium phase indefinitely and prevent the immunoselection 
of tumor cell variants possessing novel mutations that eventuate in resistance to immune 
attack.   
 
Summary of Human Cancer Immunoediting 
As discussed above, there is considerable clinical evidence for the cancer 
immunoediting process in humans even though cancer patients are a genetically and 
immunologically diverse population. The confluence of these very complex factors may 
explain why spontaneous immune responses occur in only a proportion of individuals and 
why some patients respond better to certain immunotherapies. The differences in an 
individual’s immune repertoire, the capacity to process and present antigens, the quality 
and quantity of tumor antigens generated as well as the ability of cancer to suppress 
antitumor immunity all help to determine the overall outcome. Future advances in gene 
expression and proteomics of human cancers and their antigens will provide greater 
insight into the mechanism of cancer immunoediting in humans, which may be critical in 
determining which patients benefit from particular treatments. 
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CANCER-RELATED INFLAMMATION AND CANCER IMMUNOEDITING: 
INTERDEPENDENT PROCESSES  
 
Inflammation is a broad and complex physiological process that maintains tissue 
homeostasis in response to tissue stressors such as infection or tissue damage (193). 
Rudolph Virchow, who established the cellular basis of pathology, was the first to 
propose the link between inflammation and cancer in the 1860s when he observed 
leukocytes infiltrating neoplastic tissues (194). We now appreciate that chronic 
inflammation can contribute to cancer initiation by generating genotoxic stress, cancer 
promotion by inducing cellular proliferation, and cancer progression by enhancing 
angiogenesis and tissue invasion. On the other hand, there is overwhelming evidence that 
immunity against transformed cells can develop to protect the host from cancer formation 
as discussed above. Each of the six cell-intrinsic hallmarks of cancer can influence the 
immune system (9) and the cancer immunoediting process attempts to describe the varied 
outcomes of tumor-immune system interactions including immunosurveillance (anti-
tumor), immunoselection (pro-tumor) and immunosubversion (pro-tumor). We maintain 
that cancer immunoediting and tumor-promoting inflammation are not mutually 
exclusive processes, but rather potentially overlapping immune algorithms (195).   
 This overlap was most clearly demonstrated in the MCA model where sarcoma 
induction was shown to depend on immune cells and molecules that promote 
inflammation including MyD88, IL-1β, IL-10, IL-23 and regulatory T cells (42, 67, 127, 
196, 197), but then led to the development of host-protective immune responses that 
resulted in tumor destruction (e.g., IFN-γ, IFN-α/β, T cells, etc.). For example, the 
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functionally related heterodimeric cytokines, IL-23 and IL-12, both contain the IL-12p40 
subunit but activate distinct receptors that share the IL-12Rβ1 subunit and play different 
roles in response to transformed cells. Specifically, loss of IL-23 reduced the incidence of 
MCA-induced sarcomas, while IL-12-deficient mice developed more sarcomas when 
compared to WT mice (67). 
 Similarly, the DMBA/TPA model of skin carcinogenesis is known to have a major 
inflammatory component contributing to tumor development, however, γδ T cells, IL-12 
and DNAM-1 all participate in immunosurveillance and prevent skin carcinoma 
formation (23, 46, 66). Therefore, tumor-promoting inflammation and cancer 
immunosurveillance can co-exist within the same tumor models at the same tissue site, 
although they may be temporally distinct. For example, both MyD88 and IL-1β have 
been shown to promote tumorigenesis in a number of primary carcinogen models (42, 
196, 198, 199), but MyD88 and IL-1β are also critical in the development of antitumor 
immunity against established tumors through the recognition of dying tumor cells 
undergoing ‘immunological death’ (200-202). Furthermore, the same component of the 
immune system may promote or prevent tumor formation depending on the biological 
context in which it acts. For example, mice genetically-deficient for TNF-α develop more 
sarcomas than WT mice after exposure to MCA (42), indicating a host-protective role for 
this cytokine, while TNF-α-deficient mice develop fewer skin carcinomas than wild-type 
mice after exposure to DMBA/TPA (58), indicating a tumor-promoting role for TNF-α. 
One mechanism for TNF-α’s ability to protect the host against tumor formation is the 
priming, proliferation, and recruitment of tumor-specific T cells that was observed in an 
oncogene-driven pancreatic cancer model (203). 
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 Finally, inflammation participates in the cancer immunoediting process during the 
tumor escape phase, where inflammatory cells and regulatory immune cells are recruited 
and activated by cancer-derived products to dampen antitumor immunity and subvert 
immune cells to promote cancer progression. To develop more effective 
immunotherapies, immunologists must identify the cellular and molecular players that 
either eliminate or promote cancer development and what conditions influence that fate. 
For this reason, inhibitors of the pro-inflammatory transcription factors NF-κB and 
STAT3 may be therapeutically useful in switching the nature of the tumor 
microenvironment from one of tumor-promoting inflammation to that of tumor-
eliminating immunity (204, 205).   
 
LESSONS FROM CANCER IMMUNOEDITING 
 
As our molecular understanding of cancer immunoediting increases, strategies can 
be developed to harness the power of immunity to protect against cancer development. 
Targets for therapeutic intervention can be found at each stage of the immunoediting 
process from elimination to equilibrium to escape. The identification of key immune 
molecules and cells important in the elimination of nascent transformed cells may 
provide opportunities to boost specific aspects of immunity to induce tumor regression.  
Furthermore, development of therapeutic strategies that stabilize tumor masses by 
inducing an equilibrium state is a viable clinical endpoint that has not been fully 
implemented by oncologists, but could greatly enhance patient survival.  Another 
potential strategy targeting the equilibrium phase are those that attempt to stabilize tumor 
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cell genetic instability, thereby halting progression from tumor equilibrium to tumor 
escape. The inhibition of tumor escape mechanisms may render tumor cells visible for 
immune-mediated destruction and thus many pharmacological agents have been 
generated for this end.  
Targets of tumor escape mechanisms currently in clinical trials or in the pipeline 
include antibody blockade of the immunosuppressive moieties CTLA-4, PD-L1, and PD-
1. In the case of CTLA-4 blockade, a recent Phase 3 clinical trial reported that patients 
with metastatic melanoma survived longer after treatment with CTLA-4 blocking 
antibodies, making this drug one of the most successful immunotherapies that targets the 
immune system (206). Furthermore, strategies to inhibit immunosuppressive cytokines 
such as VEGF, enzymes such as IDO and anti-apoptotic molecules such as Bcl-2 are also 
being pursued. Undoubtedly, chronic inflammation contributes to both cellular 
transformation and tumor progression, but less is known about what aspects specifically 
induce cancer formation. Inhibitors of pro-inflammatory transcription factors may reduce 
tumor development and switch the tumor microenvironment from tumor-promoting 
inflammation to tumor-eliminating immunity. 
Ultimately, high-throughput screening of cancer genomes and proteomes are 
required to identify polymorphisms and mutations in immune pathways that limit human 
cancer development and progression. Insights gained from deciphering the molecular 
underpinnings of the cancer immunoediting process could lead to strategies for 
manipulating the cellular and molecular microenvironment of tumors in the hope of 
inducing immune-mediated eradication or stabilization of malignant disease.   
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CHAPTER 2 
 
Global Neutralization of IFN-γ  Confirms its 
Role in Preventing Primary Tumors and 
Shaping Tumor Immunogenicity 
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INTRODUCTION 
 
IFN-γ  in Tumor Immunity 
IFN-γ Protects the Host from Transplantable and Primary Tumors 
 Over a decade ago, renewed interest in cancer immunosurveillance came from 
several studies that revealed a critically important role for IFN-γ in host tumor immunity.  
The first was the demonstration that endogenously produced IFN-γ protected the host 
against the growth of transplanted tumors and the formation of primary chemically 
induced and spontaneous tumors. Using tumor transplantation approaches, the LPS-
dependent rejection of the MethA fibrosarcoma was abrogated in mice treated with 
neutralizing antibodies specific for IFN-γ (clone H22) (15).  Second, using models of 
MCA-induced tumor formation, 129/SvEv mice lacking either the IFN-γ receptor or 
STAT1 were found the be approximately 10-20 times more sensitive than wild type mice 
to tumor formation after carcinogen exposure.  Specifically, IFN-γ insensitive mice 
developed more tumors than their wild type counterparts and showed a shortened tumor 
latency period (16). These results were confirmed by subsequent independent 
experiments using mice on a different genetic background that lacked the gene encoding 
IFN-γ itself (40). Similarly, mice lacking both the p53 tumor suppressor gene and 
IFNGR1 formed a wider spectrum of tumors compared to IFN-γ-sensitive mice lacking 
only p53 (16). In addition, Ifng-/- mice on a C57BL/6 background showed an increased 
incidence of disseminated lymphomas despite the presence of a normal p53 tumor 
suppressor gene (22). Taken together, data from transplantation approaches as well as 
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chemical and spontaneous tumor induction studies clearly demonstrate a physiologically 
important role for IFN-γ in host-protection against tumors. 
 
IFN-γ Acts Directly on Tumor Cells to Exert its Antitumor Effects 
 The demonstration that endogenous IFN-γ is critical to protect the host from both 
transplantable and primary tumors prompted a search for the physiologically important 
targets of the antitumor actions of IFN-γ. Due to fact that nearly every host cell expresses 
the IFN-γ receptor and that IFN-γ is very pleiotropic, there are many likely cellular 
targets in vivo that are important for the direct actions of IFN-γ in the tumor rejection 
process. A recently published study from our lab used bone-marrow chimera approaches 
to demonstrate that IFN-γ sensitivity in both non-hematopoietic and hematopoietic host 
tissues are contributing to the antitumor response of IFN-γ (25). A fellow graduate 
student in lab, Sang-hun Lee, has recently generated a conditional floxed IFNGR1 mouse 
to address which hematopoietic and non-hematopoietic cells of the host are targets of 
IFN-γ’s antitumor effects.  Future studies using this mouse will elucidate which host cells 
require IFN-γ sensitivity to mediate tumor rejection, but there is also evidence that IFN-γ 
acts directly on tumor cells to exert its antitumor effects.  In one study, MethA tumor 
cells described above were engineered to be unresponsive to IFN-γ by overexpression in 
these cells of a mutant dominant-negative IFNGR1 (IFNGR1ΔIC) (15). The paralysis of 
cellular IFN-γ responsiveness abrogated the LPS-dependent rejection of MethA when 
transplanted into syngeneic wild type mice.  In a second study, an opposite approach was 
employed using a tumor generated in an Ifngr1-/- mouse. When transplanted into wild 
type mice, the Ifngr1-/--derived tumor, RAD.gR28, grew progressively.  However, the 
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reconstitution of IFNGR1 expression in this tumor resulted in its rejection upon 
transplantation into syngeneic immunocompetent mice (16). These results have 
subsequently been corroborated by the observed increases in tumorigenicities of the SCK 
mammary adenocarcinoma and K1735 melanoma when both tumors were significantly 
impaired in their IFN-γ responsiveness using the dominant-negative IFNGR1ΔIC (207).  
Taken together, these data from different tumor systems show that IFN-γ acts directly on 
tumor cells to exert its antitumor effects. 
Although there is a plethora of data demonstrating that IFN-γ is critical to mediate 
protection against primary and transplantable tumors, there is less direct evidence of IFN-
γ as an immunoeditor.  In this study, we globally neutralize IFN-γ in wild type mice with 
an anti-IFN-γ mAb (clone H22) and treat these mice with the chemical carcinogen, MCA, 
to generate sarcomas that developed in the absence of IFN-γ, but retain sensitivity to IFN-
γ (as opposed to tumors generated in Ifngr1-/- mice).  A subset of these sarcomas are 
rejected in wild type mice and thus are highly immunogenic tumors that resemble 
unedited tumors derived from Rag2-/- mice (19). These results provide definitive evidence 
that IFN-γ edits primary MCA sarcomas.  
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MATERIALS AND METHODS 
 
Mice.  Ifngr1-/- mice (208) on a 129/Sv background were originally provided by Dr. 
Michel Aguet and were bred in our specific pathogen-free animal facility. Wild type and 
Rag2-/- mice were purchased from Taconic Farms. All mice were on a C57BL/6 
background and were housed in our specific pathogen-free animal facility.   For all 
experiments, mice were 8-12 weeks of age and performed in accordance with procedures 
approved by the AAALAC accredited Animal Studies Committee of Washington 
University in St. Louis. 
 
Generating primary MCA sarcomas. 3-methylcholanthrene (MCA) (Sigma) was 
dissolved in corn oil at a concentration of 0.66 µg/ml by placing a polystyrene container 
in a water bath that is just below boiling temperature for 3-4 hrs.  Stock MCA was then 
diluted with additional corn oil to desired concentration and injected into the shaved 
flanks of mice in a volume of 150 µl as previously described (16). 
 
Tumor cell lines.  3-methylcholanthrene (MCA) induced sarcomas used in this study 
were generated in C57BL/6 strain wild type or Rag2-/- mice and banked as low passage 
tumor cells as previously described (19).  Tumor cells derived from frozen stocks were 
propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% FCS 
(Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the flanks of 
recipient mice.  Tumor cells were >90% viable at the time of injection as assessed by 
trypan blue exclusion and tumor size was quantified as the average of two perpendicular 
diameters. 
	  	  	   52 
Antibodies.  Anti-IFN-γ (H22), anti-CD4 (GK1.5), anti-CD8α (YTS169.4) mAbs and 
control immunoglobulin (PIP, a mAb specific for bacterial glutathione S-transferase) 
were produced from hybridoma supernatants and purified in endotoxin-free form by 
Protein G affinity chromatography (Leinco Technologies, St. Louis, MO).  IFNGR1-PE, 
H-2Db-PE, H-2Kb-PE and purified anti-CD16/32 were purchased from BioLegend (San 
Diego, CA).  
 
Expression vectors. The dominant negative version of the IFNGR1 subunit 
(IFNGR1ΔIC) was expressed into H31m1 and d42m1 tumor cells as previously described 
(15). 
 
Measurement of MHC class I expression. Tumor cells were treated with 100U/ml IFN-
γ for 48-72 hrs. MHC class I expression on the cell surface was analyzed by flow 
cytometry using H-2Kb or H-2Db antibodies conjugated to PE. 
 
Flow cytometry.  For flow cytometry, cells were stained for 20 minutes at 4°C with 500 
ng of Fc block (anti-CD16/32) and 200 ng of H-2Kb, H-2Db, or IFNGR1 in 100 µL of 
staining buffer (PBS with 1% FCS and 0.05% NaN3 (Sigma)).  Propidium iodide (PI) 
(Sigma) was added at 1 µg/mL immediately before FACS analysis. Events were collected 
on a FACSCalibur (BD Biosciences) and analyzed using FloJo software.  
 
Statistical Analysis.  Samples were compared using an unpaired, two-tailed Student’s t 
test and Mantel-Cox for tumor incidence.   
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RESULTS 
 
Global Neutralization of IFN-γ  Prevents Primary MCA Sarcoma Formation  
Using IFN-γ neutralizing antibodies (H22), we sought to corroborate the finding 
that mice lacking IFN-γ are more susceptible to MCA-sarcoma induction.  A key 
distinction from the previous studies that used gene-targeted mice lacking either IFN-γ 
responsiveness (Ifngr1-/-) or IFN-γ itself  (Ifng-/-) is that tumors generated in anti-IFN-γ 
mAb treated mice will be of wild type origin and have normal IFN-γ sensitivity. Two 
cohorts of 15 female C57BL/6 mice were injected with 25 µg of the MCA chemical 
carcinogen.  One cohort was treated with 750 µg of anti-IFN-γ mAb (H22) on Day -1 and 
then 250 µg of anti-IFN-γ mAb weekly for the duration of the experiment.  The second 
cohort was treated with a similar dosing schedule, but was treated with control 
immunoglobulin (PIP).  When wild type C57BL/6 mice injected with 25 µg of MCA 
were chronically treated with the control Ig, 67% (10/15) of mice developed 
progressively growing sarcomas.  In contrast, wild type C57BL/6 mice chronically 
treated with neutralizing anti-IFN-γ mAbs developed more MCA sarcomas (14/15; 93%) 
with a shorter latency than control mice, confirming that IFN-γ protects the host from 
primary carcinogenesis (Mantel-Cox p=0.0373) (Figure 1). This result verifies that IFN-γ 
is a critical player in the immunosurveillance against primary MCA sarcomas. 
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Figure 1.  Global neutralization of IFN-γ  protects against primary MCA sarcoma 
formation. Two cohorts of 15 C57BL/6 mice were each treated with 25 µg of the 
carcinogen MCA.  One cohort received weekly injections of control antibodies (PIP) 
(black) while the other cohort received weekly injections of neutralizing IFN-γ antibodies 
(H22) (red). Tumor incidence was monitored weekly and compared using Mantel-Cox 
(p=0.0373). 
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Global Neutralization of IFN-γ  Shapes MCA Sarcoma Immunogenicity 
 To test whether IFN-γ edits MCA sarcomas from wild type mice, tumors from 
mice treated with control mAbs or anti-IFN-γ mAbs were harvested, disaggregated, 
collagenase-treated, and cultured to generate tumor cell lines.  All MCA-sarcoma cell 
lines were frozen after four in vitro passages, subsequently thawed and injected into both 
wild type and Rag2-/- recipients.  All of the tumors derived from control Ig treated wild 
type mice grew progressively when transplanted into both wild type and Rag2-/- hosts 
(data not shown). Similarly, all tumors derived from IFN-γ-neutralized mice grew 
progressively when transplanted into Rag2-/- mice (Figure 2).  In contrast, 30% (3/10) of 
cell lines derived from IFN-γ-neutralized mice were spontaneously rejected upon 
transplantation into wild type mice, indicating that these tumors are highly immunogenic 
unedited sarcomas (Figure 2) similar to MCA sarcomas generated in Rag2-/- or Ifnar1-/- 
immunodeficient mice (19, 24). These data suggest that IFN-γ sculpts tumor 
immunogenicity and, to date, is the best evidence that endogenous IFN-γ can alter tumor 
immunogenicity during primary tumor development.  In addition, this is the first 
demonstration that unedited sarcomas can be generated using blocking monoclonal 
antibodies in wild type mice. 
 
Highly Immunogenic Sarcomas that Developed in the Absence of IFN-γ  Require 
CD4+ T cells, CD8+ T cells and IFN-γ  for Their Rejection 
 Three highly immunogenic sarcomas from wild type mice chronically treated with 
neutralizing IFN-γ antibodies are spontaneously rejected when transplanted into wild type 
mice (Figure 2).  We have designated these three tumors (H22-28027, H22-28030, and 
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H22-28032) collectively as H22 regressor tumors since they display an unedited 
phenotype similar to a subset of tumors derived from immunodeficient Rag2-/- mice that 
we have termed Rag2 regressors (19).  The fact that these H22 tumors grow progressively 
in Rag2-/- mice, strongly suggests that lymphocytes are critical mediators of their 
rejection.  We next explored what specific components of adaptive immunity are required 
to reject each of these highly immunogenic H22 regressor tumors.  For the first tumor, 
wild type mice were transplanted with 1x106 H22-28027 tumor cells and subsequently 
treated with antibodies that neutralize IFN-γ (H22), deplete CD4+ T cells (GK1.5) or 
CD8+ T cells (YTS-169.4) and were monitored for tumor growth. The unedited H22-
28027 tumor grows progressively in wild type mice that were treated with antibodies that 
neutralize IFN-γ, deplete CD4+ T cells or CD8+ T cells, suggesting that all of these 
adaptive immune components are required for tumor rejection (Figure 3).  Similar results 
were obtained for the other two H22 regressor tumors H22-28030 and H22-28032 (Figure 
3), suggesting that IFN-γ, CD4+ and CD8+ T cells are required for the rejection of all 
three immunogenic tumors derived from MCA-treated, IFN-γ-neutralized wild type mice.  
The requirement of adaptive immunity to specifically target these highly immunogenic 
sarcomas is identical for the subset of unedited sarcomas derived from Rag2-/- mice, 
providing further evidence that these H22 regressors are unedited due to the blockade of 
IFN-γ signaling in the host. 
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Figure 2. Tumors from IFN-γ-neutralized mice show an unedited phenotype. In a 
panel of 10 MCA sarcomas from wild type mice that were chronically treated with anti-
IFN-γ mAbs (H22), three (30%) tumor cell lines were spontaneously rejected upon 
transplantation into wild type recipients (highlighted in blue). 
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Figure 3. Highly immunogenic sarcomas require components of adaptive immunity 
for their rejection in wild type hosts.  a, All three highly immunogenic H22 regressors, 
H22-28027, H22-28030, and H22-28032 grow progressively when transplanted (1 x 106 
cells) into wild type mice that are treated with mAbs that deplete CD4+ T cells (GK1.5), 
deplete CD8+ T cells (YTS-169.4), or neutralize IFN-γ. b, Percentage of mice with 
progressively growing tumors from 2-3 independent tumor transplantation experiments. 
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Differential Requirements for Tumor Cell and Host Cell IFN-γ  Responsiveness for 
the Rejection of Each Individual H22 Regressor Tumor 
The finding that highly immunogenic H22 regressors grow progressively in wild 
type mice treated with IFN-γ neutralizing antibodies (Figure 3) established that IFN-γ is 
critical for the rejection of these tumors.  However, IFN-γ can exert its antitumor effects 
on both cells of the host and well as the tumor cell itself (15, 16, 25).  To test whether 
IFN-γ responsiveness was required at the level of the host, tumor cells were transplanted 
into Ifngr1-/- recipients.  Both H22-28027 and H22-28030 were mostly rejected upon 
transplantation into mice lacking host IFN-γ responsiveness.  In contrast, H22-28032 
grew progressively when transplanted into Ifngr1-/- mice (Figure 4).  These results 
suggest that H22-28032 requires host IFN-γ sensitivity for its rejection while H22-28027 
and H22-28030 tumors do not require IFN-γ sensitivity at the level of the host alone for 
their rejection.  Given that global neutralization of IFN-γ through the use of anti-IFN-γ 
mAbs results in the growth of all three H22 regressors, but only H22-28032 requires IFN-
γ sensitivity at the level of the host for its rejection, we next addressed whether IFN-γ 
sensitivity at the level of the tumor is required for tumor rejection.   
To generate IFN-γ-insensitive variants of the H22 regressors, each tumor was 
transduced with a dominant negative version of the IFNGR1 subunit, which lacks the 
intracytoplasmic domain required for IFN-γ receptor mediated signaling (IFNGR1ΔIC) 
that has been previously described (15).  Each tumor cell line expressing IFNGR1ΔIC 
upregulates H-2Db and H-2Kb class I proteins in response to recombinant murine IFN-α5 
and IFN-β, but fails to express any class I proteins on its cell surface after treatment with 
recombinant murine IFN-γ, indicating that IFNGR1ΔIC tumors are selectively and 
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completely insensitive to IFN-γ (Figure 5).  H22-28027 tumor cells lacking IFN-γ 
responsiveness (H22-28027ΔIC) grow progressively when transplanted into wild type 
mice in a manner that is indistinguishable from growth in Rag2-/- mice (Figure 6).  Thus, 
IFN-γ responsiveness at the level of tumor, but not the host, is necessary for the rejection 
of H22-28027 tumor cells.  Interestingly, H22-28030ΔIC tumor cells are rejected upon 
transplantation into wild type mice suggesting that neither IFN-γ sensitivity at the level of 
the host nor at the level of the tumor alone is sufficient for tumor rejection.  To test 
whether IFN-γ sensitivity at the level of the host and tumor are both required for tumor 
rejection, H22-28030ΔIC tumor cells should be transplanted into Ifngr1-/- mice.  Unlike 
H22-28027 and H22-28030 tumors, which are rejected upon transplantation into Ifngr1-/- 
mice, host IFN-γ responsiveness alone is required to mediate tumor rejection of H22-
28032 as this tumor grows progressively in Ifngr1-/- mice. Nevertheless, we investigated 
whether IFN-γ responsiveness at the level of the tumor was also contributing to rejection 
of H22-28032 tumors. H22-28032ΔIC tumor cells that are insensitive to IFN-γ display a 
partial growth phenotype when transplanted into wild type mice (Figure 6). Overall, in 
two independent experiments, H22-28032ΔIC tumors grew in half of wild type mice 
(5/10) upon transplantation (Figure 6), suggesting that there is a role for IFN-γ sensitivity 
at the level of the tumor and the host.  Similar to H22-28030, IFN-γ responsiveness at the 
level of the tumor and the host may both be required to achieve maximal protection from 
H22-28032 tumors. 
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Figure 4. H22-28032 grows progressively in Ifngr1-/- hosts.  Mice deficient for 
IFNGR1 and thus lack IFN-γ responsiveness in host cells were injected with 1 x 106 cells 
of H22-28027, H22-28030, or H22-28032. (Experiments performed by Sang Hun Lee, a 
pre-doctoral candidate in the Schreiber laboratory). 
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Figure 5.  H22 regressor sarcoma cells rendered insensitive to IFN-γ .  H22-28027, 
H22-28030, H22-28032 tumor cells were transduced with a dominant negative version of 
the IFNGR1 subunit (IFNGR1ΔIC) or control retrovirus (RV) and tested for capacity to 
upregulate expression of cell surface MHC class I molecules (H-2Db) using flow 
cytometry after the addition of murine recombinant IFN-α5, IFN-β, or IFN-γ for 48 hrs in 
vitro. 
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Figure 6.  H22-28027 and H22-28032 require tumor cell responsiveness to IFN-γ  for 
tumor rejection.  a, Dominant negative versions of the IFNGR1 receptor subunit were 
expressed in H22-28027, H22-28030, and H22-28032 unedited sarcomas and 
transplanted into wild type mice (blue) or Rag2-/- mice (red).  In addition tumors 
transduced with an empty retrovirus vector were transplanted into wild type mice (black) 
as a control. b, Percentage of mice with progressively growing tumors from two 
independent tumor transplantation experiments.
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DISCUSSION 
 
 Several studies from our lab and others have demonstrated that IFN-γ is critical in 
mediating anti-tumor immunity, especially from primary tumor formation.  Mice 
deficient in IFN-γ (Ifng-/-), IFN-γ responsiveness (Ifngr1-/-), or IFN-γ signaling (Stat1-/-) 
all develop more chemically induced MCA sarcomas and spontaneous tumors upon aging 
than their wild type counterparts (16, 19, 22, 34). Recently, a new study reported that 
IFN-γ also protects from primary skin carcinomas induced by intradermal injection of 
MCA (55). This study confirms earlier reports that IFN-γ is necessary for the prevention 
of skin carcinomas and papillomas in the DMBA/TPA inflammatory model (23).  Due to 
the powerful antitumor actions of IFN-γ, one would expect that tumors would evolve 
mechanisms of immune escape by rendering components of IFN-γ signaling ineffective.  
Indeed, many human and mouse cancers have lost responsiveness to IFN-γ due to 
mutations in signaling components downstream of the IFN-γ receptor (16, 97). For 
example, JAK1 is epigenetically silenced in the human prostate cancer cell line LNCaP 
and thus is unable to upregulate class I antigen processing and presentation machinery in 
response to IFN-γ and IFN-α/β (103). 
 In addition to the tumor-preventing roles of IFN-γ, there are a few studies that 
also provide evidence for the tumor-sculpting roles of IFN-γ on developing cancers. One 
such study generated cell lines from MCA-treated Ifngr1-/- mice and showed that 
reconstitution of these cell lines with IFNGR1 results in tumor rejection when 
transplanted into naïve wild type mice (16). Subsequent studies demonstrated that these 
cell lines could also be rendered immunogenic by enforcing expression of TAP1 (19) or 
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H-2Db (A.T. Bruce and R.D. Schreiber, unpublished results). However, spontaneous 
lymphomas that formed in C57BL/6 Ifng-/- mice were found not to be immunogenic and 
grew progressively when transplanted into wild type recipients (22).  In contrast, 
spontaneous lymphomas from perforin-deficient mice were immunogenic and were 
rejected when transplanted into wild type mice (20, 22). Thus, although there is evidence 
that IFN-γ is important for sculpting tumor immunogenicity, it is mostly inferred either 
from (a) already edited tumors that have lost IFN-γ sensitivity, or (b) tumors that lack 
functional IFN-γ receptors rendered immunogenic by reconstitution of functional 
receptors. Here, we unequivocally demonstrate that IFN-γ is involved in editing tumor 
immunogenicity in a primary tumor model and confirm its actions on both host cells and 
tumor cells to mediate host-protective, anti-tumor functions. 
 Using neutralizing antibodies against IFN-γ, we chronically treated wild type 
mice exposed to MCA and documented that these mice develop more primary MCA 
sarcomas than control Ig treated mice, further validating IFN-γ’s role in preventing 
primary tumors.  Importantly, we generated 10 tumor cell lines from these mice and 
found that 3/10 (30%) sarcomas spontaneously rejected in wild type mice—a finding that 
is remarkably similar to Rag2-/- mice and Ifnar1-/- mice where 40% and 36% of the MCA 
sarcomas are highly immunogenic regressors, respectively (19, 24). In addition, these 
highly immunogenic H22 regressors resemble typical unedited sarcomas generated in 
Rag2-/- mice in that they require IFN-γ, CD4+ T cells and CD8+ T cells for their rejection. 
As these tumors require IFN-γ for tumor rejection, we next explored whether host cells or 
tumor cells were the critical targets for IFN-γ. In support of previous studies, we found 
IFN-γ responsiveness is required on both tumor cells and host cells for tumor rejection 
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(15, 16, 25). However, each of the three H22 regressors had different combinations of 
host and tumor cell requirements for IFN-γ responsiveness to mediate tumor rejection, a 
result that is in contrast to Rag2-/- MCA sarcomas generated on a 129/Sv background 
where either IFN-γ responsiveness at the level of the host or the tumor alone is sufficient 
to mediate tumor rejection (25) (C.M. Koebel and R.D. Schreiber, unpublished results). 
 Taken together, these data suggest that IFN-γ sculpts tumor immunogenicity and, 
to date, is the best evidence that endogenous IFN-γ can alter tumor immunogenicity 
during primary tumor development.  In addition, this is the first demonstration that 
unedited sarcomas can be generated using blocking monoclonal antibodies in wild type 
mice. Although we do not yet know the host cell targets and thus the mechanisms of 
action for IFN-γ, one likely mechanism is IFN-γ’s role in facilitating the recognition of 
tumor-specific antigens by lymphocytes that leads to tumor cell destruction. The 
remainder of this thesis dissertation will explore the role that tumor antigens play in 
driving the cancer immunoediting process. 
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CHAPTER 3 
 
Exome Sequencing of the Highly 
Immunogenic, Unedited d42m1 Sarcoma 
Identifies its Major Rejection Antigen 
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INTRODUCTION 
 
A central tenet of tumor immunology in general, and the cancer immunoediting 
process in particular, is that tumor cells express antigens that distinguish them from their 
non-transformed counterparts, thus permitting their recognition by T cells and their 
ultimate destruction by immunological mechanisms. Since the first human tumor antigen 
was identified in 1991 (209), several tumor antigens have been cloned and can be 
classified in the following five categories: 1) differentiation antigens (e.g., melanocyte 
differentiation antigens, tyrosinase); 2) mutational antigens (e.g., abnormal forms of p53); 
3) overexpressed/amplified normal proteins (e.g., HER2/neu); 4) cancer-testis antigens 
(e.g., NY-ESO-1); and 5) viral antigens (e.g., human papilloma virus) (8).  Subsequent 
studies have also identified tumor antigens in the murine system (210, 211).  
Inherit genomic instability of tumor cells allows some variants to acquire 
additional mutations that are able to evade immunological detection. Specifically, tumor 
cells may lose sensitivity to the interferons, resulting in the reduction of tumor antigen 
processing and presentation (97, 101).  Furthermore, numerous studies have 
demonstrated that the immune system can select for tumor variants better suited for 
survival in an immunologically intact environment.  Specifically, when P815 
mastocytoma or ultraviolet-induced 1591 fibrosarcoma cells are serially transplanted into 
immunocompetent hosts, tumor variants emerge with reduced immunogenicity (211, 
212). 
Although a deep understanding of human and mouse tumor antigens currently 
exists (32), it comes nearly entirely from analyses of tumor cells derived from 
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immunocompetent hosts which were likely subjected to the sculpting forces of cancer 
immunoediting.  Little is known about the antigens expressed in nascent tumor cells, 
whether they are sufficient to induce host-protective, anti-tumor immune responses or 
whether their expression is modulated by the immune system. We realized that these 
questions might be answered by defining the antigens expressed in unedited sarcoma cell 
lines derived from 3’-methylcholanthrene (MCA) treated, immunodeficient Rag2-/- mice 
since these tumors phenotypically resemble highly immunogenic, nascent primary tumor 
cells (87). However, current methods to identify tumor antigens using expression cloning 
approaches (209, 211) are time and effort intensive and are not well suited to establishing 
a tumor’s antigenic profile.  Recent advances in the field of genome sequencing have 
made possible rapid and cost effective methods to define cancer genomes and have 
established that whereas cancer cells acquire some mutations involved in the 
transformation process (driver mutations), they also express many passenger mutations 
that develop, in part, as a consequence of genomic instability (213). These tumor-specific 
mutant proteins have been proposed, but never proven, to represent tumor-specific 
antigens for T cells (214).    
Herein, we use a modified from of exome sequencing to define the mutational 
profile of two independent, unedited MCA sarcomas (d42m1 and H31m1). This 
technique, involving cDNA capture by biotinylated mouse exome probes (Agilent) 
followed by deep sequencing (hereafter referred to as cDNA Capture Sequencing or 
cDNA CapSeq) showed that the two tumor cell lines display largely non-overlapping 
patterns of mutations. By pipelining the cDNA CapSeq data for one of these tumors 
(d42m1) into MHC class I epitope prediction algorithms, we identify a potential major 
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antigen of this unedited tumor, validate its identity as the major rejection antigen using 
expressing cloning techniques, and show that antigen-loss via a T cell dependent 
immunoselection process represents the mechanism underlying cancer immunoediting of 
this tumor. This study, thus, provides mechanistic insights into the process of cancer 
immunoediting and points to the future potential that cancer genome analysis may have 
on the fields of tumor immunology and cancer immunotherapy.  
 
This study was performed in a combined and equal effort with Dr. Hirokazu Matsushita, 
a post-doctoral fellow in the lab and thus, his data and my own are presented here 
together for clarity.  
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MATERIALS AND METHODS 
 
Mice.  Ifngr1-/- mice (208) and Ifnar1-/- mice (215) on a 129/Sv background were 
originally provided by Dr. Michel Aguet and were bred in our specific pathogen-free 
animal facility. Wild type and Rag2-/- mice were purchased from Taconic Farms. All 
mice were on a 129/Sv background and were housed in our specific pathogen-free animal 
facility.   For all experiments, mice were 8-12 weeks of age and performed in accordance 
with procedures approved by the AAALAC accredited Animal Studies Committee of 
Washington University in St. Louis. 
 
Tumor transplantation.  3-methylcholanthrene (MCA) induced sarcomas used in this 
study were generated in 129/Sv strain wild type or Rag2-/- mice and banked as low 
passage tumor cells as previously described (19).  Tumor cells derived from frozen stocks 
were propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% 
FCS (Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the 
flanks of recipient mice.  Tumor cells were >90% viable at the time of injection as 
assessed by trypan blue exclusion and tumor size was quantified as the average of two 
perpendicular diameters. 
 
Isolation of normal skin fibroblasts.  Skin fibroblasts were isolated from three 
independent 129/Sv Rag2-/- pups by harvesting skin and incubating in 0.25% trypsin 
(Hyclone) at 37°C for 30 minutes prior to washing in DMEM media (Hyclone).  After 
washing, chunks of skin were filtered to achieve single cell suspensions and cultured in 
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vitro with DMEM media. After 3 passages, skin fibroblasts were harvested to isolate 
genomic DNA and total RNA. 
 
Extraction of genomic or complementary DNA.  Genomic DNA from sarcoma cells 
and normal skin fibroblasts was extracted using DNeasy Blood & Tissue Kit (Qiagen).  
For cDNA isolation, total RNA from sarcoma cells and normal skin fibroblasts was 
isolated using RNeasy Mini kit (Qiagen) and cDNA was synthesized using oligo (dT) 
primers and SuperScript II Reverse Transcriptase (Invitrogen). 
 
cDNA capture, sequencing, and alignment (cDNA CapSeq).  cDNA samples from 
each tumor (100 ng) were constructed into Illumina libraries according to the 
manufacturer’s protocol (Illumina Inc, San Diego, CA) with the following modifications:  
1) cDNA was fragmented using Covaris S2 DNA Sonicator (Covaris, Inc. Woburn, MA) 
in 1X end-repair buffer followed by the direct addition of the enzyme repair cocktail 
(Lucigen, Madison, WI).  Fragment sizes ranged between 100 and 500 bp.  2) Illumina 
adapter-ligated DNA was amplified in four 50 µl PCRs for five cycles using 4 µl adapter-
ligated cDNA, 2X Phusion Master Mix and 250 nM forward and reverse primers, 
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATC and 5’	  
CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTC
CGATC, respectively.  3) Solid Phase Reversible Immobilization (SPRI) bead cleanup 
was used to purify the PCR-amplified library and to select for 300-500 bp fragments. 500 
ng of the size-fractionated Illumina library was hybridized with the Agilent mouse exome 
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reagent.  After hybridization at 65°C for 24 hrs, we added 50 µl of DynaBeads M-270 
Streptavidin-coated paramagnetic beads (10 mg/ml) to selectively remove the 
biotinylated Agilent probes and hybridized cDNA library fragments.  The beads were 
washed according to manufacturer’s protocol (Agilent) and the captured library 
fragments were released into solution using 50 µl of 0.125 N NaOH and neutralized with 
an equal volume of neutralization buffer (Agilent). The recovered fragments then were 
PCR amplified according to the manufacturer’s protocol using 11 cycles in the PCR.  
Illumina library quantification was completed using the KAPA SYBR FAST qPCR Kit 
(KAPA Biosystems, Woburn, MA). The qPCR result was used to determine the quantity 
of library necessary to produce 180,000 clusters on a single lane of the Illumina GAIIx.  
One lane of 100 bp paired-end data was generated for each captured sample (since cDNA 
was used as the source for sequencing, we refer to this process as cDNA Capture 
Sequencing or CapSeq). Illumina reads were aligned to the NCBI build 37 (Mm9) mouse 
reference sequence using BWA (216) v0.5.5 (with –q 5 soft trimming). Alignments from 
multiple lanes for the same sample were merged together using SAMtools r599, and 
duplicates were marked using Picard v1.29.   
 
Mutation detection and annotation.  Putative somatic mutations were identified using 
VarScan 2 (v2.2.4) (217) with the parameters “--min-coverage 3 --min-var-freq 0.08 --p-
value 0.10 --somatic-p-value 0.05 --strand-filter 1” and specifying a minimum mapping 
quality of 10. Variants whose supporting reads exhibited read position bias (average read 
position <10 or >90), strand bias (>99% of reads on one strand), or mapping quality 
(score difference >30, or mismatch quality sum difference >100) relative to reference 
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supporting reads were removed as probable false positives. We also required that the 
variant allele be present in at least 10% of tumor reads and no more than 5% of normal 
reads. The single nucleotide variants (SNVs) meeting these criteria were annotated using 
an internal database of Genbank/Ensembl transcripts (v58_73k). In the event that a 
variant was annotated using multiple transcripts, the annotation of most severe effect was 
used. Non-silent coding mutations (missense, nonsense/nonstop, or splice-site) were 
prioritized for downstream analysis. 
 
Mutation rate and overlap comparisons.  Mutation rates were estimated for each tumor 
sample using the number of putative “tier 1” SNVs (missense, nonsense/nonstop, splice 
site, silent, or noncoding RNA). To account for variability in coverage between samples, 
the SNV count for each tumor sample (S) was divided by a coverage factor (F), computed 
as the fraction of all tier 1 SNVs identified in any tumor sample (n=16,991) that were 
covered by at least 4 reads in a given sample. For example, in the d42m1 parental sample, 
15,852 of 16,991 tier 1 SNV positions were covered, for a coverage factor of 93.30%. 
The number of coverage-adjusted mutations in each sample was divided by the total size 
of tier 1 space in the mouse genome (43.884 Mbp) to determine the number of coding 
mutations per megabase (R).  
R = (S / F) / (43.884 Mbp) 
For the mutation overlap comparisons and relatedness-to-parental-tumor analysis, only 
high-confidence missense mutations were used (i.e., 20X or above). A mutation was 
considered “shared” between two samples if both samples had a predicted mutation at the 
same genomic position. For the comparison of mutated genes between d42m1 and 
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H31m1 parental lines, a gene was considered “shared” if both d42m1 and H31m1 
samples had a predicted missense mutation in that gene, even if the mutations did not 
occur at the same position. 
 
MHC class I epitope prediction.  All missense mutations for each d42m1 tumor variant 
were analyzed for the potential to form MHC class I neoepitopes that bind to either H-
2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the 
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used 
to predict epitope binding affinities (218) and the results were ultimately expressed as 
“Affinity Values”  (Affinity Value = 1/IC50 X 100). 
 
Antibodies.  Anti-H-2Kb (B8-24-3) and anti-H-2Db (B22/249) mAbs were generously 
provided by Dr. Ted H. Hansen (Washington University School of Medicine). Anti-CD4 
(GK1.5), anti-CD8α (YTS169.4) mAbs and control immunoglobulin (PIP, a mAb 
specific for bacterial glutathione S-transferase) were produced from hybridoma 
supernatants and purified in endotoxin-free form by Protein G affinity chromatography 
(Leinco Technologies, St. Louis, MO).  Purified Rat IgG was purchased from Sigma (St. 
Louis, MO).  CD45-FITC, CD45-PE, CD8-APC, and purified anti-CD16/32 were 
purchased from BioLegend (San Diego, CA).  
 
cDNA library construction and screening.  To generate a d42m1 tumor cell cDNA 
library, mRNA was isolated from parental d42m1 tumor cells using a QuickPrep mRNA 
Purification kit (Amersham), converted into cDNA using SuperScript II First Strand 
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Synthesis System (Invitrogen) and inserted into the EcoRI site of the expression vector 
pcDNA3 (Invitrogen).  The cDNA library was divided into pools of 100 bacterial 
colonies with 200-300 ng of DNA from each pool transfected into 2.5 x 104 monkey COS 
cells engineered to ectopically express mouse H-2Db (COS-Db) cells using Lipofectamine 
2000.  After 48 hr, 5 x 103 C3 CTL cells were added, and supernatants were assayed for 
IFN-γ release 24 hrs later by ELISA.  A single positive cDNA clone was isolated after 
screening 120,000 cDNA colonies.  The putative H-2Db-binding peptide VAVVNQIAL 
was predicted using the algorithm available at the Immune Epitope Database and 
Analysis Resource, http://www.immuneeptiope.org/.  The peptides were kindly produced 
by Dr. Paul Allen and Steve Horvath (Washington University School of Medicine).  
 
Expression vectors.  Full length cDNA encoding wild type spectrin-β2 and mutant 
spectrin-β2 were cloned from parental d42m1 tumor cells by RT-PCR using primer pairs 
5’-TGAGACAGTCAAGATGACGACCACGGTAGCCACA-3’ and 5’-
CGGGACAACAGGGAAGTTCACTTCTTCTTGCCGA-3’.  Wild type and mutant 
spectrin-β2 cDNA were subcloned from the TOPO-XL vector (Invitrogen) into the RV-
GFP vector (219).  To generate the RV-RFP vector, full length cDNA encoding RFP was 
cloned from the pTurboRFP-C vector (Evrogen) by RT-PCR using primer pairs 5'- 
ATCTCAGAATTCATGAGCGAGCTGATCAAGGA - 3' and 5'- 
ATCTCAGGATCCTTATCTGTGCCCCAGTTTGCTAG - 3'.  RFP cDNA was then 
cloned into the RV vector.  To remove candidate T cell epitopes in RFP, the nucleotide A 
was replaced by G at position 334 in the cDNA, resulting in amino acid substitution 
N112D.  Coding sequences of the constructs were verified by DNA sequencing (Big Dye 
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method; Applied Biosciences). The dominant negative version of the IFNGR1 subunit 
(IFNGR1ΔIC) was expressed into H31m1 and d42m1 tumor cells as previously described 
(15). 
 
Establishment of CTL lines and clones.  To generate the d42m1 specific C3 CTL clone, 
wild type mice were injected with 1 x 106 parental d42m1 tumor cells.  Fourteen days 
later, the spleen was harvested from a mouse that rejected the tumor and a CTL line was 
established by stimulating 40 x 106 splenocytes with 2 x 106 parental d42m1 tumor cells 
pre-treated for 48 hr with 100 U/ml of recombinant murine IFN-γ and irradiated (100 
Gy). After CD8+ T cell purification using magnetic-beads (Miltenyi Biotec) and limiting 
dilution, the CTL clone C3 was obtained. 
 
Measurement of IFN-γ  production.  To generate target cells, tumor cells were treated 
with 100U/ml IFN-γ for 48 hrs and irradiated with 100 Gy prior to use.  The C3 CTL 
clone was co-cultured at the indicated ratios with target tumor cells (10,000 or 5,000 
cells) in 96-well round-bottomed plates overnight.  IFN-γ in supernatants was quantified 
using an IFN-γ ELISA kit (eBioscience).  For blocking assays, 10 µg/ml of α-CD8 (YTS-
169.4), α-CD4 (GK1.5), or control immunoglobulin (PIP) were added to the cell culture 
of effector (C3 CTL clone) and target cells (tumors). 
 
Fluorescence-activated cell sorting analysis.  For flow cytometry, cells were stained for 
20 minutes at 4°C with 500 ng of Fc block (anti-CD16/32) and 200 ng of CD45, CD4, or 
CD8α in 100 µL of staining buffer (PBS with 1% FCS and 0.05% NaN3 (Sigma)).  
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Propidium iodide (PI) (Sigma) was added at 1 µg/mL immediately before FACS analysis. 
For quantitative analysis of tumor-infiltrating lymphocytes/leukocytes (TIL) and lymph 
node populations, a CD45+PI– gate was used and gated events were collected on a 
FACSCalibur (BD Biosciences) and analyzed using FloJo software.  
 
Tumor, draining lymph node, and spleen harvest.  After tumor cell transplantation, 
established tumors were excised from mice, minced and treated with 1 mg/ml type IA 
collagenase (Sigma) in HBSS (Hyclone) for 2 hrs at room temperature.  The ipsilateral 
inguinal tumor-draining lymph nodes and spleen were also harvested and crushed 
between two glass slides and vigorously resuspended to make single-cell suspensions.  
 
Tetramers.  H-2Db tetramers conjugated to phycoerythrin (PE) were prepared with 
mutant spectrin-β2 peptides and produced by the NIH Tetramer Core Facility (Emory 
University, Atlanta, GA). 
 
Mutation specific RT-PCR and real-time RT-PCR.  Total RNA from tumor cells was 
isolated by RNeasy Mini kit (Qiagen) and cDNA was synthesized from the total RNA 
using oligo (dT) primers and SuperScript II Reverse Transcriptase (Invitrogen). Real-
time PCR specific for wild type spectrin-β2, mutant spectrin-β2 and GAPDH using the 
SYBR Green Mastermix kit (Applied Biosystems) were performed on ABI 7000.  The 
primer sequences for used for mutant spectrin-β2 are 5’-GGTGAACCAGATTGCACT-
3’ and 5’-TGTCCACCAGTTCTCTGAACT-3’.   
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Detection of mutation in spectrin-β2 cDNA.  The point mutation in the spectrin-β2 
gene creates a PstI restriction site (CGGCAG to CTGCAG, underlined italic letters 
indicate the site of mutation).  To amplify spectrin-β2 cDNA we used a forward primer 
(ACCCTGGCCCTGTACAAGAT) and reverse primer 
(TAGACTCGATGACCTTGGTCT).  The PCR conditions used were 94°C for 2 min, 
followed by 35 cycles of 94°C for 30s, 55°C for 30s and 72°C for 30s.  The PCR 
products were digested for 2 hrs at 37°C with PstI restriction enzyme, which cleaved 
mutant spectrin-β2, but not wild-type spectrin-β2, and generates a 200 bp fragment from 
cDNA.  The products were resolved by electrophoresis on a 1.2% agarose gel and 
visualized by ethidium bromide staining. 
 
Isolation of non-transformed cells from frozen primary d42m1 tumor chunk.  A 
frozen d42m1 tumor chunk from the original d42m1 tumor was thawed and treated with 1 
mg/ml type IA collagenase (Sigma) in HBSS for 2 hrs at room temperature. After 
filtration, single-cell suspensions were stained for 20 minutes at 4°C with 500 ng of Fc 
block (anti-CD16/32) and 200 ng of CD45-PE in 100 µL of staining buffer.  Propidium 
iodide was added at 1 µg/mL immediately before sorting. A CD45+PI– gate was used and 
the top 15% percent and the bottom 15% of gated events were collected using a 
FACSAria II (BD Biosciences). 
 
Statistical Analysis.  Samples were compared using an unpaired, two-tailed Student’s t 
test.   
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RESULTS 
 
cDNA CapSeq of Unedited MCA Sarcomas Reveals a Similarity to Carcinogen-
induced Human Cancers  
For this study, we chose two representative, highly immunogenic, unedited MCA 
sarcoma cell lines, d42m1 and H31m1, that grow progressively when transplanted 
orthotopically into Rag2-/- mice, but are immunologically rejected when transplanted into 
naive wild type mice (19) (Figure 1 and 2).  Using cDNA CapSeq, we identified 3,737 
non-synonymous mutations in d42m1 cells (3,398 missense, 221 nonsense, 2 nonstop and 
116 splice site mutations) and 2,677 non-synonymous mutations in H31m1 cells (2,391 
missense, 160 nonsense, 3 nonstop and 123 splice site mutations) (Figure 3a and Figure 
4). However, d42m1 and H31m1 share only 119 identical missense mutations when 
comparing sequences with at least 20X coverage (Figure 3b), thus explaining the unique 
antigenicity that each cell line displays (Figure 3c). Whereas d42m1 and H31m1 had 
mutations in 73 and 42 cancer-associated genes (220), respectively, most of these do not 
correspond to known activating or inactivating gene mutations in human cancers (221). 
However, d42m1 and H31m1 display mutations in Kras (d42m1 Kras G12C; H31m1 
Kras G12D) and in Trp53 (d42m1: Trp53 E295stop; H31m1: Trp53 S152R and S258I) 
that are frequently observed in human and mouse cancers, including edited MCA 
sarcomas from wild type mice (222). These same mutant proteins have been shown to 
induce cancers de novo when co-expressed in transgenic mice (223, 224).   
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Figure 1. d42m1 is a highly immunogenic, unedited tumor.  d42m1 tumor cells were 
injected at a dose of 1x106 into syngeneic wild type (a-d), Rag2-/- (a and c), Ifnar1-/- (c), 
or Ifngr1-/- (d) mice.  b, Groups of wild type mice injected with 1x106 d42m1 tumor cells 
were treated with control IgG, anti-CD4, or anti-CD8α mAbs.  d, d42m1 tumor cells 
were rendered insensitive to IFN-γ (d42m1ΔIC) by expressing a dominant-negative 
version of IFNGR1 (IFNGR1ΔIC) and were then transplanted (1x106 cells) into wild type 
mice.  Data are presented as average tumor diameter ± s.e.m. of 3-5 mice per group and 
are representative of at least three independent experiments. Samples were compared 
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001).   
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Figure 2. H31m1 is a highly immunogenic, unedited tumor.  H31m1 tumor cells were 
injected at a dose of 1x106 into syngeneic wild type (a-d), Rag2-/- (a and c), Ifnar1-/- (c), 
or Ifngr1-/- (d) mice.  b, Groups of wild type mice injected with 1x106 H31m1 tumor cells 
were treated with control IgG, anti-CD4, or anti-CD8α mAbs.  d, H31m1 tumor cells 
were rendered insensitive to IFN-γ (H31m1ΔIC) by expressing a dominant-negative 
version of IFNGR1 (IFNGR1ΔIC) and were then transplanted (1x106 cells) into wild type 
mice.  Data are presented as average tumor diameter ± s.e.m. of 4-9 mice per group and 
are representative of at least three independent experiments. Samples were compared 
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001). 
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Figure 3. d42m1 and H31m1 are distinct antigenic and immunogenic tumors. a, 
Number of somatic, non-synonymous mutations (missense, nonsense, nonstop, and splice 
site) in d42m1 and H31m1 tumor cells as detected by cDNA CapSeq. b, Venn diagram 
comparing the number of unique and shared missense mutations expressed in d42m1 and 
H31m1 tumor cells that had at least 20x sequencing coverage for each genomic site. c, 
IFN-γ ELISA assay using the bulk CTL lines developed against either parental d42m1 
(left panel) or H31m1 (right panel) and tested against unedited MCA sarcoma cell lines, 
d42m1, H31m1, F510, 1773, 1782, and 1779 or the edited F244 MCA sarcoma derived 
from a wild type 129/Sv mouse.  Data are representative of at least two independent 
experiments and are presented as average IFN-γ release ± s.e.m. Samples were compared 
using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001). 
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Figure 4. Exome sequencing coverage.  Percentage of exome sequence coverage (20x, 
15x, 10x, 5x, 1x, 0x) is displayed for the MCA sarcoma cell lines and normal skin 
fibroblasts that were isolated from three independent syngeneic 129/Sv Rag2-/- mice. 
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When we compared the cDNA CapSeq data of d42m1 and H31m1 sarcoma cells 
to those of human cancer genomes (225-233), two similarities were observed.  First, the 
overall mutation rates of d42m1 and H31m1 most closely resemble those of carcinogen-
induced lung cancers from smokers, and particularly of “hypermutators” whose smoking 
induced-lung cancers develop mutations in genes encoding DNA repair components 
(Figure 5a). Interestingly, d42m1 and H31m1 also have mutations in DNA repair genes, 
including Trp53, Atm, Brca2, Brip1, Fancd2, Fancg and Xpc.  Second, 46% and 47% of 
mutations in d42m1 and H31m1, respectively, are C/A or G/T transversions and thus 
represent typical carcinogen signatures (229, 230) similar to those established for lung 
cancers from smokers (44-46%), but distinct from those for other human cancers, 
including lung cancers from individuals who never smoked (15%) (Figure 5b). Thus, the 
current genomic analyses reveal the oft-proposed, but never documented similarity 
between MCA sarcomas in mice and carcinogen-induced human cancers.  
 
cDNA CapSeq of d42m1 Tumor Variants  
The d42m1 sarcoma cell line displays a sporadic tendency to produce escape 
variants following transplantation into naïve, syngeneic wild type mice (Figure 6a).  In 
fact, escape variants are observed in about 20% of naïve wild type mice injected with 
parental d42m1 tumor cells (Figure 6c).  Cell lines made from three such escape variants 
(d42m1-es1, d42m1-es2 and d42m1-es3) consistently formed progressively growing 
tumors when transplanted into naïve syngeneic recipients (Figure 6d and 7).  In contrast, 
parental d42m1 tumor cells passaged through immunodeficient Rag2-/- mice retained 
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their immunogenicity (Figure 6b, d). Thus, unedited d42m1 tumor cells can undergo 
immunoediting when transplanted into wild type mice. 
To determine the basis for the heterogeneous behavior of d42m1 tumor cells in 
naive immunocompetent mice, we generated single cell clones from the parental cell line 
and tested the immunogenicity of each.  Whereas 8 of 10 clones were rejected when 
transplanted into wild type mice, two (d42m1-T3 and d42m1-T10) grew progressively 
and displayed growth kinetics similar to the d42m1 escape variants (Figure 7). Thus, the 
parental d42m1 cell line consisted of a disproportionate mixture of regressor and 
progressor tumor cell clones. 
cDNA CapSeq of d42m1 clones and escape variants revealed that all expressed 
similar numbers of mutations compared to parental d42m1 tumor cells (Figure 8a). 
Moreover, the missense mutations in clones and escape variants were similar to parental 
d42m1 cells, but distinct from those in H31m1 parental cells (Figure 8b). However, a 
greater percentage of mutations in d42m1 regressor clones were shared with parental 
d42m1 tumor cells (71-78%) than those shared between parental d42m1 tumor cells and 
d42m1 progressor clones (48%) or escape variants (33-35%) (Figure 8b), a result that 
further supports the conclusion that the d42m1 cell line consists of a related, but 
heterogeneous population of tumor cells. 
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Figure 5. Unedited MCA sarcomas, d42m1 and H31m1, resemble carcinogen-
induced human cancers. a, Log mutation rate/10 Mbp for d42m1 and H31m1 sarcomas 
as compared to previously generated data from a panel of human cancers including acute 
myelogenous leukemia (225, 226) (AML), chronic lymphocytic leukemia (232) (CLL), 
breast cancer (breast-lobular (228), breast-basal (227), aromatase inhibitor (AI)-resistant, 
and AI-sensitive (Ding et al., manuscript in review)), ovarian cancer (OVC1, 3, 4, 5) 
(manuscript in preparation), liver cancer (Hepatitis C Virus (HCV)-positive) (231), 
melanoma (ultraviolet (UV)-induced) (233), and lung cancers (non-small cell (NSC) 
(229), small cell (SC) (230), Never-Smoker, Smoker, and Hypermutator (manuscript in 
progress)). Only protein-coding alterations (Tier 1 SNVs) were used to calculate mutation 
rates. b, Spectrum of DNA nucleotide transitions and transversions detected in d42m1 
and H31m1 sarcomas and human cancers described in a.
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Figure 6.  Escape variants of d42m1 display reduced immunogenicity and an edited 
growth phenotype. a, d42m1 tumor cells (1x106) were transplanted into wild type (solid 
lines) or Rag2-/- (dashed lines) mice.  b, The escape variant d42m1-es3 (harvested from 
the wild type mouse bearing an escaped d42m1 tumor in a and generated into a cell line) 
(n=5, diamonds) or d42m1-RagPass (n=5, squares) were transplanted (1x106 cells) into 
wild type mice. Data presented as average tumor diameter ± s.e.m of 5 mice per group 
over time. c, Wild type mice or Rag2-/- mice were challenged with 1x106 d42m1 tumor 
cells. Data presented as percent tumor positive from 2-4 independent experiments (n=4-6 
mice per group).  d,  Wild type mice were challenged with 1x106 d42m1-RagPass, 
d42m1-es1, d42m1-es2, or d42m1-es3 tumor cells. Data presented as percent tumor 
positive from two independent experiments (n=4-5 mice per group). Samples were 
compared using an unpaired, two-tailed Student’s t test (**p<0.01 and ***p<0.001) 
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Figure 7. d42m1 tumor cell clones display heterogeneous growth characteristics. 
d42m1 tumor clones (d42m1-T1, -T2, -T3, -T4, -T5, -T6, -T7, -T8, -T9, and -T10) and 
escape variants (d42m1-es1, -es2, and -es3) were transplanted at a dose 1 x 106 cells into 
wild type mice (n=5, squares). Data are presented as average tumor diameter ± s.e.m. and 
are representative of two-three independent experiments.  
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Figure 8. d42m1 tumor cell clones are closely related to d42m1 parental cells. a, 
Number and type of non-synonymous somatic mutations (missense, nonsense, nonstop, 
and splice site mutations) in d42m1 tumor variants. b, Percent of shared missense 
mutations expressed in each d42m1 tumor cell variant when compared with d42m1 
parental cells (left) or H31m1 parental cells (right).
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Identifying Potential d42m1 Tumor Antigens From Genomic Data 
We next assessed the theoretical capacity of peptides containing each missense 
mutation to bind to MHC class I proteins (i.e., to function as neoantigens) by in silico 
analysis (218).  As these tumors were generated on a 129/Sv genetic background, we 
restricted our analysis to H-2Db and H-2Kb.  Remarkably, among the large number of 
potential mutant epitopes examined for binding to H-2Db or H-2Kb, only 32 (0.06%) and 
138 (0.27%) displayed high affinity binding potential (IC50 < 50nM; Affinity Value > 2) 
to H-2Db and H-2Kb, respectively (Figure 9).  
To further simplify the pattern, we asked whether all of the d42m1 regressor 
variants shared a common rejection antigen.  Using a d42m1 specific CD8+ cytotoxic T 
lymphocyte (CTL) clone (C3) derived from a wild type mouse that had rejected parental 
d42m1 tumor cells, we observed reactivity in vitro (as evidenced by IFN-γ production) 
with parental d42m1 tumor cells and with regressor d42m1 tumor cell variants, but not 
with progressor d42m1 tumor cell variants or unrelated MCA sarcoma cells (Figure 10a, 
b). Together, these results reveal that the regressor d42m1 tumor cell variants, indeed, 
share a common rejection antigen. This conclusion was supported by the additional 
finding that the original CD8+ T cell line from which the C3 clone was derived displayed 
a limited oligoclonality, as evidenced by Vβ usage limited only to Vβ6 and Vβ8.1/8.2.  
This result suggests that d42m1 expresses only a limited number of rejection antigens, 
perhaps even a single immunodominant antigen. Therefore, we focused on the limited 
number of epitopes that were common to all d42m1 regressor variants (Figure 11). 
Furthermore, recognition of all d42m1 regressor variants by the C3 clone was restricted 
by H-2Db (Figure 12). Based on these results, the R913L mutation in spectrin-β2 
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represents the best potential rejection antigen candidate because of its high affinity for H-
2Db (Figure 11). The mutation in spectrin-β2 most likely represents a passenger rather 
than a driver mutation since (a) spectrin-β2 is a cytoskeletal protein whose only known 
role is maintaining plasma membrane integrity, (b) expression of mutant spectrin-β2 is 
not required for the neoplastic phenotype of d42m1 tumor cell clones, and (c) it is not on 
the list of known human cancer genes (220). 
 
Mutant spectrin-β2 is a d42m1 Specific Tumor Antigen 
To verify the predicted importance of mutant spectrin-β2 on d42m1 antigenicity, 
we used a T cell based expression cloning approach (209) to independently identify the 
tumor antigen recognized by the C3 CTL clone. After three rounds of screening 120,000 
cDNA clones, a single positive cDNA was identified encoding a 1,722 bp fragment with 
a sequence identical to spectrin-β2 except for a single G to T point mutation resulting in 
an amino acid substitution of arginine to leucine at position 913. Thus, conventional 
antigen expression cloning identified the same sequence that was predicted using the 
cDNA capture sequencing/in silico approach. 
To establish whether mutant spectrin-β2 represents a tumor-specific antigen, we 
first assessed expression of mutant spectrin-β2 mRNA in the various d42m1 cell variant 
populations by mutation specific qRT-PCR.  Mutant spectrin-β2 mRNA was expressed in 
parental d42m1 cells and d42m1 regressor clones, but not in d42m1 progressor clones or 
escape variants (Figure 13).  Moreover, the mutant form of spectrin-β2 was not observed 
in normal tissue derived from the very same mouse as the d42m1 tumor, revealing that 
the mutation was truly tumor cell specific and not due to a mouse-specific polymorphism. 
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We then asked whether T cells could discriminate between the mutant and native 
spectrin-β2 905-913 peptide sequences when presented on H-2Db.  For this purpose, we 
synthesized wild type (VAVVNQIAR) and mutant (VAVVNQIAL) 905-913 spectin-β2 
peptides and tested their ability to stimulate IFN-γ production from the C3 clone when 
presented on an unrelated H-2Db expressing cell line.  Whereas the mutant peptide 
stimulated C3 CTL cells in a dose-dependent manner, the wild type peptide did not, even 
when added in 1000-fold excess (Figure 14).  
To document that the anti-R913L spectrin-β2 response occurred under 
physiologic conditions, we used labeled H-2Db tetramers generated with the 905-913 
spectrin-β2 mutant peptide to identify CD8+ T cells in d42m1 variant tumors.  Mutant 
spectrin-β2 specific CD8+ T cells were detected in parental d42m1 tumors and draining 
lymph nodes (DLNs) as early as 6 days after tumor injection and gradually increased in 
numbers until day 11 (just prior to tumor rejection), where they reached a maximum of 
5% and 0.5% of the CD8+ T cells in the tumor and DLN, respectively (Figure 15). In 
contrast, no mutant spectrin-β2 specific CD8+ T cells were detected in d42m1-es3 tumors 
or DLNs (Figure 15). Together these data demonstrate that a mutated gene expressed 
selectively in unedited d42m1 tumor cells, gives rise to a mutant protein that evokes a 
naturally occurring T cell response in naïve wild type mice. Thus mutant spectrin-β2 is 
an authentic tumor-specific antigen of d42m1 sarcoma cells.     
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Figure 9. Affinity value profiles of predicted MHC class I epitopes from tumor-
specific mutations. All missense mutations for each d42m1 tumor variant were analyzed 
for the potential to form MHC class I neoepitopes that bind to either H-2Db or H-2Kb 
molecules. The artificial neural network (ANN) algorithm provided by the Immune 
Epitope Database and Analysis Resource was used to predict epitope binding affinities 
and the results were ultimately expressed as “Affinity Values”  (Affinity Value = 1/IC50 
X 100). Mutant epitopes present in each individual d42m1 tumor variant are displayed.  
Arrow is pointing to one of the H-2Db epitopes created by the R913L point mutation in 
spectrin-β2 that is expressed only in d42m1 cell variants that are rejected in wild type 
mice.  
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Figure 10.  CD8+ T cells selectively recognize highly immunogenic d42m1 tumor 
variants. a, b, IFN-γ ELISA assay of C3 CTL cells generated from splenocytes of a 
mouse that rejected d42m1, against five different unedited sarcoma cell lines (a) or 
against d42m1 tumor clones and escape variants (b). Data are representative of two 
independent experiments. Samples were compared using an unpaired, two-tailed 
Student’s t test (*p<0.05 and **p<0.01; n.s. is non-significant).
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Figure 11. Shared epitopes among highly immunogenic d42m1 variants.  MHC class 
I epitopes predicted to be shared in all of the highly immunogenic d42m1 tumor variants 
(d42m1 parental, -T1, -T2, and -T9), but not in d42m1 tumor variants that display 
reduced immunogenicity (d42m1-T3, -T10, -es1, -es2, and -es3) for H-2Db (top) and H-
2Kb (bottom). One of the H-2Db epitopes created by the R913L point mutation in 
spectrin-β2 is highlighted in red.
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Figure 12. CD8+ T cell recognition of d42m1 parental tumor cells is H-2Db 
restricted.  IFN-γ ELISA assay of C3 CTL cells against d42m1 parental tumor cells with 
the addition of antibodies that block CD4, CD8α, H-2Db, or H-2Kb. Data are 
representative of two independent experiments. Samples were compared using an 
unpaired, two-tailed Student’s t test (**p<0.01). 
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Figure 13. Expression of mutant spectrin-β2 is restricted to highly immunogenic 
d42m1 tumor variants.  qRT-PCR analyses using primer pairs specific for mutant 
spectrin-β2 in d42m1 parental, d42m1 clones and escape variants and 1773, an unrelated 
unedited sarcoma. 
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Figure 14. C3 CTL clone recognizes mutant 905-913 spectrin-β2 peptide. a, 
Estimation of IC50 (nM) for wild type and mutant spectrin-β2 epitopes on H-2Db by 
Immune Epitope Database and Analysis Resource. b, IFN-γ ELISA assay of C3 CTL 
cells against COS-Db cells pulsed with wild type (circles) or mutant (squares) spectrin-β2 
peptides. Data are representative of two independent experiments. Samples were 
compared using an unpaired, two-tailed Student’s t test (*p<0.05 and **p<0.01).
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Figure 15. Mutant spectrin-β2 specific CD8+ T cells infiltrate d42m1 parental 
tumors, but not d42m1-es3 tumors. Time course of tetramer positive CD8α+ T cells in 
tumors and DLNs from d42m1 or d42m1-es3 tumor-bearing mice.  Tumors and DLNs 
were harvested from d42m1 (n=3, circles) or d42m1-es3 (n=3, squares) -bearing mice at 
days 6, 9, 11, and 13.  Data includes results from 3 mice per group and is representative 
of two independent experiments (left). Tumors and draining lymph nodes (DLNs) were 
harvested at day 11 and CD8α+ T cells were stained with mutant spectrin-β2 tetramers 
(right). Data are representative of two independent experiments. Samples were compared 
using an unpaired, two-tailed Student’s t test (*p<0.05 and **p<0.01).
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Mutant spectrin-β2 is the Major Rejection Antigen of d42m1 Tumor Cells 
In order to explore whether mutant spectrin-β2 represents the major rejection 
antigen of parental d42m1 tumor cells, we enforced expression of either the mutant or 
wild type forms of spectrin-β2 into d42m1-es3 cells (Figure 16). When injected into wild 
type mice, d42m1-es3 tumor cell clones expressing GFP alone or GFP plus wild type 
spectrin-β2 (WT.1 and WT.3) grew progressively and displayed similar growth kinetics 
to the parental d42m1-es3 cell line (Figure 17a, c).  In contrast, d42m1-es3 tumor cell 
clones expressing GFP plus mutant spectrin-β2 (mu.6 and mu.14) were rejected in wild 
type mice, but not in Rag2-/- mice (Figure 17b, c, d).  CD8+ T cells specific for mutant 
spectrin-β2 did not infiltrate d42m1-es3 tumors expressing wild type spectrin-β2 (WT.3), 
but were detected by tetramer staining in rejecting d42m1-es3 tumors that had been 
reconstituted with mutant spectrin-β2 (mu.14) (Figure 17e).  The frequency of antigen-
specific T cells infiltrating mutant spectrin-β2 expressing tumors was similar to that in 
mice rejecting parental d42m1 tumors.  These results demonstrate that expression of 
mutant spectrin-β2 is both necessary and sufficient for the rejection of d42m1 tumors and 
thus, validates it as the major rejection antigen of d42m1 sarcoma cells.          
 
Immunoselection is the Immunoediting Mechanism for d42m1 Tumor Cells   
The results presented thus far identified mutant spectrin-β2 as the major rejection 
antigen of d42m1, established that the d42m1 tumor cell line is heterogeneous in its 
expression of mutant spectrin-β2, and showed that loss of mutant spectrin-β2 in d42m1 
cells following exposure to an intact immune system results in tumor cell variants that 
escape immune control.  Since our cDNA CapSeq analyses were performed on cDNA 
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derived from tumor cells, we tested whether these observations could be explained by 
epigenetic silencing of the mutated form of the spectrin-β2 gene. We therefore, treated 
clones and escape variants of d42m1 that did not express mutant spectrin-β2 with 
methyltransferase and histone deacetylase inhibitors (i.e., 5-azacytidine and trichostatin 
A, respectively) alone or in combination and assessed expression of mutant spectrin-β2 
mRNA. Mutant spectrin-β2 expression was not induced in d42m1 progressor clones or 
escape variants (H. Matsushita and R.D. Schreiber, data not shown). We therefore 
formulated the hypothesis that T cell dependent immunoselection was a likely 
mechanism favoring outgrowth of tumor variants that lack strong rejection antigens.  This 
possibility is consistent with our finding that every d42m1 clone that expresses mutant 
spectrin-β2 was rejected while every clone or variant that lacks mutant spectrin-β2 
formed progressively growing tumors.  To formally test this hypothesis, we assessed the 
in vivo behavior of a disproportionate mixture of a highly immunogenic d42m1 tumor 
cell clone expressing mutant spectrin-β2 (i.e., d42m1-T2) and a limiting amount of a 
d42m1 tumor cell clone lacking mutant spectrin-β2 (i.e., d42m1-T3).  To distinguish 
between these two cell populations in vivo we labeled d42m1-T2 with an altered, non-
immunogenic form of RFP that lacked class I epitopes and labeled d42m1-T3 with GFP. 
We first documented that the inherent in vivo growth characteristics of the two cell lines 
were not altered (Figure 18a).  We then tested several different ratios of the two clones 
and found that we could recapitulate the tumor growth phenotype of parental d42ml at a 
ratio of 95% regressor d42m1-T2RFP cells to 5% progressor d42m1-T3GFP cells (Figure 
18b).  At this ratio, 100% of Rag2-/- mice developed progressively growing tumors. 
Similar results were obtained using wild type mice depleted of either CD4+ or CD8+ T 
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cells (Figure 18c).  In contrast, 5/20 (25%) wild type mice injected with the tumor cell 
mixture developed escape tumors, a result that closely resembles the behavior of parental 
d42m1 tumor cells in wild type recipients.  Tumors harvested from Rag2-/- mice were 
comprised of 84% RFP+ d42m1-T2 tumor cells and 14% GFP+ d42m1-T3 cells (Figure 
18d) as detected by flow cytometry, a ratio that is very similar to the initial 95:5 mixture 
that was injected. At tumor harvest, the cell mixture expressed mutant spectrin-β2 as 
detected by mutation specific qRT-PCR (Figure 18e).  In contrast, tumors that grew out 
in wild type mice consisted of 98% GFP+ d42m1-T3 tumor cells and lacked mutant 
spectrin-β2 expression.  Thus, escape variants of parental d42m1 tumor cells develop as a 
consequence of a T cell dependent immunoselection process that favors the outgrowth of 
tumor cell clones that lack the major rejection antigen. 
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Figure 16.  Enforced expression of mutant spectrin-β2 in d42m1 escape variant 
tumor cells. qRT-PCR analysis using a primer pair specific for mutant spectrin-β2 in 
d42m1-es3 tumor cell clones that have been engineered to express either wild type or 
mutant spectrin-β2. Data is displayed as relative expression after normalization to control 
GAPDH expression and is representative of two independent experiments 
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Figure 17. Mutant spectrin-β2 is the major rejection antigen of d42m1 tumor cells. 
a, b, d, d42m1-es3 tumor cell clones reconstituted with wild type or mutant spectrin-β2 
and control d42m1-es3 expressing only GFP were transplanted at a dose of 1x106 cells 
into five-member groups of wild type (a, b) or Rag2-/- mice (d). Data are presented as 
average tumor diameter ± s.e.m. over time.  c, Percent tumor positive with five wild type 
mice per group from 2-3 independent experiments is shown.. e, d42m1-es3 tumors 
reconstituted with wild type (WT.3) or mutant spectrin-β2 (mu.14) were harvested at day 
11 (a) and CD8α+ T cells were stained with mutant spectrin-β2 tetramers. Samples were 
compared using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and 
***p<0.001; n.s. is non-significant). 
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Figure 18.  Immunoselection of d42m1 tumor cell clones that lack mutant spectrin-
β2 results in tumor escape.  a, d42m1-T2 clone labeled with RFP (d42m1-T2RFP) 
(n=5, squares) or d42m1-T3 clone labeled with GFP (d42m1-T3GFP) (n=5, triangles) 
were transplanted (1 x 106 cells) into wild type mice.  Data are presented as average 
tumor diameter ± s.e.m. and are representative of three independent experiments.  b, A 
mixture of d42m1-T2RFP (95%) and of d42m1-T3GFP (5%) was transplanted at a total 
dose of 1 x 106 cells into wild type (solid lines) or Rag2-/- (dashed lines) mice. c, Rag2-/- 
mice or wild type mice left untreated or treated with antibodies that deplete CD4+ or 
CD8+ T cells  were challenged with 1x106 d42m1 mixture (95% T2RFP and 5% T3GFP). 
Data presented as percent tumor positive from 2-4 independent experiments (n=2-5 mice 
per group.  d, GFP and RFP expression was analyzed in the d42m1-T2RFP/d42m1-
T3GFP tumor cell mixture before injection and from tumors that grew out in Rag2-/- mice 
or escaped in wild type mice by flow cytometry.  Data are representative of two 
independent experiments.  e, Mutation specific qRT-PCR analysis for mutant spectrin-β2 
in the d42m1-T2RFP/d42m1-T3GFP tumor cell mixture before injection and from tumors 
that grew out in Rag2-/- mice (RagPass) or escaped in wild type mice. Data are 
representative of two independent experiments. Samples were compared using an 
unpaired, two-tailed Student’s t test (**p<0.01 and ***p<0.001). 
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DISCUSSION 
 
Recent advances in genome sequencing have resulted in unprecedented 
opportunities to assess genetic influences on disease development.  For cancer, most 
genome sequencing studies have focused on identifying new driver mutations that 
promote neoplastic development and metastasis in the hope of obtaining insights that lead 
to novel cancer-targeted therapeutics or that provide prognostic value. However, we show 
herein that this same technology, when combined with in silico epitope prediction 
algorithms, can be used to identify expressed mutations in cancers that may result in 
formation of tumor-specific antigens which function as targets for immune-mediated 
elimination. To our knowledge, the current study is the first to use cDNA capture 
sequencing (CapSeq) analysis of expressed genes to assess the spectrum of non-
synonymous mutations in unedited tumors derived from immunodeficient mice and 
provide information pointing to potential antigens that may be responsible for immune-
mediated tumor rejection. We also demonstrate that the immunoediting of a tumor 
studied here in detail is the result of T cell dependent immunoselection for tumor cell 
variants that fail to express this mutation.  These results thus not only provide definitive 
evidence for at least one mechanism underlying the cancer immunoediting process, but 
also demonstrate the key role that tumor-specific mutations play in development of a 
tumor’s immunogenic phenotype and subsequent fate.  
 For d42m1 tumor cells, we show that an immunoselection process acting on an 
oligoclonal parental tumor cell population leads to the outgrowth of tumor cell variants 
that lack the major tumor rejection antigen—mutant spectrin-β2.  Currently, we are 
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unable to distinguish between the possibility that d42m1 clones in the parental d42m1 
sarcoma line that lack mutant spectrin-β2 either never expressed this antigen or lost 
expression. Nevertheless, the immunoselection that occurs upon exposure to an intact 
immune system is dependent on adaptive immunity since neither parental d42m1 tumor 
cells nor the mixture of regressor and progressor d42m1 tumor cell clones undergo 
editing when passaged through Rag2-/- mice, but are indeed edited following 
transplantation into immunocompetent wild type mice.  Additional experiments involving 
depletion of CD4+ or CD8+ lymphocytes point strongly to T cells as the specific effectors 
of this editing. These results are consistent with the finding that both T cells and perforin 
are required for editing of primary MCA sarcomas (87), primary lymphomas (22), and 
UV-induced tumors (212), although the targets of editing in these earlier studies were not 
defined.  Thus, in the case of d42m1, the target of the immunoselection process has been 
clearly identified as the major rejection antigen.  However, this finding does not rule out 
the possibility that similar immunoediting mechanisms might select for mutations in 
other critical components of the MHC class I antigen processing and presentation 
pathway such as the class I heavy chain (97), β2 microglobulin (100), or components of 
IFN-γ receptor signaling (27), all of which are known to regulate tumor cell recognition 
by tumor-specific CD8+ T cells.    
We find it surprising that a single mutant protein functions as the sole major 
rejection antigen in d42m1 tumor cells despite the fact that these tumor cells contain 
thousands of mutations.  Thus, the immunodominance of the mutant spectrin-β2 derived 
epitope, in some ways, resembles the known immunodominance of certain viral antigens 
(234).  Many factors may contribute to the immunodominance of mutant spectrin-β2.  On 
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the basis of in silico analysis, the mutant 905-913 sequence is predicted to interact with 
H-2Db with very high affinity, as opposed to the corresponding wild type sequence that is 
predicted to bind only weakly.  However, several other factors may also contribute to the 
immunodominance of mutant spectrin-β2 including (1) antigen abundance, (2) antigen 
cross-presentability, (3) T cell repertoire, or (4) presence of epitopes recognized by 
regulatory T cells.  Clearly, more work is needed in order to refine our capacity to 
accurately predict the ultimate antigenicity of a mutated protein.  
 Chemically induced tumors have played a critical role in the history of tumor 
immunology, providing the first unequivocal evidence for the existence of tumor-specific 
antigens (235-237).  It is therefore surprising that so little attention has been given to 
identifying the transplantation rejection antigens of this class of tumors.  Despite the 
widely held assumption that mutations account for the immunogenicity of these tumors, 
only one study thus far has identified a mutant protein recognized by CD8+ T cells (238). 
 In contrast, other studies of mouse and human tumors have chosen to focus on antigens 
that are shared among different tumors and sometimes even normal tissues.  With the 
growing recognition of the importance of mutational antigens as tumor-specific targets 
for immune recognition, there is a critical need to develop experimental systems that 
facilitate their identification.  The approach we have taken in this study, combining deep 
sequencing, algorithm analysis, and T cell epitope cloning, provides a new use for the 
powerful data that is rapidly accumulating from analyses of cancer genomes. We predict 
that this approach may not only provide new insights into basic mechanisms underlying 
cancer immunoediting, but also new opportunities for individualized cancer 
immunotherapy. It may also be useful in identifying subsets of cancer patients whose 
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tumors express antigens that can be most effectively targeted by checkpoint blockade 
immunotherapy, such as that involving anti-CTLA-4 or anti-PD-1.  Finally, this approach 
may provide a mechanism to longitudinally evaluate changes in a tumor’s antigenic 
profile as a consequence of ongoing immunotherapy.  
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	   135 
	  	  	  	  	  
CHAPTER 4 
 
Exome Sequencing of d42m1 Escape Variants 
as an Approach to Identify the Antigenic 
Targets of Checkpoint Blockade Therapy 
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INTRODUCTION 
 
 The previous chapter in this dissertation established that exome sequencing of a 
highly immunogenic, unedited sarcoma (d42m1) could be used to identify the major 
rejection antigen of this tumor (R913L spectrin-β2 mutant).  Nevertheless, d42m1 escape 
variants that lack mutant spectrin-β2 emerge that can grow in an immunologically 
unrestricted manner.  In this chapter, we will explore whether the many thousands of 
mutations still expressed by d42m1 escape variants and progressor clones exhibit residual 
immunogenicity.  Specifically, we will use antibodies that block negative co-stimulators 
that have recently been very successful in human cancer patients (206) to determine 
whether the potential antigens identified by exome sequencing of d42m1 escape variants 
and progressor clones can be targeted by this form of cancer immunotherapy. 
 
Checkpoint Blockade Therapy 
 Mechanisms of tumor escape from immune control may be directly at the level of 
the tumor, whereby alterations at the tumor cell surface results in decreased recognition 
(i.e. loss of MHC components) by immune cells or tumors may indirectly impede 
immunosurveillance through the recruitment of cells (i.e. regulatory T cells) or the 
liberation of cytokines (i.e. IL-10 or TGF-β) involved in immunosuppression.  The 
negative co-stimulatory molecules cytotoxic T lymphocyte-associated protein 4 (CTLA-
4) and programmed cell death 1 (PD-1) and its ligand (PD-L1) are likely candidates that 
may be facilitating tumor escape due to their potent ability to attenuate cytotoxic T cell 
responses. The blockade of these negative co-stimulatory molecules to boost anti-tumor 
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immunity and overcome cancer-induced immunosuppression is termed “checkpoint 
blockade” therapy. 
 
CTLA-4 in Inhibiting Tumor Immunity 
 These negative co-stimulatory molecules attenuate T cell responses during the 
physiological contraction phase of an immune response and help maintain peripheral 
tolerance.  CTLA-4 is a homologue of CD28 binds to the same receptors as CD28, both 
B7.1 (CD80) and B7.2 (CD86) (239, 240). The profound ability of CTLA-4 to inhibit T 
cell responses is dramatically displayed by gene-targeted mice deficient for CTLA-4, 
which succumb to lethal lymphoproliferative disease as a result of excessive T cell 
activation (241).  Subsequent studies have demonstrated that CTLA-4 expression on 
regulatory T cells (Tregs) and effector T cells is critical to prevent autoimmune 
lymphoproliferative disease (242, 243).  There are two general mechanisms proposed to 
explain how CTLA-4 is regulating immunity.  The first general mechanism involves 
CTLA-4 reducing the threshold of activation required for T cells to become activated in 
response to stimuli (threshold model).  The second general mechanism involves CTLA-4 
reducing or attenuating T cell proliferation after it has become activated (attenuation 
model) (244).  Substantial evidence exists for both models as CTLA-4 prevents binding 
of CD28 to CD80/CD86, recruits and activates phosphatases to the immunological 
synapse which degrade T cell receptor mediated signaling and inhibits cell cycle 
progression (245).  These data formed the basis for the concept that CTLA-4 could be 
blocked in the presence of an established tumor to reduce the threshold for T cell 
activation, enhance T cell proliferation, and boost anti-tumor activity.   
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 Considerable evidence exists for both mice and humans for using CTLA-4-
specific blocking monoclonal antibodies to eradicate or limit the growth of established 
tumors.  Initial studies in mice were promising as CTLA-4 blockade resulted in tumor 
rejection in a number of pre-clinical models of lymphomas, colon, renal, and prostatic 
carcinomas (246-249).  When CTLA-4 mAb treatment failed to lead to the rejection of 
poorly immunogenic tumors, synergistic strategies proved very effective.  Most often, 
CTLA-4 immunotherapy was combined with irradiated tumor vaccines engineered to 
secrete particular cytokines such as GM-CSF, to cause rejection of poorly immunogenic 
tumors (250).  In human cancer patients, both CTLA-4 monotherapy and combinatorial 
therapies have been successful in reducing melanoma, prostate and renal carcinoma 
tumor burdens and occasionally eliminating cancer altogether (206, 245). 
  
PD-1/PD-L1 Axis in Inhibiting Tumor Immunity 
Similar to CTLA-4, PD-1 and its ligand, PD-L1, regulate the contraction phase of 
the immune response and maintain peripheral tolerance. Additionally, PD-1 expression 
by antigen-specific CD8+ T cells induces exhaustion during chronic viral infections 
(251).  Initial studies investigating the role of PD-L1 as a mechanism of tumor escape 
involved enforced expression of PD-L1 on murine tumor cell lines.  In these studies it 
was observed that T cell activation and tumor killing were diminished in vitro and tumors 
grew more aggressively in vivo (252, 253).  Using the 4T1 mammary carcinoma model, 
tumor cells were found to upregulate the expression of PD-L1 in vivo, rendering the 
immunotherapy with anti-4-1BB mAb ineffective (254).  Furthermore, PD-L1 blockade 
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using anti-PD-L1 mAb delayed the growth of a myeloma cell line known to 
endogenously express PD-L1 (253).   
 Recent studies are now beginning to explore the use of combining PD-1, PD-L1, 
and CTLA-4 antibodies to boost the anti-tumor immune response and enhance the 
efficacy of these immunotherapies (255).  Although it is well established that these 
antibodies enhance the proliferation and cytokine secretion of both CD4+ and CD8+ T 
cells, the exact mechanism of how these antibodies mediate tumor rejection remains 
unknown.  There is some evidence that pre-existing immunity to tumor antigens prior to 
CTLA-4 therapy in human patients results in better outcomes (256). This suggests that 
tumors that express antigens of moderate strength may be capable of eliciting a robust 
immune response in the absence of immunosuppression or if the threshold for T cell 
activation is lowered in some manner. 
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MATERIALS AND METHODS 
 
Mice.  Batf3-/- mice (38) on a 129/Sv background were originally provided by Dr. 
Kenneth Murphy and were bred in our specific pathogen-free animal facility. Wild type 
and Rag2-/- mice were purchased from Taconic Farms. All mice were on a 129/Sv 
background and were housed in our specific pathogen-free animal facility.   For all 
experiments, mice were 8-12 weeks of age and performed in accordance with procedures 
approved by the AAALAC accredited Animal Studies Committee of Washington 
University in St. Louis. 
 
Tumor transplantation.  3-methylcholanthrene (MCA) induced sarcomas used in this 
study were generated in 129/Sv strain wild type or Rag2-/- mice and banked as low 
passage tumor cells as previously described (19).  Tumor cells derived from frozen stocks 
were propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% 
FCS (Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the 
flanks of recipient mice.  Tumor cells were >90% viable at the time of injection as 
assessed by trypan blue exclusion and tumor size was quantified as the average of two 
perpendicular diameters. 
 
MHC class I epitope prediction.  All missense mutations for each d42m1 tumor variant 
were analyzed for the potential to form MHC class I neoepitopes that bind to either H-
2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the 
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used 
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to predict epitope binding affinities (218) and the results were ultimately expressed as 
“Affinity Values”  (Affinity Value = 1/IC50 X 100). Missense mutations were detected 
using tumor cDNA exome capture and Illumina deep sequencing as previously described 
in Chapter 3 of this dissertation. 
 
Antibodies.  Anti-H-2Kb (B8-24-3) and anti-H-2Db (B22/249) mAbs were generously 
provided by Dr. Ted H. Hansen (Washington University School of Medicine). Anti-CD4 
(GK1.5), anti-CD8α (YTS169.4), anti-IFN-γ (H22) mAbs and control immunoglobulin 
(PIP, a mAb specific for bacterial glutathione S-transferase) were produced from 
hybridoma supernatants and purified in endotoxin-free form by Protein G affinity 
chromatography (Leinco Technologies, St. Louis, MO).  Purified Rat IgG was purchased 
from Sigma (St. Louis, MO).  CD45-FITC, CD45-PE, CD8-APC, and purified anti-
CD16/32 were purchased from BioLegend (San Diego, CA).  Anti-CTLA-4 (9H10), anti-
PD-1 (RMP1-14), and anti-PD-L1 (10F.9G2) were purchased from BioLegend (San 
Diego, CA). 
 
Establishment of CTL lines and clones.  To generate the d42m1 escape variant specific 
CTL lines, wild type mice were injected with 1 x 106 d42m1-T3 or d42m1-es3 tumor 
cells and treated with antibodies against CTLA-4, PD-L1, or PD-1.  Fourteen days after 
the tumor had been rejected, the spleen was harvested and a CTL line was established by 
stimulating 40 x 106 splenocytes with 2 x 106 d42m1-T3 or d42m1-es3 tumor cells pre-
treated for 48 hr with 100 U/ml of recombinant murine IFN-γ and irradiated (100 Gy). 
CTL lines were purified using CD8+ magnetic-beads (Miltenyi Biotec). 
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Measurement of IFN-γ  production.  To generate target cells, tumor cells were treated 
with 100U/ml IFN-γ for 48 hrs and irradiated with 100 Gy prior to use.  A CTL line was 
co-cultured at the indicated ratios with target tumor cells (10,000 or 5,000 cells) in 96-
well round-bottomed plates overnight.  IFN-γ in supernatants was quantified using an 
IFN-γ ELISA kit (eBioscience).  For blocking assays, 10 µg/ml of α-H-2Kb (B8-24-3) 
and/or α-H-2Db (B22/249) were added to the cell culture of effector (CTL lines) and 
target cells (tumors). 
  
Checkpoint blockade therapy.  Mice transplanted with tumors were treated with 200 µg 
of anti-CTLA-4, anti-PD-1, or ant-PD-L1 on day 3, 6, 9, 12, 15, and 18 post transplant.  
 
Tumor and spleen harvest.  After tumor cell transplantation, established tumors were 
excised from mice, minced and treated with 1 mg/ml type IA collagenase (Sigma) in 
HBSS (Hyclone) for 2 hrs at room temperature.  The spleen was also harvested and 
crushed between two glass slides and vigorously resuspended to make single-cell 
suspensions.  
 
Statistical Analysis.  Samples were compared using an unpaired, two-tailed Student’s t 
test.   
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RESULTS 
 
d42m1 Variants Lacking Mutant Spectin-β2 Exhibit Residual Immunogenicity 
To test whether d42m1 tumor variants that lack the major rejection antigen, 
mutant spectrin-β2, would exhibit residual immunogenicity, we transplanted tumors into 
wild type mice and treated them with blocking antibodies specific for PD-1, PD-L1, or 
CTLA-4. When transplanted into wild type mice and treated with control Ig, both d42m1-
T3 and d42m1-es3 grew progressively (Figure 1).  In contrast, d42m1-T3 and d42m1-es3 
were rejected in wild type mice that were treated with anti-PD-1, anti-PD-L1, or anti-
CTLA-4 (Figure 1). These data reveal that antigen loss variants of the unedited sarcoma 
d42m1 manifest residual immunogenicity and are rejected in wild type mice when treated 
with antibodies specific for negative co-stimulatory molecules. 
We next determined what are the critical immune components required to reject 
d42m1 antigen loss variants in this therapeutic setting.  Specifically, neutralizing 
antibodies against IFN-γ, depleting antibodies against CD4+ T cells and CD8+ T cells, 
and gene-targeted Rag2-/- mice that lack lymphocytes and Batf3-/- mice that lack CD8α+ 
(38) and CD103+ (257) dendritic cells were used for the characterization of the immune 
response involved in the rejection of d42m1-T3 after anti-PD-L1 or anti-CTLA-4 
treatment.  As previously shown, d42m1-T3 grows progressively when transplanted into 
wild type mice but is rejected when mice are treated with anti-PD-L1.  In contrast, 
d42m1-T3 grows progressively in wild type mice treated with anti-PD-L1 when mice are 
additionally treated with anti-CD4, anti-CD8, anti-CD4/CD8 combined, or anti-IFN-γ 
(Figure 2).  Additionally, d42m1-T3 grows progressively when transplanted into Rag2-/-  
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and Batf3-/- mice treated with anti-PD-L1 (Figure 2).  Thus, CD4+ and CD8+ T cells, IFN-
γ and CD8α+/CD103+ dendritic cells are required to mediate d42m1-T3 rejection after 
PD-L1 blockade therapy. Similar findings were obtained with d42m1-T3 after anti-
CTLA-4 treatment (Figure 2).  Furthermore, a memory response develops against the 
tumors after rejection due to checkpoint blockade therapy.  Specifically, mice that 
initially rejected d42m1-T3 or d42m1-es3 tumors with anti-PD-1 therapy are protected 
from secondary challenge with the same tumor several weeks later without any additional 
therapy (Figure 3).  Secondary challenged mice reject d42m1-T3 or d42m1-es3 tumors 
rapidly with tumors reaching a smaller peak size, results that are consistent with a 
memory response (Figure 3).  Taken together, all of these adaptive immune components 
are required to detect unveiled antigens and eliminate poorly immunogenic tumor cells 
after PD-L1 or CTLA-4 blockade and establish a memory response to the tumor antigens 
expressed in these antigen loss variants of d42m1. 
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Figure 1.  d42m1-es3 and d42m1-T3 are rejected in mice treated with antibodies 
that block CTLA-4, PD-L1, or PD-1. Cohorts of five mice were transplanted with 1 x 
106 d42m1-T3 (left) or d42m1-es3 (right) tumor cells and subsequently were treated with 
200 µg of anti-CTLA-4 (9H10), anti-PD-1 (RMP1-14), anti-PD-L1 (10F.9G2) or control 
Ig (PIP) on day 3, 6, 9, 12, 15, and 18 post transplant.   
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Figure 2.  Adaptive immune components are required to mediate rejection of 
d42m1-T3 after checkpoint blockade therapy. Cohorts of Rag2-/-, Batf3-/-, or wild type 
mice treated with control Ig (PIP), anti-CD4, anti-CD8α, or anti-IFN-γ mAbs were 
transplanted with 1 x 106 d42m1-T3 tumor cells and subsequently treated with 200 µg of 
anti-CTLA-4 (9H10) (top) or anti-PD-L1 (10F.9G2) (bottom) on day 3, 6, 9, 12, 15, and 
18 post transplant.   
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Figure 3.  Checkpoint blockade therapy induces a memory immune response against 
d42m1 antigen loss variants. Cohorts of wild type mice were transplanted with 1 x 106 
d42m1-T3 (top) or d42m1-es3 (bottom) tumor cells and treated with 200 µg of control Ig 
(PIP) or anti-PD-1 (RPM1-14) mAbs on days 3, 6, 9, 12, 15, and 18 post transplant.  
Mice that rejected d42m1-T3 or d42m1-es3 tumors after anti-PD-1 therapy were 
subsequently challenged with same tumor (d42m1-T3 or d42m1-es3) several weeks later. 
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d42m1 Variants Confer Cross-protective Immunity to One Another 
To test whether d42m1 tumor variants share similar antigens that may be cross 
protective, we first transplanted d42m1-T3 into wild type treated with antibodies specific 
for PD-1 to induce rejection.  Several weeks later, these mice were challenged 
secondarily with d42m1-T3, d42m1-es3, or F244 (Figure 4).  Mice initially challenged 
with d42m1-T3 tumor cells and treated with anti-PD-1 were able to reject d42m1-T3 and 
d42m1-es3 upon secondary challenge, suggesting that these tumors share antigens strong 
enough to mediate cross-protection (Figure 4).  In contrast, secondary transplantation 
with F244 resulted in tumor outgrowth. The converse was also true, where d42m1-es3 
was initially transplanted into wild type mice treated with anti-PD-1 and then the same 
mice were subsequently transplanted with d42m1-es3, d42m1-T3, and F244. Again, 
d42m1-es3 and d42m1-T3 cells were rejected, but F244 tumor cells grew in an 
unrestricted manner (Figure 4).  Finally, when wild type mice that had spontaneously 
rejected parental d42m1 tumor cells were challenged with d42m1-T3, d42m1-es3, or 
F244 tumor cells, both d42m1-T3 and d42m1-es3, but not F244, were rejected. 
Importantly, when mice that had rejected F244 after treatment with anti-PD-1 were 
subsequently challenged with F244, d42m1-T3 or d42m1-es3, only F244 tumor cells 
were rejected, demonstrating that d42m1-T3 and d42m1-es3 do not share antigens with 
F244 (Figure 5).  Taken together, these data show that the antigens expressed by d42m1-
T3 and d42m1-es3 that may be the targets of checkpoint blockade are most likely shared. 
We previously established through exome sequencing that all of the d42m1 
variants including d42m1 parental, regressor d42m1 variants (d42m1-T1, d42m1-T2, and 
d42m1-T9), progressor d42m1 variants (d42m1-T3 and d42m1-10), and escape variants 
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(d42m1-es1, d42m1-es2, and d42m1-es3) share a high percentage of missense mutations 
with one another.  Thus it is likely that these tumor variants may share similar antigens.  
In serial transplantation experiments, d42m1-T3, d42m1-es3 and parental d42m1 tumor 
cells appear to share antigens that can protect against secondary challenges.  We sought 
to extend this analysis to one additional progressor d42m1 clone (d42m1-T10) and one 
additional d42m1 escape variant (d42m1-es2).  Wild type mice initially transplanted with 
d42m1-es3 and treated with anti-CTLA-4 to induce the rejection of d42m1-es3 cells were 
subsequently challenged with d42m1-T10 or d42m1-es2 tumor cells.  Both d42m1-10 
and d42m1-es2 tumor cells were rejected, suggesting that d42m1-es3 cells share common 
antigens with d42m1-T10 and d42m1-es2 cells that are strong enough to mediate 
rejection, even when challenged several months after the initial d42m1-es3 challenge 
(Figure 4).  These results demonstrate the d42m1 variants express common antigens that 
are strong enough to mediate protection from secondary challenges of distinct, but related 
d42m1 variants.   
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Figure 4.  Serial transplantation of related but distinct d42m1 tumor variants 
results in cross-protective immunity.  Cohorts of wild type mice were transplanted with 
1 x 106 d42m1-T3 or d42m1-es3 tumor cells and treated with 200 µg of control Ig (PIP), 
anti-CTLA-4 (9H10) or anti-PD-1 (RPM1-14) mAbs on days 3, 6, 9, 12, 15, and 18 post 
transplant.  Mice that rejected d42m1-T3 or d42m1-es3 tumors after anti-PD-1 or anti-
CTLA-4 therapy were subsequently challenged with d42m1-T3, d42m1-T10, d42m1-es2, 
d42m1-es3, or F244 tumor cells several weeks later.  Also, mice that rejected d42m1 
parental tumors spontaneously were transplanted with d42m1-T3, d42m1-es3, or F244 
tumor cells several weeks later. 
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Figure 5.  Serial transplantation of F244 does not cross-protect against d42m1 
tumor variants. Cohorts of wild type mice were transplanted with 1 x 106 F244 tumor 
cells and treated with 200 µg of control Ig (PIP) or anti-PD-1 (RPM1-14) mAbs on days 
3, 6, 9, 12, 15, and 18 post transplant.  Mice that rejected F244 tumors after anti-PD-1 
therapy were subsequently challenged with d42m1-T3, d42m1-es3, or F244 tumor cells 
several weeks later.   
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Exome Analysis Limits the Number of Candidate Antigens Targeted by 
Immunotherapy 
Although we do not have direct evidence that the antigens targeted by checkpoint 
blockade therapy are expressed by all the d42m1 tumor variants, the ability of d42m1 
tumor variants to protect against other d42m1 tumor variants upon secondary 
transplantation suggests that they do indeed share common antigens.  Thus, we decided to 
mine our exome sequencing data we had recently generated that catalogues all the 
mutations expressed in the d42m1 tumor variants to see how many potential antigens 
were shared among all the variants. When we combined all the mutations sequenced that 
were found to be shared in all d42m1 variants (d42m1 parental, d42m1-T1, d42m1-T2, 
and d42m1-T9 regressor variants and well as d42m1-T3, d42m1-T10, d42m1-es1, 
d42m1-es2, and d42m1-es3 progressor variants), there were only a limited number of 
shared mutations that may be acting as the immunotherapeutic targets of progressor 
d42m1 variants (e.g., d42m1-T3 and d42m1-es3).  When the shared missense mutations 
were submitted to the immunoepitope database (218), very few mutations resulted in 
potential H-2Kb epitopes and only three formed potential H-2Db epitopes (Figure 6a). 
Since the most antigenic tumor-specific mutations most likely create peptides that bind 
with higher affinity to class I molecules than the wild type form of the peptide, we 
analyzed the potential antigen candidates for whether the mutant form of the peptide 
created a much stronger MHC class I binder than the wild type form (Affinity Value x 
Fold-Change).  When this additional filter was used, only three mutations resulted in 
potential H-2Kb epitopes and none formed potential H-2Db epitopes (Figure 6b).  Thus, 
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these results would predict that if the antigenic target of checkpoint blockade were shared 
among all the d42m1 variants that it would be restricted to H-2Kb. 
Next, we isolated and purified CD8+ T cells from the spleens of mice that had 
rejected d42m1-T3 after treatment with anti-CTLA-4/PD-L1 to generate CTL lines that 
recognize these tumor cells. To determine the MHC restriction of this bulk CTL line, we 
incubated the CD8+ T cells with irradiated d42m1-T3 tumor cells in the presence of 
antibodies that block H-2Db or H-2Kb.  IFN-γ production was detected when CD8+ T 
cells were co-cultured with d42m1, d42m1-T3, and d42m1-T3 in the presence of 
blocking H-2Db antibodies.  In contrast, IFN-γ production was blocked when antibodies 
specific for H-2Kb were added to the culture, indicating that the putative antigen 
expressed in d42m1-T3 tumor cells and recognized by this CTL line is presented on H-
2Kb (Figure 7).  This result corroborates the finding that shared antigens among the 
d42m1 tumor variants that were predicted by exome sequencing coupled to MHC class I 
epitope prediction algorithms would most likely be H-2Kb restricted. 
Of the limited number of H-2Kb restricted peptides common to all the d42m1 
tumor variants, the three peptides with the greatest change in H-2Kb binding represent the 
best candidate antigens targeted by checkpoint blockade (Figure 6b).  Among the three 
(Gpr108 R101L; Olfr684 D72Y; Olfr1239 C177S), one mutant peptide (Gpr108 R101L, 
SVRSYRSL) is of particular interest due to its high affinity binding for H-2Kb (predicted 
IC50 < 11 nM) and it resembles mutant spectrin-β2 in that it has an R to L change at the 
anchoring residue (position 8 for H-2Kb) (Figure 7).  Thus, we speculate that the CTL 
line generated against d42m1-T3 recognizes this R101L mutation in G-protein receptor 
108 (Gpr108).  Additional CTL lines have been generated against both d42m1-T3 and 
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d42m1-es3 using various combinations of checkpoint blockade antibodies that will be 
tested first, for their capacity to recognize d42m1 tumor variant cells and secondly, for 
their capacity to recognize synthesized mutant peptides (e.g. Gpr108 SVRSYRSL) 
presented on an unrelated H-2Kb expressing cells.   
 Although exome sequencing has provided a short list of putative epitopes that 
may be the targets of checkpoint blockade therapy for d42m1-T3 and d42m1-es3, more 
work is needed to identify the specific antigens and demonstrate its capacity to stimulate 
antigen-specific T cells in vivo.  Nevertheless, the approach described herein that 
combines deep sequencing of tumor exomes and class I prediction algorithms with 
isolation of CD8+ T cells has greatly limited the number of potential antigens to three, 
and particularly one that most likely functions as the target of immune-mediated 
elimination of tumor cells by checkpoint blockade therapy. 
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Figure 6.  Potential antigens shared among all the d42m1 tumor cell variants.  a, 
Common missense mutations shared by all d42m1 tumor cell variants (d42m1 parental, 
d42m1-T1, d42m1-T2, d42m1-T3, d42m1-T9, d42m1-T10, d42m1-es1, d42m1-es2, and 
d42m1-es3) and detected using cDNA capture sequencing were analyzed for their 
capacity to form neoantigens to H-2Db (top) or H-2Kb (bottom) using the class I 
prediction algorithm available from the Immune Epitope and Analysis Resource Center.  
Predicted IC50 values were expressed as “Affinity Values” (Affinity Value = 1/IC50 X 
100).  b, Affinity Values for H-2Db (top) and H-2Kb (bottom) were multiplied by the 
fold-change of predicted IC50 values from the wild type form to mutant form of the 
peptide. 
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Figure 7.  A CTL line generated against d42m1-T3 after checkpoint blockade 
therapy is restricted to H-2Kb.  CD8+ T cells isolated from a mouse that had rejected 
d42m1-T3 after anti-CTLA-4 and anti-PD-L1 combination therapy were incubated with 
irradiated (100 Gy) d42m1 parental, d42m1-T3, or H31m1 tumor cells pre-treated with 
100 U/ml IFN-γ for 48 hrs.  CTLs and target tumor cells were co-cultured overnight in 
the presence or absence of antibodies that block H-2Db or H-2Kb and supernatants were 
collected for IFN-γ ELISA assay.
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Figure 8.  Best potential antigen candidates for H-2Kb shared among all the d42m1 
tumor cell variants.  The top three antigen candidates that are predicted to bind to H-2Kb 
with high affinity and are shared among all d42m1 tumor cell variants are listed.  For 
comparison, the major rejection antigen of the regressor d42m1 variants, mutant spectrin-
β2, is listed. 
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DISCUSSION  
 
These data reveal that antigen loss variants of the unedited sarcoma d42m1 
manifest residual immunogenicity and are rejected in wild type mice when treated with 
antibodies specific for negative co-stimulatory molecules.  The rejection of d42m1 
tumors that lack mutant spectrin-β2 by checkpoint blockade therapy requires CD4+ T 
cells, CD8+ T cells, IFN-γ, and CD8α+/CD103+ dendritic cells.  Moreover, rejection of 
d42m1-T3 or d42m1-es3 by anti-PD-1 therapy establishes a long-lasting memory 
response to the original tumor such that secondary tumor challenge results in spontaneous 
rejection.  Thus, edited d42m1 tumor cells retain expression of antigens that can serve as 
functional targets for immunotherapuetically induced anti-tumor immune responses.  
We next established through serial transplantation experiments that d42m1 escape 
variants (d42m1-es2 and d42m1-es3), progressor d42m1 clones (d42m1-T3 and d42m1-
T10) and parental d42m1 tumor cells confer cross-protective immunity for one another.  
Thus, both highly immunogenic d42m1 tumor cells and poorly immunogenic d42m1 
tumor cells share common antigens strong enough to confer protective immunity.  In 
contrast, cross-protective immunity was not observed between d42m1-related cells and 
an unrelated edited MCA sarcoma, F244, confirming previous exome sequencing 
analyses described in Chapter 3 that d42m1 tumor variants are a closely related, but 
heterogeneous group of tumor cell lines.  Using the exome sequencing data, we found 
that only a limited number of antigens predicted to bind to H-2Db or H-2Kb with high 
affinity are shared in the d42m1 tumor variants that induce cross-protective immunity.  
And when we apply an additional filter to identify those mutant proteins that form mutant 
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peptides with high binding affinity to class I molecules that have very low binding 
affinity as wild type peptides (i.e., neoantigens), we find only three potential antigens for 
H-2Kb and none for H-2Db.  In fact, a CTL line generated from a mouse that rejected 
d42m1-T3 when treated with anti-CTLA-4 and anti-PD-L1 combination therapy 
recognized d42m1 parental and d42m1-T3 tumor cells in a H-2Kb restricted manner.  
Thus, these results point to an H-2Kb restricted mutant peptide functioning as the 
antigenic target of checkpoint blockade therapy.  
Among the three best antigen candidates restricted to H-2Kb, one seems very 
promising based on its high affinity for H-2Kb and its point mutation creates an amino 
acid substitution (R to L) at anchoring residue position 8 known to physiologically 
stabilize the peptide-MHC complex.  Although exome sequencing has provided a short 
list of putative epitopes (one in particular – R101L mutation in G-protein receptor 108) 
that may be the targets of checkpoint blockade therapy for d42m1-T3 and d42m1-es3, 
more work is needed to identify the specific antigens and demonstrate its capacity to 
stimulate antigen-specific T cells in vivo. To this end, additional CTLs lines have been 
generated and the wild type and mutant forms of the peptides (Gpr108 R101L; Olfr684 
D72Y; Olfr1239 C177S) have been synthesized.  Specifically, three distinct CTL lines 
have been generated from mice that rejected d42m1-T3 or d42m1-es3 tumors in response 
to checkpoint blockade therapy.  Next, the specificity of these CTL lines will be tested 
using the synthesized candidate peptides.  If any mutant peptides presented on unrelated 
H-2Kb expressing cells activates one of these CTL lines, then these peptides will be used 
to assemble soluble H-2Kb MHC class I tetramers to track mutation-specific CD8+ T cells 
in vivo.  Additionally, mutant peptides will be used to immunize wild type mice prior to 
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d42m1-T3 or d42m1-es3 tumor cell challenge to test if the peptide can be used to 
vaccinate against d42m1 antigen loss variants.   
Although the identification of the antigens targeted by checkpoint blockade 
therapy are have yet to be identified, the approach described herein that combines deep 
sequencing of tumor exomes and class I prediction algorithms with isolation of CD8+ T 
cells has greatly limited the number of potential antigens to three, and particularly one 
that most likely functions as the target of immune-mediated elimination of tumor cells by 
checkpoint blockade therapy.  We predict that the additional experiments outlined above 
will demonstrate which of the candidate antigens functions as the target for 
immunotherapeutically induced anti-tumor immune responses.
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CHAPTER 5 
 
Residual Immunogenicity of a Subset of 
Edited Sarcomas is Revealed by Checkpoint 
Blockade Therapy 
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INTRODUCTION 
 
The findings from the previous chapter provide additional support to the growing 
body of evidence that checkpoint blockade can induce powerful anti-tumor responses in 
both mice and humans (206, 245, 258).  Although the underlying mechanism of this type 
of immunotherapy remains to be elucidated, it seems likely that antigen expression by the 
tumor cells is critical to allow for tumor-targeted, immune-mediated destruction of 
transformed cells.  In fact, human cancer patients that had the best clinical responses to 
anti-CTLA-4 therapy, had pre-existing immunity to the cancer-associated antigen, NY-
ESO-1 (259, 260).  Despite dramatic reductions in tumor-burden in some cancer patients 
treated with anti-CTLA-4, the majority of individuals treated do not respond to this from 
of therapy for reasons that remain unknown (206).   
A number of pre-clinical studies have explored whether edited tumors that 
develop in immunocompetent mice can respond to checkpoint blockade therapy to 
determine the quality of the immune response necessary to induce tumor rejection.  For 
example, one earlier study in mice demonstrated that a transplanted edited sarcoma could 
be successfully treated with antibodies specific for CTLA-4 (249), and laid the 
groundwork for future investigations into using these antibodies to boost anti-tumor 
immunity.  Many poorly immunogenic tumors studied to date require additional therapies 
to be used in combination with checkpoint blockade therapy to induce host-protective 
immune responses.  Specifically, the experimental tumor B16 melanoma does not 
respond to anti-CTLA-4 monotherapy or a GM-CSF expressing DC vaccine (GVAX) 
alone, but in combination this therapy causes tumor rejection that provides long-lasting 
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immunity against B16 melanoma cells (250).  In this study, we sought to determine 
whether a large panel of edited, poorly immunogenic tumors derived from MCA-treated 
wild type mice also exhibit residual immunogenicity and respond to checkpoint blockade 
therapy. 
In contrast to d42m1 antigen loss variants, where all tumor variants tested 
responded to checkpoint blockade therapy, only 70% (9/13) of edited MCA sarcomas 
were rejected from wild type mice treated with anti-CTLA-4 therapy.  Moreover, the four 
different edited sarcomas that failed anti-CTLA-4 therapy also failed combinatorial 
therapies with anti-CTLA-4/PD-1 mAbs and thus, appear to be non-immunogenic.  These 
results suggest tumor-specific mutations in edited tumors most likely arise stochastically 
and therefore express different levels of antigenicity/immunogenicity.  To address this 
question, we used massively parallel sequencing of the exons from a panel of ten edited 
sarcomas, eight of which respond to anti-CTLA-4 therapy and two of which do not, and 
found that they display similar numbers of mutations.  Current analysis is underway to 
determine whether there are differences in the number of potential neoantigens that form 
from these mutations between tumors that exhibit residual immunogenicity and tumors 
that appear to be non-immunogenic and fail checkpoint blockade therapy.  Thus, it is 
tempting to speculate that the level of residual antigenicity remaining in a naturally 
immunoedited tumor and not the mutational load plays an important role in determining 
whether it can be effectively controlled by checkpoint blockade therapy.  
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MATERIALS AND METHODS 
 
Mice.  Wild type and Rag2-/- mice were purchased from Taconic Farms. All mice were 
on a 129/Sv or C57BL/6 background and were housed in our specific pathogen-free 
animal facility.   For all experiments, mice were 8-12 weeks of age and performed in 
accordance with procedures approved by the AAALAC accredited Animal Studies 
Committee of Washington University in St. Louis. 
 
Tumor transplantation.  3-methylcholanthrene (MCA) induced sarcomas used in this 
study were generated in 129/Sv or C57BL/6 strain wild type and banked as low passage 
tumor cells as previously described (19).  Tumor cells derived from frozen stocks were 
propagated in vitro in RPMI media (Hyclone, Logan, UT) supplemented with 10% FCS 
(Hyclone) and injected subcutaneously in 150 µl of endotoxin-free PBS into the flanks of 
recipient mice.  Tumor cells were >90% viable at the time of injection as assessed by 
trypan blue exclusion and tumor size was quantified as the average of two perpendicular 
diameters. 
 
Isolation of normal skin fibroblasts from wild type mice.  Skin fibroblasts were 
isolated from three independent 129/Sv wild type pups by harvesting skin and incubating 
in 0.25% trypsin (Hyclone) at 37°C for 30 minutes prior to washing in DMEM media 
(Hyclone).  After washing, chunks of skin were filtered to achieve single cell suspensions 
and cultured in vitro with DMEM media. After 3 passages, skin fibroblasts were 
harvested to isolate genomic DNA and total RNA. 
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Extraction of genomic or complementary DNA.  Genomic DNA from sarcoma cells 
and normal skin fibroblasts was extracted using DNeasy Blood & Tissue Kit (Qiagen).  
For cDNA isolation, total RNA from sarcoma cells and normal skin fibroblasts was 
isolated using RNeasy Mini kit (Qiagen) and cDNA was synthesized using oligo (dT) 
primers and SuperScript III Reverse Transcriptase (Invitrogen). 
 
cDNA capture, sequencing, and alignment (cDNA CapSeq) with Roche NimbleGen 
Exome Capture Array.  cDNA samples from each tumor (100 ng) were constructed into 
Illumina libraries according to the manufacturer’s protocol (Illumina Inc, San Diego, CA) 
with the following modifications:  1) cDNA was fragmented using Covaris S2 DNA 
Sonicator (Covaris, Inc. Woburn, MA) in 1X end-repair buffer followed by the direct 
addition of the enzyme repair cocktail (Lucigen, Madison, WI).  Fragment sizes ranged 
between 100 and 500 bp.  2) Illumina adapter-ligated DNA was amplified in four 50 µl 
PCRs for five cycles using 4 µl adapter-ligated cDNA, 2X Phusion Master Mix and 250 
nM forward and reverse primers, 
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATC and 5’	  
CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTC
CGATC, respectively.  3) Solid Phase Reversible Immobilization (SPRI) bead cleanup 
was used to purify the PCR-amplified library and to select for 300-500 bp fragments. 500 
ng of the size-fractionated Illumina library was hybridized with the Agilent mouse exome 
reagent.  After hybridization at 65°C for 24 hrs, we added 50 µl of DynaBeads M-270 
Streptavidin-coated paramagnetic beads (10 mg/ml) to selectively remove the 
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biotinylated Agilent probes and hybridized cDNA library fragments.  The beads were 
washed according to manufacturer’s protocol (Roche NimbleGen) and the captured 
library fragments were released into solution using 50 µl of 0.125 N NaOH and 
neutralized with an equal volume of neutralization buffer (Roche NimbleGen). The 
recovered fragments then were PCR amplified according to the manufacturer’s protocol 
using 11 cycles in the PCR.  Illumina library quantification was completed using the 
KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, MA). The qPCR result was 
used to determine the quantity of library necessary to produce 180,000 clusters on a 
single lane of the Illumina GAIIx.  One lane of 100 bp paired-end data was generated for 
each captured sample (since cDNA was used as the source for sequencing, we refer to 
this process as cDNA Capture Sequencing or CapSeq). Illumina reads were aligned to the 
NCBI build 37 (Mm9) mouse reference sequence using BWA (216) v0.5.5 (with –q 5 
soft trimming). Alignments from multiple lanes for the same sample were merged 
together using SAMtools r599, and duplicates were marked using Picard v1.29.   
 
Mutation detection and annotation.  Putative somatic mutations were identified using 
VarScan 2 (v2.2.4) (217) with the parameters “--min-coverage 3 --min-var-freq 0.08 --p-
value 0.10 --somatic-p-value 0.05 --strand-filter 1” and specifying a minimum mapping 
quality of 10. Variants whose supporting reads exhibited read position bias (average read 
position <10 or >90), strand bias (>99% of reads on one strand), or mapping quality 
(score difference >30, or mismatch quality sum difference >100) relative to reference 
supporting reads were removed as probable false positives. We also required that the 
variant allele be present in at least 10% of tumor reads and no more than 5% of normal 
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reads. The single nucleotide variants (SNVs) meeting these criteria were annotated using 
an internal database of Genbank/Ensembl transcripts (v58_73k). In the event that a 
variant was annotated using multiple transcripts, the annotation of most severe effect was 
used. Non-silent coding mutations (missense, nonsense/nonstop, or splice-site) were 
prioritized for downstream analysis. 
 
Mutation rate and overlap comparisons.  Mutation rates were estimated for each tumor 
sample using the number of putative “tier 1” SNVs (missense, nonsense/nonstop, splice 
site, silent, or noncoding RNA). To account for variability in coverage between samples, 
the SNV count for each tumor sample (S) was divided by a coverage factor (F), computed 
as the fraction of all tier 1 SNVs identified in any tumor sample (n=16,991) that were 
covered by at least 4 reads in a given sample. For example, in the d42m1 parental sample, 
15,852 of 16,991 tier 1 SNV positions were covered, for a coverage factor of 93.30%. 
The number of coverage-adjusted mutations in each sample was divided by the total size 
of tier 1 space in the mouse genome (43.884 Mbp) to determine the number of coding 
mutations per megabase (R).  
R = (S / F) / (43.884 Mbp) 
 
MHC class I epitope prediction.  All missense mutations for edited wild type sarcoma 
were analyzed for the potential to form MHC class I neoepitopes that bind to either H-
2Db or H-2Kb molecules. The artificial neural network (ANN) algorithm provided by the 
Immune Epitope Database and Analysis Resource (www.immuneepitope.org) was used 
to predict epitope binding affinities (218) and the results were ultimately expressed as 
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“Affinity Values”  (Affinity Value = 1/IC50 X 100). An additional analysis using Affinity 
Value multiplied by the Fold Change (wild type IC50/mutant IC50) was also used. 
 
Antibodies.  Anti-CTLA-4 (9H10) was generously provided by Dr. James Allison, anti-
PD-1 (RMP1-14) by Dr. Hideo Yagita, and anti-PD-L1 (10F.9G2) by Drs. Arlene Sharpe 
and Gordon Freeman.  Subsequent quantities of these clones were purchased from 
BioLegend (San Diego, CA).  Distinct clones of anti-CTLA-4 (9D9), anti-PD-1 (4H2), 
and anti-PD-L1 (14D8) were provided by Bristol Myers Squibb (New York, NY). 
  
Checkpoint blockade therapy.  Mice transplanted with tumors were treated with 200 µg 
of anti-CTLA-4, anti-PD-1, or ant-PD-L1 on day 3, 6, 9, 12, 15, and 18 post transplant.  
 
Statistical Analysis.  Samples were compared using an unpaired, two-tailed Student’s t 
test.   
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RESULTS 
 
A Subset of Edited Sarcomas from Wild Type Mice Manifest Residual 
Immunogenicity 
As opposed to d42m1 antigen loss variants, where all progressor clones and 
escape variants are rejected with checkpoint blockade therapy, when a panel of edited 
MCA sarcomas derived from wild type mice were tested for anti-CTLA-4 sensitivity, 
only 70% (9/13) of sarcomas were rejected in wild type mice after transplantation of 
sarcoma cells and treatment with anti-CTLA-4 mAbs (Figure 1).  Specifically, 10 edited 
sarcomas derived from 129/Sv strain mice (F279, F244, F236, H118m1, d4m3, d22m1, 
d22m2, c20m1, c1m2, and H128m8462) (19) and three edited sarcomas derived from 
C57BL/6 strain mice (9609, 9614, and 1956) (C.M. Koebel, J.D. Bui and R.D. Schreiber, 
unpublished results) were transplanted into syngeneic hosts and treated with anti-CTLA-
4.  Of the nine edited sarcomas that responded, eight were 129/Sv tumors (F244, F236, 
H118m1, d22m1, d22m2, c20m1, c1m2, and H128m8462) and one was a C57BL/6 
tumor (1956), leaving two edited 129/Sv tumors (F279 and d4m3) and two edited 
C57BL/6 tumors (9609 and 9614) that did not respond to anti-CTLA-4 therapy (Figure 
1).  These results suggest that edited MCA sarcomas have varying levels of residual 
immunogenicity that can be revealed by checkpoint blockade therapy.  
All edited sarcomas tested that are rejected with anti-CTLA-4 therapy are also 
rejected by either anti-PD-L1 mAb alone, anti-CTLA-4 mAb alone, or anti-PD-L1 and 
anti-CTLA-4 mAbs in combination.  Thus, F244, F236, and 1956 edited sarcomas exhibit 
residual immunogenicity and are rejected when mice harboring these tumors are treated 
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with any checkpoint blockade antibodies (Figure 2).  On the other hand, d4m3, F279, 
9614, and 9609 appear to be non-immunogenic when assayed by this method since 
treatment with other checkpoint blockade antibodies did not restrain tumor growth in any 
manner, even when used in combination (Figure 3).  Therefore, there is a subset of edited 
MCA sarcomas derived from wild type mice that appear to be non-immunogenic.   
 
Exome Sequencing of Edited MCA Sarcomas  
It is unknown whether the varying levels of residual immunogenicity remaining in 
naturally immunoedited tumors is determined by varying levels of antigenicity and thus, 
helps determine whether a tumor can be effectively controlled by checkpoint blockade 
therapy.  Therefore, we performed exome sequencing on eight edited MCA sarcoma cell 
lines that respond to checkpoint blockade therapy (F244, F236, H118m1, d4m3, d22m1, 
d22m2, and H128m8462) and two edited MCA sarcoma cell lines that do not respond to 
checkpoint blockade therapy (F279 and d4m3) in order to characterize the mutations and 
identify the array of potential antigens expressed in edited sarcomas.  These ten edited 
sarcomas were chosen to be sequenced among the panel of 13 edited sarcomas because 
they were all derived from wild type 129/Sv mice treated with 100 µg of MCA, and thus 
are genetically- and carcinogen-load–matched.  In addition, three normal skin fibroblast 
cell lines derived from wild type mice were generated and cDNA was isolated, exome 
captured and sequenced to serve as the reference sequence for the identification of non-
synonymous mutations in the sarcoma cell lines.  Specifically, cDNA was isolated from 
all 10 of these sarcoma cell lines and 3 normal fibroblast lines, constructed into Illumina 
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libraries, hybridized to mouse exome probes (Roche NimbleGen) and submitted for 
Illumina sequencing. 
Exome sequencing revealed that edited sarcomas display a range of protein-
coding mutations (tier 1 SNVs).  The average number of non-synonymous mutations in 
all ten edited sarcomas was 2,267 with a range from 1,317 to 3,380 mutations for 
individual edited sarcomas (Figure 4).  As a control, d42m1 parental cells, which are 
highly immunogenic and were derived in a Rag2-/- immunodeficient mouse was included 
in this cDNA CapSeq experiment and found to express 2,707 non-synonymous 
mutations.   Thus, there does not appear to be a significant difference in the number of 
mutations present in edited sarcomas when compared to those in unedited sarcomas.   
However, using two rounds of exome capture with Agilent mouse exome probes with 
d42m1 parental cell cDNA, we detected 3,737 non-synonymous mutations.  Here we 
used a single round of exome capture with Roche NimbleGen mouse exome probes and 
detected nearly 1,000 fewer mutations.  This discrepancy may be due in part to 
differences in the percentage of genes captured by the two different commercial exome 
mouse probe reagents (Agilent and Roche NimbleGen) as well as the differences in 
sequencing coverage that can be minimized by repeating cDNA CapSeq.  Clearly, one 
approach is to perform cDNA CapSeq with the NimbleGen mouse exome probe reagent 
an additional time for parental d42m1 and edited sarcoma samples to enhance exome 
sequencing coverage and enhance mutation call accuracy.    
Nevertheless, this preliminary sequencing data does provide some initial insight 
into the mutational landscape of edited sarcomas.  First, it appears that there is no 
difference between edited and unedited MCA sarcomas, suggesting that the mutational 
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load present in these tumor cells is not greatly influenced by the host’s immune status.  
Secondly, there is a very broad range of mutations detected in edited sarcomas with some 
tumors having nearly three times the number of mutations (Figure 4).  For example, 
1,317 mutations were detected in F279 tumor cells and 3,380 mutations were detected in 
c1m2 tumor cells.  Interestingly, F279 tumors cannot be controlled in immunocompetent 
hosts treated with checkpoint blockade antibodies, while c1m2 tumors are rejected 
following anti-CTLA-4 treatment (Figure 1).  However, the other edited sarcoma that 
fails checkpoint blockade, d4m3, has 2089 mutations which is comparable to the other 
sarcomas that do respond to anti-CTLA-4 therapy such as F236 which has 1,606 
mutations.   Thus, although there is a trend for edited sarcomas that fail anti-CTLA-4 
therapy (F279 and d4m3) to have fewer mutations than those that do respond to 
immunotherapy, there is no statistical difference between the numbers of mutations in the 
two subsets of edited sarcomas (Figure 4).  Current analysis is underway to determine if 
the number of potential antigens is distinct between sarcomas that respond and sarcomas 
that fail to respond to checkpoint blockade therapy by pipelining the exome sequencing 
data into MHC class I prediction algorithms.   
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Figure 1.  A subset of edited MCA sarcomas derived from immunocompetent wild 
type mice respond to anti-CTLA-4 therapy.  A panel of 13 edited MCA sarcomas were 
transplanted into wild type mice treated with 200 µg of control Ig (PIP) (black) or anti-
CTLA-4 (9D9) (red) on days 3, 6, 9, 12, 15, and 18 post transplant.  Ten of the 13 tumors 
are 129/Sv strain tumors (F279, F244, F236, H118m1, d4m3, d22m1, d22m2, c20m1, 
c1m2, and H128m8462) (19) and the remaining three edited sarcomas were derived from 
C57BL/6 strain mice (9609, 9614, and 1956) (C.M. Koebel, J.D. Bui and R.D. Schreiber, 
unpublished results).
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Figure 2.  Edited MCA sarcomas that respond to anti-CTLA-4 therapy also respond 
to anti-PD-1 and anti-PD-L1 therapy.  F244, F236, and 1956 were transplanted into 
wild type mice at a dose of 1 x 106 cells and treated with 200 µg of control Ig (PIP) 
(black), anti-CTLA-4 (9H10) (red), anti-PD-L1 (10F.9G2) (blue), anti-PD-1 (RMP1-14) 
(green) or combination of anti-CTLA-4/PD-L1 (purple) on days 3, 6, 9, 12, 15, and 18 
post transplant.
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Figure 3.  Edited MCA sarcomas that fail to respond to anti-CTLA-4 therapy also 
fail to respond to anti-PD-1 and anti-PD-L1 therapy or anti-CTLA-4/anti-PD-L1 
combination therapy.  F279, d4m3, 9606, and 9614 were transplanted into wild type 
mice at a dose of 1 x 106 cells and treated with 200 µg of control Ig (PIP) (black), anti-
CTLA-4 (9H10) (red), anti-PD-L1 (10F.9G2) (blue) or combination of anti-CTLA-4/PD-
L1 (green) on days 3, 6, 9, 12, 15, and 18 post transplant.
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Figure 4.  Number of mutations present in edited sarcomas as detected by exome 
sequencing.  Number of mutations detected by exome sequencing on eight edited MCA 
sarcoma cell lines that respond to checkpoint blockade therapy (“Edited Sarcomas (+)” = 
F244, F236, H118m1, d4m3, d22m1, d22m2, and H128m8462) and two edited MCA 
sarcoma cell lines that do not respond to checkpoint blockade therapy (“Edited Sarcomas 
(+)” = F279 and d4m3).  In addition, the unedited sarcoma d42m1 parental was included 
as a positive control for the NimbleGen mouse exome capture reagent (“Unedited 
Sarcoma”). 
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DISCUSSION 
 
In this study, we have examined a set of edited sarcomas derived from MCA-
treated immunocompetent wild type mice for residual immunogenicity by using 
checkpoint blockade therapy.  When cohorts of wild type mice were transplanted with 13 
different edited MCA sarcomas and subsequently treated with anti-CTLA-4 therapy, 9/13 
(70%) sarcomas were rejected, suggesting that not all edited sarcomas exhibit residual 
immunogenicity.  In addition, the four sarcomas that failed anti-CTLA-4 therapy also 
failed anti-PD-L1, anti-PD-1 therapy and anti-CTLA-4/PD-1 combination therapy. 
Similar to this panel of edited sarcomas, it is unclear why significant clinical responses to 
CTLA-4 blockade have been noted in some, but not all cancer patients (206).  Perhaps 
the stochastic nature of the process that gives rise to antigens derived from tumor-specific 
mutations will produce edited tumors that express different levels of 
antigenicity/immunogenicity.   
 To address this issue, the exomes of MCA sarcomas derived from 
immunocompetent wild type mice were sequenced to first ask how many mutations are 
present in these tumors and second, whether the number of mutations differ between 
tumors generated in wild type mice (edited) versus tumors derived from Rag2-/- mice 
(unedited)?  First, there is a very broad range of mutations detected in edited sarcomas 
with some tumors have nearly three times the number of mutations.  For example, 1,317 
mutations were detected in F279 tumor cells and 3,380 mutations were detected in c1m2 
tumor cells.  Secondly, it appears that there is no difference between the number of 
mutations in edited and unedited MCA sarcomas, suggesting that the mutational load 
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present in these tumor cells is not greatly influenced by host’s immune status.  
Interestingly, there was a slight trend for edited sarcomas that fail anti-CTLA-4 therapy 
(F279 and d4m3) to have fewer mutations than those that do respond to immunotherapy, 
but there was no statistical difference between the numbers of mutations in the two 
subsets of edited sarcomas.   
Pipelining the mutations identified by next-generation sequencing into MHC class 
I epitope prediction programs will be used to generate the antigenic profiles of tumors 
that have escaped immune control.  It will be very interesting to use these antigenic 
profiles of edited tumors to correlate the quantity and quality of the potential antigens 
with response to immunotherapy.  Current analyses are in progress to generate the 
antigenic profiles of all the edited sarcomas and results are pending. The ultimate test will 
be to use the antigenic profiles of experimental tumors to predict which respond to 
immunotherapy, which could have potential ramifications for human cancer 
immunotherapy. 
In future studies, we will generate CD8+ CTL lines against edited sarcomas that 
respond to checkpoint blockade therapy, determine the MHC restriction of these CTL 
lines and synthesize peptide epitope candidates recognized by these CTL lines to identify 
the antigen(s) expressed in edited tumor cells that are putatively targeted by checkpoint 
blockade therapy.  To confirm whether an identified antigen candidate is targeted by 
checkpoint blockade therapy in vivo, MHC class I tetramers specific for the mutant 
peptide recognized by the CTL lines will be generated to track endogenous mutant-
specific CD8+ T cells.  Ultimately, we will enforce expression of the mutant antigen from 
a susceptible tumor cell line in a tumor line that is not normally rejected by checkpoint 
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blockade therapy and will assess whether it now drives rejection following anti-CTLA-4 
or anti-PD-1 therapy. 
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CHAPTER 6 
 
Summary and Future Directions 
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SUMMARY AND CONCLUSIONS 
 
The research presented in this dissertation represents a significant transition in the 
evolution of the cancer immunoediting concept.  In the past, our efforts mostly centered 
on demonstrating that the process occurs, identifying the key players in it and attempting 
to define the positions that they play.  We now enter a new phase in which we can begin 
to elucidate the molecular mechanisms that drive the process.  We shifted our focus from 
the immune components that edit tumor immunogenicity, to the tumor cells themselves to 
ask whether the quality or quantity of tumor antigens expressed in nascent transformed 
cells determines immune-mediated elimination or sculpting.  Thus, the overarching goal 
of this thesis was to understand what drives the editing of highly immunogenic tumor 
cells to those of reduced immunogenicity that grow in an immunologically unrestricted 
manner. 
In the first study, we set out to further examine the editing of tumor 
immunogenicity by IFN-γ.  Although other studies have shown that IFN-γ is critical to 
mediate immunosurveillance against primary tumors, these tumors lacked IFNGR1 and 
thus required additional manipulations to unmask their highly immunogenic character 
(16, 19).  In fact, lymphomas that spontaneously form in gene-targeted mice deficient in 
IFN-γ do not reject when transplanted into wild type mice, suggesting that have been 
edited by non-IFN-γ mechanisms (22).  To unequivocally demonstrate that IFN-γ plays a 
critical role in shaping tumor immunogenicity, we took the “gold standard” approach of 
generating primary MCA-induced sarcomas in an environment that lacks IFN-γ, 
harvested those tumors, generated cell lines, and transplanted them into wild type hosts to 
	  	  	   194 
see whether any unmanipulated sarcomas spontaneously reject in immunocompetent 
recipients.   
Using a cohort of C57BL/6 mice exposed to MCA, we chronically treated these 
mice with neutralizing IFN-γ antibodies (H22) to generate sarcomas that developed in the 
absence of IFN-γ, but retained normal IFN-γ receptor signaling.  These IFN-γ neutralized 
mice developed more MCA-induced sarcomas than their control counterparts, confirming 
previous reports that IFN-γ prevents development of primary tumors (16, 19, 55).  In 
addition, 3/10 (30%) of MCA-induced sarcomas from IFN-γ neutralized mice 
spontaneously rejected when transplanted into naïve wild type hosts—a finding that is 
remarkably similar to Rag2-/- mice and Ifnar1-/- mice where 40% and 36% of the MCA 
sarcomas are highly immunogenic regressors, respectively (19, 24).  These three highly 
immunogenic sarcomas, termed “H22-regerssors” required CD4+ T cells, CD8+ T cells, 
and IFN-γ for their rejection, providing further evidence that they phenotypically 
resemble unedited tumors.  Each of the three individual H22-regressors had different 
requirements for IFN-γ responsiveness at the level of the host and/or tumor to mediate 
tumor rejection, a result that is in contrast to Rag2-/- MCA sarcomas generated on a 
129/Sv background where either IFN-γ responsiveness at the level of the host or the 
tumor alone is sufficient to mediate tumor rejection (25) (C.M. Koebel and R.D. 
Schreiber, unpublished results).  Taken together, these data suggest that IFN-γ sculpts 
tumor immunogenicity and, to date, is the best evidence that endogenous IFN-γ can alter 
tumor immunogenicity during primary tumor development.  In addition, this is the first 
demonstration that unedited sarcomas can be generated using blocking monoclonal 
antibodies in wild type mice.  
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In the second study of this thesis, we show that cancer exome sequencing 
technology when combined with in silico epitope prediction algorithms can be used to 
identify expressed mutations in cancers that result in formation of tumor-specific antigens 
which function as targets for immune-mediated elimination.  Initial work revealed that 
the highly immunogenic Rag2-/- unedited tumors, H31m1 and d42m1, share a similar 
mutational landscape as carcinogen-induced human lung cancers.  Although d42m1 and 
H31m1 display largely non-overlapping mutations that helps explain their distinct 
immunogenicities, they do share mutations in Kras (d42m1 Kras G12C; H31m1 Kras 
G12D) and in Trp53 (d42m1: Trp53 E295stop; H31m1: Trp53 S152R and S258I) that are 
frequently observed in human and mouse cancers (222-224).  Next, we combined deep 
sequencing, algorithm analysis, and T cell epitope cloning to identify mutant spectrin-β2 
as a potential rejection antigen for d42m1 tumor cells.  CD8+ T cells specific for mutant-
spectrin-β2 infiltrate d42m1 tumors just prior to rejection, but do not infiltrate d42m1 
escape variants that lack mutant spectrin-β2 expression.  However, enforced expression 
of mutant spectrin-β2 into these escape variants induces the infiltration of mutant-specific 
CD8+ T cells and tumor rejection, demonstrating that mutant spectrin-β2 is the major 
rejection antigen of d42m1. 
To our knowledge, this is the first study to identify an antigen from an unedited 
tumor (d42m1) that is responsible for tumor rejection.  Moreover, we show that a T cell-
dependent immunoselection process acting on an oligoclonal parental tumor cell 
population leads to the outgrowth of tumor cell variants that lack the immunodominant, 
tumor-specific rejection antigen—mutant spectrin-β2.  These results are consistent with 
the finding that both T cells and perforin are required for editing of primary MCA 
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sarcomas (87), primary lymphomas (22), and UV-induced tumors (212), although the 
targets of editing in these earlier studies were not defined.  Thus, in the case of d42m1, 
the target of the immunoselection process has been clearly identified as the major 
rejection antigen.  Certainly, similar mechanisms might also produce tumor variants with 
defects in MHC class I antigen processing and presentation or IFN-γ receptor signaling, 
which have been observed in clinically apparent human cancers (27, 97). 
 The apparent singular importance of mutant spectrin-β2 in driving rejection of 
d42m1 in many ways resembles the known immunodominant behavior of certain viral 
antigens (234).  However, preliminary analyses of other unedited MCA sarcomas (such 
as H31m1) reveal that some express multiple strong antigens.  Thus, it is possible that the 
presence of one or more highly antigenic protein contributes to deciding whether a 
nascent tumor is eliminated or undergoes editing.  Our results thus not only provide 
definitive evidence for at least one mechanism underlying the cancer immunoediting 
process, but also demonstrate the key role that tumor-specific mutations play in 
development of a tumor’s immunogenic phenotype and subsequent fate.   
In the third study, we examined whether d42m1 antigen loss variants exhibit 
residual immunogenicity.  Since exome sequencing of d42m1 tumor variants detected 
thousands of mutations that result in protein-coding alterations and since one mutant 
protein (the R913L spectrin-β2 mutant) was responsible for immune-mediated 
elimination of regressor d42m1 tumor cells, we asked whether these other mutations 
formed antigens that conferred residual immunogenicity.  To test this, we used antibodies 
that block negative co-stimulatory molecules to boost anti-tumor immunity and overcome 
cancer-induced immunosuppression.  Currently, this form of cancer immunotherapy, 
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termed “checkpoint blockade” therapy, has been the most successful form of 
immunotherapy to date (245).  Specifically, anti-CTLA-4 therapy is quickly becoming a 
frontline therapeutic against malignant melanoma (206).  When we transplanted d42m1-
T3 and d42m1-es3 tumor cells into wild type mice and subsequently treated these mice 
with anti-CTLA-4, anti-PD-1, or anti-PD-L1 mAbs, both tumors were readily rejected.  
Rejection of d42m1-T3 and d42m1-es3 in the context of checkpoint blockade therapy 
required CD4+ T cells, CD8+ T cells, CD8α+/CD103+ DCs, and IFN-γ.  Thus, antigen 
loss variants of d42m1, indeed, express antigens that confer residual immunogenicity 
and, presumably, these antigens are targeted by checkpoint blockade therapy.  In 
addition, distinct d42m1 tumor variants could induce cross-protective immunity in serial 
transplantation experiments, suggesting that d42m1-related cells share common antigens.  
In contrast, d42m1 tumor variants could not protect against secondary challenge by an 
unrelated sarcoma, F244, indicating that there are unique antigens shared by the d42m1 
variants capable of inducing protective immunity.  
Based on these results, we mined our previous exome sequencing/in silico 
analysis for mutations that form potential antigens that are shared among the d42m1 
variants.  We found that there were only three potential antigens for H-2Kb and none for 
H-2Db.  In fact, a CTL line generated from a mouse that rejected d42m1-T3 when treated 
with anti-CTLA-4 and anti-PD-L1 combination therapy recognized d42m1 parental and 
d42m1-T3 tumor cells in a H-2Kb restricted manner.  Thus, these results point to an H-
2Kb restricted mutant peptide functioning as the antigenic target of checkpoint blockade 
therapy.  Although exome sequencing has provided a short list of putative epitopes (one 
in particular – R101L mutation in G-protein receptor 108) that may be the targets of 
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checkpoint blockade therapy for d42m1-T3 and d42m1-es3, more work is needed to 
identify the specific antigens and demonstrate its capacity to stimulate antigen-specific T 
cells in vivo.  To this end, additional CTLs lines have been generated and the wild type 
that rejected d42m1-T3 or d42m1-es3 tumors in response to checkpoint blockade therapy 
and mutant forms of the peptides (Gpr108 R101L; Olfr684 D72Y; Olfr1239 C177S) have 
been synthesized.  We predict that the additional experiments outlined above will 
demonstrate which of the candidate antigens functions as the target for 
immunotherapeutically induced anti-tumor immune responses. 
In the final study of this thesis, we explored whether edited MCA-induced 
sarcomas that developed in immunocompetent wild type mice also exhibited residual 
immunogenicity.  Using the checkpoint blockade therapy, we found that 9/13 (70%) of 
edited sarcomas respond to anti-CTLA-4 therapy.  Edited sarcomas that are rejected due 
to CTLA-4 therapy also rejected in mice treated with anti-PD-1 or anti-PD-L1 mAbs.  In 
contrast, the four edited sarcomas that fail anti-CTLA-4 therapy (F279, d4m3, 9609, and 
9614) do not respond to anti-PD-1 or anti-PD-L1 mAbs, even when used in combination 
with anti-CTLA-4 therapy.  Thus, a subset of edited sarcomas respond to checkpoint 
blockade therapy and a subset of edited sarcomas fail to respond to checkpoint blockade 
therapy, a situation that resembles the clinical scenario.  Currently, it is unknown why 
certain human cancer patients respond or fail to respond to anti-CTLA-4 therapy, but one 
study demonstrated that the patients that had the best clinical responses had pre-existing 
immunity to a cancer-associated antigen, NY-ESO-1 (259, 260).  This result suggests that 
antigen expression by the tumor cells may be critical to allow for tumor-targeted, 
immune-mediated destruction of transformed cells by checkpoint blockade therapy.  
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To attempt to address this question, we sequenced the exons of ten edited wild 
type sarcomas, two of which fail to respond to anti-CTLA-4 therapy (F279 and d4m3).  
Although there was a trend for fewer numbers of mutations in F279 and d4m3 than the 
other eight edited sarcomas that do respond to anti-CTLA-4 therapy, it was not 
statistically significant.  Moreover, the number of mutations in edited sarcomas was 
similar to the number detected in the highly immunogenic, unedited tumors (H31m1 and 
d42m1).  These results suggest that the number of mutations present in MCA-induced 
sarcomas is due to the carcinogen-load, location, and tissue-type involved and not due to 
the immune status of the host.  Thus, it is tempting to speculate that the level of residual 
antigenicity remaining in a naturally immunoedited tumor plays an important role in 
determining whether it can be effectively controlled by checkpoint blockade therapy.  We 
are currently analyzing whether the mutations present in edited sarcomas form 
neoantigens using class I prediction algorithms. 
Taking together, the data presented in this thesis has attempted to further our 
understanding of the factors that drive the cancer immunoediting process.  We show that 
tumor-specific antigens of high affinity are targeted by the cancer immunosurveillance 
network to eliminate tumors cells and that antigen loss variants of reduced 
immunogenicity emerge due to a T-cell dependent immunoselection process.  
Furthermore, residual antigenicity is unmasked in antigen loss variants of d42m1 and 
edited wild type sarcomas using checkpoint blockade therapy.  The approach of exome 
sequencing, in silico analysis, and CD8+ T cell cloning used in this thesis may be of 
beneficial use to both basic and clinical scientists.  By defining the specific antigenic 
targets of immunotherapeutically-induced, immune-mediated tumor cell elimination, we 
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should obtain new levels of understanding of host responses to tumors during ongoing 
therapy that may facilitate the development of new therapeutic opportunities to direct the 
power and specificity of the immune system into controlling and/or destroying cancer.  It 
may also be useful in identifying subsets of cancer patients whose tumors express 
antigens that can be most effectively targeted by checkpoint blockade immunotherapy 
and may provide a mechanism to longitudinally evaluate changes in a tumor’s antigenic 
profile as a consequence of ongoing immunotherapy.  Therefore, we predict that a 
genomic approach to tumor antigen identification such as the one reported here may, in 
the future, facilitate the development of individualized cancer immunotherapies directed 
at tumor-specific—rather than cancer-associated—antigens. 
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FUTURE DIRECTIONS 
 
What are the host targets for IFN-γ  mediated tumor rejection? 
 
 We now have extensive evidence that IFN-γ is critical for preventing primary 
tumor formation and for sculpting tumor immunogenicity (16, 19, 22, 55).  In this thesis, 
we generated three unedited sarcomas from MCA-treated wild type mice chronically 
administered IFN-γ neutralizing antibodies (H22).  All three of these tumors required 
IFN-γ for their rejection and for one tumor, H22-28027, IFN-γ responsiveness at the level 
of the tumor alone was sufficient to mediate rejection, confirming previous results from 
our laboratory (15).  For H22-28032 tumors, IFN-γ responsiveness at the level of the host 
was sufficient to mediate tumor rejection, as H22-28032 tumor cells grew out in the 
majority of Ifngr1-/- recipients.  However, it has yet to be determined which host cells 
stimulated by IFN-γ are critical to mediate IFN-γ’s anti-tumor effects.  Currently, a 
fellow graduate student in the Schreiber laboratory, Sang-hun Lee, recently generated 
conditional Ifngr1 gene-targeted mice to selectively delete IFNGR1 in specific tissues to 
address this issue.  Unedited tumors will be transplanted into tissue-specific Ifngr1-/- mice 
to determine which IFN-γ responsive host cells are required for tumor rejection.  The two 
unedited tumors he will use for this analysis will be H22-28032 that was generated as 
part of this thesis and 1969 that, in addition to requiring host cell IFN-γ responsiveness, 
also requires type I (IFN-α/β) interferon responsiveness at the level of CD11c+ cells to 
mediate tumor rejection (25). 
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Identifying the antigenic targets of checkpoint blockade therapy in antigen loss 
variants 
 
Although exome sequencing and class I prediction algorithms has provided a 
short list of putative epitopes for d42m1-T3 and d42m1-es3, more work is needed to 
identify the specific antigens that are targeted by checkpoint blockade therapy.  
Specifically, CTL lines developed against d42m1-T3 and d42m1-es3 will be tested for 
their capacity to recognize candidate epitopes and if so, demonstrate that the mutant 
peptide stimulates antigen-specific T cells in vivo.  To this end, additional CTLs lines 
have been generated from wild type mice that rejected d42m1-T3 or d42m1-es3 tumors 
in response to checkpoint blockade therapy and mutant forms of the peptides (Gpr108 
R101L; Olfr684 D72Y; Olfr1239 C177S) have been synthesized.  The synthesized 
candidate peptides are currently being tested against the CTL line that recognizes d42m1 
and d42m1-T3 parental cells in an H-2Kb restricted manner.  If any mutant peptides 
presented on unrelated H-2Kb expressing cells activates this CTL line or any of the other 
CTL lines to be tested, then these peptides will be used to assemble soluble H-2Kb MHC 
class I tetramers to track mutation-specific CD8+ T cells in vivo.  Alternatively, mutant 
peptides will be used to immunize wild type mice prior to d42m1-T3 or d42m1-es3 tumor 
cell challenge to test if the peptide can be used to vaccinate against d42m1 antigen loss 
variants.  We predict that the additional experiments outlined above will demonstrate 
which of the candidate antigens functions as the target for immunotherapeutically 
induced anti-tumor immune responses. 
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Do edited sarcomas that respond to anti-CTLA-4 therapy have more potential antigens 
than edited sarcomas that fail to respond to anti-CTLA-4 therapy? 
 
Recently, we sequenced the exons of ten different edited sarcomas derived from 
immunocompetent 129/Sv wild type mice that were initially treated with 100 µg of the 
MCA carcinogen.  Two (F279 and d4m3) of the ten edited sarcomas (20%) do not 
respond to checkpoint blockade immunotherapy (i.e., anti-CTLA-4, anti-PD-1, or anti-
PD-L1) even when used in combination, suggesting that these edited sarcomas are non-
immunogenic.  Exome sequencing revealed that these tumors express slightly fewer 
mutations, but the mutational load is essentially the same between edited sarcomas that 
respond to anti-CTLA-4 therapy and those that do not respond to anti-CTLA-4 therapy.  
In fact, there appears to be no difference in the number of mutations between highly 
immunogenic, unedited sarcomas (d42m1 and H31m1) and edited sarcomas of reduced 
immunogenicity.  Thus, for MCA-induced sarcomas, the level of residual 
immunogenicity cannot be inferred from the mutational load or the number of mutations 
they express.  However, it is still possible that the potential antigenic array differs 
between unedited and edited sarcomas as well as between edited sarcomas that respond to 
anti-CTLA-4 therapy and those that fail anti-CTLA-4 therapy.  Currently, we are in the 
process of submitting our exome sequencing data from edited sarcomas into class I 
prediction algorithms to generate antigenic profiles for each individual tumor.  In order to 
correlate the quality and quantity of potential antigens of a tumor with sensitivity to 
checkpoint blockade immunotherapy, additional tumors may need to be sequenced to 
enhance the statistical power of the dataset.   
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Identifying the antigenic targets of checkpoint blockade therapy in edited tumors 
 
One approach to identifying the antigens expressed in transplantable, edited 
tumors that respond to checkpoint blockade therapy is to use the cDNA CapSeq/in silico 
analysis described in this thesis.  As detailed above, we have already sequenced the exons 
of a panel of edited sarcoma cell lines, some of which respond to anti-CTLA-4 therapy 
and some that do not.  Thus, any potential antigens predicted by class I algorithms can be 
synthesized and tested for their capacity to stimulate CTL lines generated from mice that 
reject edited tumors after checkpoint blockade therapy.  Any mutant epitope that 
positively stimulates a CTL could be used to generate soluble MHC class I tetramers to 
track endogenous antigen-specific CD8+ T cells in vivo.  
The second and more rigorous approach is to perform a similar analysis on 
primary MCA sarcomas in wild type mice.  Here, the same general principles apply in 
that tumor cDNA will be sequenced, potential antigens will be predicted, and tumor-
specific CTLs will be generated but, the tumor tissue will come from developing primary 
tumors undergoing tumor progression or immunotherapeutically induced tumor 
regression.  Specifically, tumor tissue will be harvested from at least 5 primary sarcomas 
that respond to checkpoint blockade therapy (as evidenced by tumor regression but before 
total elimination of the tumor) and at least 5 primary MCA sarcomas that do not respond 
to checkpoint blockade therapy (as evidenced by tumor progression), cDNA will be 
isolated, Illumina libraries will be generated, hybridized to mouse exome probes 
(Agilent) and submitted for sequencing. The study of primary MCA sarcomas as opposed 
to cell lines not only has the advantage of most closely resembling the clinical scenario of 
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anti-CTLA-4 therapy in terms of tumor development (autochthonous tumor model) and 
in terms of anti-CTLA-4 therapeutic responses, but also provides the opportunity to 
isolate normal tissue from the same individual mouse as the tumor for comparative 
genome analyses.  By pipelining the exome sequencing data into MHC class I epitope 
prediction algorithms, we will generate antigenic profiles for each individual sarcoma and 
compare whether the sarcomas that respond to immunotherapy have a greater number of 
potential high- to medium-binding affinity antigens than sarcomas that fail to respond to 
immunotherapy.  Finally, any mouse that rejects its primary MCA sarcoma during the 
course of checkpoint blockade therapy will be used to generate a CD8+ CTL line against 
the primary sarcoma cells in an attempt to identify the tumor-specific antigens targeted 
by this form of immunotherapy.  
 
Potential clinical implications for cancer genome sequencing on tumor immunology 
 
 Cancer genome sequencing analyses has provided many important insights into 
the nature of mutations that facilitate transformation (261).  Although, the primary focus 
of this field is to identify the “driver” mutations, it is becoming apparent that the vast 
majority of mutations present in cancer cells are “passenger” mutations that may function 
as targets for elimination by immunotherapy (213, 214).  The large datasets of 
information from the many cancer genome initiatives could be of extreme value to tumor 
immunologists to define the “antigen landscape” as opposed to the “mutational 
landscape” of human cancers (262).  One application of this approach is that it could be 
used to identify the subset of cancer patients whose tumors express antigens that can be 
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most effectively targeted by checkpoint blockade immunotherapy.  In addition, this 
approach may provide a mechanism to longitudinally evaluate changes in a tumor’s 
antigenic profile as a consequence of ongoing immunotherapy.  
  It is difficult to predict whether this type of analysis will yield prognostic value in 
the clinic, as genome analysis can be costly and requires streamlined computational 
analysis.  Nevertheless, third-generation sequencing technologies are already 
commercially available and costs for cancer genome sequencing are predicted to fall 
sharply over the next decade (263), thus this type of analysis may be feasible to perform 
on a individual patient’s cancer cells in the not-to-distant future.  Whether it proves 
useful will require extensive studies performed initially in pre-clinical models like the 
ones used in this thesis as well as retrospective and longitudinal clinical studies.   
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